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The enzyme adenosine triphosphate phosphoribosyltransferase (ATP-PRT)
catalyses the first reaction of the histidine biosynthetic pathway. ATP-PRT
also represents a metabolic control point, directing the flux of metabolites
through this energetically expensive pathway. Two distinctly different forms
of ATP-PRT exist, the long form and the short form, which differ in the
presence of a C-terminal regulatory domain. In the short form, where this
domain is absent, it is functionally replaced by a regulatory protein, called
HisZ. ATP-PRT activity is modulated by two layers of regulation: active site
inhibition by adenosine monophosphate, which reflects cellular energy levels,
and pathway end product feedback inhibition by histidine. In the long form
ATP-PRT histidine binds to the allosteric site at the regulatory domain, but
the exact nature of the inhibitory mechanism is still debated.
This thesis characterises a new member of the ATP-PRT long form
from Campylobacter jejuni (CjeATP-PRT) and investigates the molecular
mechanisms involved in the feed back inhibition by histidine.
Chapter 2 describes the characterisation of the CjeATP-PRT including
a detailed description of its crystal structure. The C. jejuni enzyme is similar
to the previously described enzymes of the ATP-PRT long form, but exists
only as hexameric species under experimental conditions, which contradicts
previous assumptions that the hexamer is exclusively inactive.
Chapter 3 investigates the catalytic apparatus of CjeATP-PRT by sep-
arating the catalytic and regulatory domains of the enzyme for individual
study. The isolated catalytic portion of the enzyme, the CjeATP-PRT Core
iii
mutant, forms a dimeric species with very limited catalytic capabilities but
high substrate and product affinities. The CjeATP-PRT Core characteristics
suggest that it exists in a permanently inhibited conformation, highlighting
the requirement of the regulatory domain not only for feedback regulation
but also for enzyme function. Additionally this supports the evolutionary
need for the recruitment of a regulatory apparatus.
In chapter 4 a potential intramolecular communication pathway from
the allosteric to the active site is probed by the generation of several single site
mutations. One of these, CjeATP-PRT R216A, is completely insensitive to
histidine inhibition, although this ligand is still able to bind at the allosteric
site, which is consistent with the involvement of R216 in the allosteric signal
communication. The catalytic abilities of CjeATP-PRT R216A are largely
impaired, leading to the assumption that this mutation causes a permanent
inhibitory response.
In summary this thesis supports the existence of a simple physical reg-
ulatory mechanism for the feedback inhibition of the ATP-PRT long form,
the change between two different hexamer conformations depending on the
presence of the allosteric effector.
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1.1 Histidine and the histidine biosynthetic
pathway
L-Histidine is one of the 22 proteogenic amino acids, the basic metabolites
from which proteins are synthesised in the fundamental process of transla-
tion. The functional group of histidine, imidazole, is able to be protonated
and deprotonated at physiological pH, which makes it an excellent proton
shuttle during enzymatic reactions. Histidine is therefore often found in en-
zyme active sites, for instance as part of the catalytic triad of peptidases.1
The side chain of histidine is also a very common coordinating ligand in
metalloproteins.2,3 Aside from the roles of histidine in protein structure and
function, it can be decarboxylated to form the common neurotransmitter
histamine.
Histidine is one of the essential amino acids that humans require as part
of their diet. Its biosynthesis is ubiquitous, occurring in all domains of life ex-
cept animals, which makes the enzymes of the histidine biosynthetic pathway
interesting targets for the development of non-toxic drugs and herbicides.4,5
1
Figure 1.1: Biosynthetic pathway of the proteogenic amino acid histi-
dine. Overview of the ten reaction steps involved in the biosynthetic production
of histidine. Participating enzymes: 1 – ATP-PRT, 2 – PR-ATP pyrophospho-
hydrolase, 3 - PR-AMP cyclohydrolase, 4 – ProFAR isomerase, 5 – IGP syn-
thase/glutaminase, 6 – IGP dehydratase, 7 – IAP aminotransferase, 8 - Hol-P
phosphatase, 9 and 10 – histidinol dehydrogenase.
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The investigation of the histidine biosynthetic pathway began in 1952
with studies on Neurospora crassa mutants6 and soon included bacteria7,8
and later plants.9 The work on the histidine biosynthetic pathway has largely
contributed to the unravelling of some of the most fundamental mechanisms
in biology during the 20th century, such as operons10 and operon polarity,11
attenuation12 and feedback inhibition.13 Today a clear picture of the reac-
tions that lead to the formation of histidine, the involved metabolites and
enzymes, in all domains of life, has been obtained.5,9, 14
Histidine biosynthesis is achieved in ten enzymatic reaction steps (Fig-
ure 1.1). Using adenosine triphosphate (ATP) and phosphoribosyl pyrophos-
phate (PRPP), from the pentose phosphate pathway, first phosphoribosyl-
adenosine triphosphate (PR-ATP) is formed by a phosphoribosyl transfer re-
action (step 1) catalysed by adenosine triphosphate phosphoribosyltransferase
(ATP-PRT). The subsequent hydrolysis of the triphosphate (step 2) is catal-
ysed by PR-ATP pyrophosphohydrolase, which results in phosphoribosyl-
adenosine monophosphate (PR-AMP). Hydrolytic opening of the adenosine
ring (step 3) produces phosphoribosyl-formimino-AICAR-phosphate (Pro-
FAR). This reaction is catalysed by PR-AMP cyclohydrolase. Depending on
the organism, PR-ATP pyrophosphohydrolase and PR-AMP cyclohydrolase
occur as two separate monofunctional enzymes, a fused bifunctional enzyme
or a single multifunctional enzyme.5 ProFAR undergoes ribose ring opening
by way of an Amadori rearrangement (step 4) to produce phosphoribulosyl-
formimino-AICAR-phosphate (PRFAR), which is then converted into imi-
dazole glycerol phosphate (IGP) and 5-aminoimidazole-4-carboxamide ribo-
nucleotide (AICAR) (step 5) by IGP synthetase/glutaminase. This enzyme
is either a non-covalent complex14 (prokaryotes) or a fused bifunctional gene
product15 (eukaryotes) and provides the ammonia required for the indole ring
formation via the deamination of glutamine. The liberation of AICAR also
connects the histidine biosynthetic pathway to the de novo purine biosyn-
thesis, as this compound is a key entry point in the purine pathway. IGP
is further dehydrated (step 6) to yield imidazole acetolphosphate (IAP) by
IGP dehydratase. After transamination (step 7) of IAP to histidinol phos-
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phate (Hol-P) by IAP aminotransferase, the Hol-P phosphatase catalyses
the dephosphorylation (step 8) of Hol-P to histidinol. In eubacteria IGP
dehydratase and Hol-P phosphatase can also appear as a single bifunctional
enzyme. Histidinol is finally oxidised by histidinol dehydrogenase in two se-
quential steps via histidinal (step 9 and 10) to form the pathway end-product
histidine.
1.2 The adenosine triphosphate phosphoribo-
syltransferase
ATP-PRT (EC 2.4.2.17) catalyses the first reaction of histidine biosynthesis,
the reversible transfer of the 5’-phosphoribosyl group of PRPP on to the
N1 atom of ATP, resulting in the products PR-ATP and PP (Figure 1.2).
The reaction is described as an equilibrium and Mg2+ is required for opti-
mal enzymatic efficiency.16 ATP-PRT is strongly inhibited by the pathway
end product histidine in both directions13,17 and also competitively inhibited
by the nucleotides adenosine monophosphate (AMP) and to a lesser extent
adenosine diphosphate (ADP). Combinations of AMP or ADP with histidine
have been shown to exhibit synergistic inhibition towards ATP-PRT.18
Figure 1.2: The ATP-PRT reaction.
As mentioned, histidine biosynthesis, as a central metabolic pathway,
is connected to the purine de novo synthesis by the pathway side prod-
uct AICAR, which is released upon the formation of IGP. Accumulation
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of AICAR has also been shown to adversely affect the synthesis of thi-
amine pyrophosphate in Salmonella enterica19 and tetrahydrofolate in Sac-
charomyces cerevisiae,20 two important metabolites. Furthermore, the sub-
strates of ATP-PRT are both energetically rich compounds, and play impor-
tant roles in cellular metabolism. It has been estimated that the synthesis
of one molecule of histidine requires a total of 41 equivalents of ATP.21 It is
therefore essential that histidine biosynthesis is tightly regulated. Catalysing
the first committed step of the pathway, ATP-PRT plays a key role in the
regulation of metabolite flux through the pathway. It is consequently con-
trolled by multiple layers of regulation, which are described in detail later
(section 1.3).
1.2.1 Classification of phosphoribosyltransferases
ATP-PRT is a member of the phosphoribosyltransferase (PRT) enzyme fam-
ily. Four types of PRTs are differentiated according to their overall fold
(Figure 1.3). The most common of these is type I, which includes enzymes
involved in nucleotide synthesis and salvage pathways. The typical type I
fold consists of a central five-stranded β sheet surrounded by three α helices,
accompanied by a predominantly N-terminal, variable “hood” domain. In
most examples of type I PRTs two individual chains form a dimeric interface
that includes residues of the active site.22 Quinolate PRT represents another
type, type II, and its chain is composed of two domains, an N-terminal anti-
parallel β openface sandwich domain and an uncommon β7α6 barrel.23 Two
chains of quinolate PRT come together to form the holo-enzyme. The only
representative of type III, anthranilate PRT, also adopts a stable dimeric
quaternary structure. The type III single chain is composed of a small N-
terminal four α helix bundle and a large C terminal α/β domain with a
central seven stranded β sheet.24,25 Notably, ATP-PRT is structurally dis-
similar to all other PRT family members, making it a separate type: type
IV PRT.26 ATP-PRT enzymes can be further subdivided into two forms,
a homo-hexameric and a hetero-octameric form. The common feature of
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both forms are two α/β sandwich domains that form the active site in the
large cleft between them. The detailed structure of ATP-PRT is described
in section 1.2.3.
Figure 1.3: Overview of the PRT type architectures. Schematic compar-
ison of PRT type structures.22–24,35 For each type the domains of a single chain
are depicted as ovals with the position of the active site indicated by a red circle.
Type IV represents the ATP-PRT family.
A 13 residue signature fold responsible for PRPP binding has been de-
scribed for the type I PRTs. The consensus sequence of this highly conserved
PRPP binding motif can be generally described as hhhhaahhsssss, where ‘h’
represents a hydrophobic side chain, ‘a’ an acidic side chain (usually as-
partic acid) and ‘s’ a short side chain. The first four hydrophobic residues
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form the central β strand of the five-stranded β sheet, while the last nine
residues of the motif compose the PRPP binding loop. The two acidic side
chains lie in hydrogen bonding distance from the ribose oxygens of PRPP
and the 5’-phosphate group binds in a positively charged pocket formed by
backbone amides and polar side chains of the last five residues, including at
least one glycine and one threonine residue. This binding loop is very po-
tent and specific for the binding of negatively charged moieties or molecules.
In crystal structures of PRT proteins, crystallised in the absence of specific
ligands, the binding site formed by this loop is nearly always occupied by
anions present in the crystallisation condition, such as sulphate, phosphate,
or sulphonate.22 Type II and III PRTs do not contain sequences similar to
this conserved motif, but have instead developed separate coordination sites
for the binding of PRPP.23,25 In type IV, which is all ATP-PRTs, the same
signature motif is found but with minor differences. Here, the second residue
in the sequence is acidic while position five is always a hydrophobic residue,
resulting in a consensus sequence, using the same nomenclature, of hahh-
hahhsssss. The last small residue is almost exclusively a threonine.27 Similar
to the type I, the first five residues form a β sheet (β9), while the remaining
residues form the binding loop.26 When the two 13 amino acid motifs from
the crystal structures of type I Trypanosoma cruzi hypoxanthine PRT and
type IV Escherichia coli ATP-PRT (EcoATP-PRT) are superimposed, they
display a striking similarity (Figure 1.4), with a root-mean-square deviation
(RMSD) of 0.895 Å, showing that the PRT binding motif is almost identical
in sequence and fold in the two PRT types.
1.2.2 Reaction mechanism
Extensive kinetic studies on the ATP-PRT from Salmonella enterica subsp.
enterica Typhimurium (SenATP-PRT) have established that the ATP-PRT
reaction proceeds via an ordered sequential binding mechanism with ATP
binding first, followed by PRPP, release of PP, and release of PR-ATP.17,28
The reaction catalysed by ATP-PRT is a nucleophilic substitution with
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Figure 1.4: The PRPP binding motif. Superposition of the PRPP binding
motif of T. cruzi hypoxanthine PRT (green) and EcoATP-PRT (marine) in the
cartoon and stick representations. Hetero-atoms are coloured according to element:
oxygen (red), nitrogen (blue), sulphur (yellow).
inversion of stereochemistry.29 Although the mechanism of the ATP-PRT re-
action has not yet been determined, two mechanisms can be proposed based
on the reaction chemistry. The first is a dissociative (SN1-like) mechanism,
in which the pyrophosphate of PRPP dissociates first, creating an oxocarbe-
nium ion intermediate, which is then attacked by the nucleoplilic N1 atom
of ATP. The second is an associative (SN2-like) mechanism, in which nu-
cleophilic attack of ATP and dissociation of the pyrophosphate group occur
simultaneously, without the formation of a discrete intermediate.
The determination of the transition state structure can discriminate
the degree of SN1-like or SN2-like character of a reaction.
30 Studies of the
kinetic isotope effect on a variety of PRT enzymes including SenATP-PRT
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have shown that most of the investigated PRT reactions follow an SN1-like
mechanism. The observed large 3H kinetic isotope effects are consistent with
the formation of an oxocarbenium ion intermediate. However the results for
SenATP-PRT were less conclusive, which could be due to the bi-directional
character of the reaction.31
Analogies can also be made to the mechanisms of PRT proteins in gen-
eral. The majority of the information available is concerning type I proteins,
where crystallographic data shows that the ribose ring of PRPP is bound
in the active site in a conformation that promotes a planar geometry at C1.
This is consistent with a partial double bond character in the C1-O4 bond,
as would be expected with the formation of an oxocarbenium ion interme-
diate. Additionally an α-phosphate oxygen of the pyrophosphate group is
in close proximity to C1, which would further stabilise the planar intermedi-
ate.32 Taken together this supports a dissociative mechanism of the type I
PRT. Furthermore, it has been shown that the ribose conformation of PRPP
is variable depending on whether it is bound to PP (substrate side) or ATP
(product side), which is thought to be consistent with a general SN1-like
mechanism for the reaction of PRT enzymes.33
Recent investigation into the anthranilate PRT from Mycobacterium
tuberculosis (type III PRT) revealed the role of flexible active site loops in
the binding of substrate molecules, where the loops can move to effectively
occlude the active site. This is thought to help protect the hypothesised
highly reactive oxocarbenium ion intermediate. Additionally, kinetic studies
of this enzyme with fluorinated substrate analogues indicate that the nucleo-
philicity of the attacking amino group (of anthranilate) is of little significance
to the overall reaction rate, further supporting an SN1-like mechanism for
PRTs.34 It is therefore generally assumed that the ATP-PRT reaction also
displays an SN1-like mechanism, but detailed analysis of the transition state
involved are still under way (Gerard-Johan Moggré, personal communication,
April 2015).
In crystal structures of almost all substrate bound PRT enzymes, Mg2+
ions have been modelled, positioned such that they would be involved in
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PRPP binding and recognition.22,25 It has also been shown that the presence
of Mg2+ in in vitro assays is essential for ATP-PRT activity.16 While it is
certain that Mg2+ forms a complex with the polyphosphate groups of both
ATP-PRT substrates,28 a clear role of the metal ion during the catalytic
mechanism has not been described.
1.2.3 Structure
Crystal structures have been solved of ATP-PRT from a variety of bacte-
rial sources, including M. tuberculosis ,35 E. coli ,26 Lactococcus lactis36 and
Thermotoga maritima.37 The Protein Data Bank (PDB) also contains the
ATP-PRT crystal structure from the archaea Methanothermobacter thermau-
totrophicus (MthATP-PRT). Interestingly, from analysis of these structures
it is clear that there are two distinct forms of ATP-PRT differentiated by
their quaternary structure. Discrimination between the two forms starts at
the primary sequence level. The first form is 280-310 amino acids in length,
and is present in archaea, bacteria and eukaryotes. It will henceforth be
denoted as “long form” ATP-PRT. The polypeptide of the second form, the
“short form” ATP-PRT, consists of only 200–220 amino acid residues. The
short form ATP-PRT has only been identified in bacteria and associates with
a second gene product, HisZ, to form a functional complex. Of the above
mentioned organisms, only T. maritima and L. lactis possess short form
enzymes, denoted TmaATP-PRT and LlaATP-PRT respectively.
The polypeptide chain of ATP-PRT long form enzymes26,35 is approx-
imately 280–310 amino acids long containing a total of ten α helices and 15
β strands that form three discrete domains (Figure 1.5), of which domain I
and II are involved in substrate binding and catalysis. The entity of both
domains will be referred to as the catalytic core. Domain I is formed from
two residue ranges, which are discontinuous, interrupted by the insertion of
domain II between them. It consists of a six-stranded anti-parallel β sheet
(β2β3β1β4β11β5) flanked by four α helices, α2 and α3 on one side and α1
and α8 on the other, with the long α8 helix forming the connection to the
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Figure 1.5: ATP-PRT long form structure. The crystal structure of apo
MtuATP-PRT (PDB code: 1NH7) displayed in the cartoon representation. The
contiguous domains I (green) and II (yellow) are connected via two loops, the C-
terminal domain III (red) is linked to domain I via a single loop. α helices and
β strands are labelled in primary sequence order. The PRPP binding motif is
highlighted in blue.
C-terminal domain III. The fold of domain II is similar to domain I, and is
composed of a twisted central β sheet (β8β7β9β6β10) surrounded by two α
helices on either side, α4 plus α5 and α6 plus α7 respectively. The cleft be-
tween domain I and II forms the active site, which includes the characteristic
PRPP binding motif.
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A very similar fold of domain I and II can also be found for the members of
the ATP-PRT short form,36,37 but with α8 being shorter (Figure 1.6).
Figure 1.6: ATP-PRT short form structure. The crystal structure of apo
TmaATP-PRT (PDB code: 1USY) displayed in the cartoon representation and
coloured according to Figure 1.5.
The C-terminal domain III, absent in the ATP-PRT short form, is also
a mixed α/β domain. The five β strands and two α helices form an anti-
parallel β sheet with both α helices on one face (Figure 1.5). This typical
βαββαβ, ferredoxin-like fold has been described as the structural charac-
teristic of the ACT-domain,38 named after three enzymes, in which it was
first identified: aspartate kinase, chorismate mutase and TyrA (prephenate
dehydrogenase).39 ACT domains are structural elements commonly found in
allosterically regulated metabolic enzymes, predominantly involved in amino
acid synthesis, but the ACT domain has also been found in DNA-binding
proteins.40 Because of the relative abundance of ferredoxin-like folds, ACT
domains have been further defined by a combination of structure and func-
tion. Characteristic features of ACT domains include highly varied modes of
self-association, effector binding at ACT domain interfaces, and transmission
of allosteric signals.41 Due to their involvement in allostery, ACT domains are
considered “regulatory switches” of enzymes. The ACT domain of long form
ATP-PRT enzymes is responsible for the binding of histidine and provides a
key interface for the oligomeric assembly of the protein.
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1.2.4 Macromolecular assembly
The quaternary structure also differs drastically between the ATP-PRT long
form and short form enzymes. Long form ATP-PRT enzymes are described to
exist in two homo-oligomeric states, a dimer and a hexamer.26,35 The ATP-
PRT dimer is composed of two chains that are arranged in a 180◦ rotational
symmetry relative to each other. The interface between two such chains
(referred to as the dimer interface) is formed by contacts between residues
of domain I of the first chain and domain II of the second chain (and vice
versa). The dimer interface buries a surface area of 965 Å2 to 1203 Å2 in M.
tuberculosis ATP-PRT (MtuATP-PRT)35 and 1192 Å2 in EcoATP-PRT.26
In contrast to the hexamer, the ATP-PRT long form dimer has not been
observed crystallographically. Evidence for the existence of the dimer has
been presented in the form of kinetic studies,42 gel-filtration35,43 and dynamic
light scattering experiments.44
All structures available for MtuATP-PRT, EcoATP-PRT and MthATP-
PRT show a homo-hexameric assembly of the enzymes. Herein, three of
the described dimers come together side-by-side to create the holo-enzyme.
Hexamer-formation is facilitated primarily by contacts between the C-terminal
ACT domains. Three ACT domains each come together to create a trimeric
assembly, one on each end of the enzyme (Figure 1.7). The ACT domains are
arranged with their β sheets facing each other in the centre, burying an indi-
vidual surface area, for each of the six interfaces, of 790 Å2 in EcoATP-PRT.26
The C-terminus is essential for the formation of this interface, contributing
almost 70% of the buried ACT domain surface area. It is positioned next to
β strand 15 of the adjacent subunit, effectively extending the ACT domain
β sheet by a fifth strand, interlocking the trimeric arrangement of the ACT
domains.
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Figure 1.7: Oligomeric assembly of the two ATP-PRT forms. The compo-
sition of each form is shown systematically from a single chain to the holo-enzyme.
The crystal structures of MtuATP-PRT (left hand side, long form) and LlaATP-
PRT (right hand side, short form) serve as examples. They are displayed in the
cartoon representation accompanied by a schematic. LHS: The single chain of
long form ATP-PRT enzymes is composed of a catalytic core (green) and a regu-
latory domain (red). Two chains come together to form a dimer and three dimers
associate into a homo-hexamer. RHS: The short form ATP-PRT enzymes also
assemble into dimers (green). Together with the regulatory protein HisZ (purple)
a hetero-octamer is formed. The schematic is turned by 90 ◦ compared to the
shown complex structure.
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Short form ATP-PRT holo-enzymes are assembled in a remarkably dif-
ferent way. Though they form dimers similar to their long form counterparts
(Figure 1.7), the holo-enzyme is assembled as a hetero-octamer requiring a
second protein, HisZ.36 HisZ is not only required for the formation of the
octamer, but has also been shown to be essential for the activity of LlaATP-
PRT.45 Like its binding partner ATP-PRT, HisZ can form dimers. Two
dimers come together in a way that the centre of the resulting complex is
formed by a crossed over, “X-shaped”, HisZ tetrameric core. The two partic-
ipating ATP-PRT dimers are bound to either side of this scaffold, completing
the arrangement.
1.2.5 Active site of ATP-PRT
The active site of ATP-PRT is positioned in the large cleft between the
two domains of the catalytic core. It is constituted by residues of both
domains and the two linkers (the β5-β6 and β10-β11 loops). Each active
site is connected with a symmetrical counterpart in the dimeric arrangement
of the ATP-PRT chains, effectively forming a large cavity on one face of
the dimer. In long form ATP-PRT hexamers three of these cavities can be
found in the inside of the oligomer, whereas the active sites of short form
hetero-octamers face the outside.
Due to the symmetric arrangement of the active sites, it is possible
for one chain to contribute amino acid residues across the dimer interface to
the neighbouring active site. These cross-interface contributions are likely
from the long side chains of the lysine and arginine residues in the β1-α1
and β3-α2 loops, which have been shown to be conserved throughout both
ATP-PRT forms.26,36
Several ATP-PRT structures have been published that feature active
site ligands with complete or partial occupancy. The most prominent of these
is the inhibitor molecule AMP bound to the active site of both MtuATP-
PRT35 (PDB code: 1NH8) and EcoATP-PRT26 (PDB code: 1H3D). Struc-
tural data is also available for the phosphoribosyl-adenine portion of the
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product PR-ATP in EcoATP-PRT (PDB code: 1Q1K) and the substrate
PRPP in the structure of the short form LlaATP-PRT36 (PDB code: 1Z7N).
Co-crystallisation of EcoATP-PRT with purified PR-ATP resulted in
the crystal structure 1Q1K, although the ligand density presented in this
structure only supports the presence of the phosphoribosyl-adenine part of
PR-ATP (Figure 1.8A). The binding mode presented for the bound molecule
allows for tight interactions of the 5’-phosphoribosyl moiety with residues
of the PRPP binding motif of domain II. Hydrogen bonding contacts are
formed between the three oxygen atoms and the backbone amides of S172–
T176 as well as the side chains of T173 and T176. The ribose oxygens
are in hydrogen bonding distance to the conserved glutamate residues E156
and D169. Taken together these interactions are thought to describe the
binding of the phosphoribosyl group of PRPP in the long form ATP-PRTs.26
The adenine group is positioned close to the double peptide linker between
domain I and II and is stacked between R16 and L170, which makes up its
only interaction with the protein.
PRPP binding to the active site of LlaATP-PRT is observed in all four
chains of the crystal structure 1Z7N (Figure 1.8B). Its 5’-phosphoribosyl
moiety interacts solely with residues of domain II, primarily of the PRPP
binding-motif, analogous to the findings in EcoATP-PRT. Main contacts
include the backbone amides of E158–T162 and the side chains of D155,
T159 and T162 as well as E142. The orientation of the pyrophosphate is
different in each of the four chains but the key interactions are thought to be
with S140 as well as to K8’, which is contributed across the dimer interface.36
The inhibitor molecule AMP has been observed in the EcoATP-PRT
crystal structure 1H3D (Figure 1.8C), in a binding mode reminiscent of the
one presented for phosphoribosyl-adenine in 1Q1K. AMP effectively mimics
(the observed) part of PR-ATP, the only difference being the connectivity
of its adenine. Since adenine forms no specific interactions other than the
hydrophobic stacking, AMP is perfectly suited to compete for binding in the
active site, which explains the competitive character of its inhibition towards
both substrates on a molecular level.26
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Figure 1.8: ATP-PRT active site ligands. Ligands (white) bound to the
active site of ATP-PRT (green) in the stick representation. Yellow dashed lines
indicate hydrogen bonding contacts. Hetero atoms are coloured according to ele-
ment: oxygen (red), nitrogen (blue), phosphorous (orange). A: Binding mode of
phosphoribosyl-adenine in EcoATP-PRT26 (PDB code: 1Q1K). B: Binding mode
of PRPP in LlaATP-PRT36 (PDB code: 1Z7N). Residue K8’ from the adjacent
subunit displayed in yellow. C: Binding mode of AMP in EcoATP-PRT (PDB
code: 1H3D).
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1.2.6 Histidine binding site
The binding of the inhibitor histidine in long form ATP-PRTs takes place at
the ACT domain approximately 40 Å away from the active site (regarding
a single chain). Histidine binding has been described in the crystal struc-
ture of MtuATP-PRT, which had been co-crystallised in the presence of both
histidine and AMP (PDB code: 1NH8). Each chain binds one molecule of his-
tidine. The binding site is situated at the interface of two neighbouring ACT
domains, presenting two unequal surfaces. Residues from both chains are re-
cruited for the coordination of histidine. On one side, the carbamino group
of histidine forms hydrogen bonding interactions with residues L234–T238,
which form a narrow loop, as well as L253 of β14. All of these interactions
are formed with the protein backbone except the hydrogen bond between the
histidine amino group and the side chain oxygen of the absolutely conserved
T238. On the other side, the imidazole moiety is stacked between the side
chains of the two aspartate residues D214’ and D216’ of β12 (Figure 1.9).35
The same binding pose for histidine is also found in MthATP-PRT
involving the residues M236–T240, equivalent to the MtuATP-PRT residues
L234–T238, for the binding of the carbamino moiety. In MthATP-PRT the
binding of the imidazole group is achieved by tight interactions with N220’,
the equivalent of D216’.
The binding of histidine causes a significant conformational change in
the MtuATP-PRT crystal structure. When superimposed on domain I and
II of the apo structure (PDB code: 1NH7), the ACT domain of the inhibitor
bound structure (PDB code: 1NH8) shows a large rotational displacement
of approximately 35◦. Due to this motion the holo-enzyme elongates and
becomes more compact with a buried subunit-accessible surface area of 3078
Å2 compared to 2417 Å2 in the apo form, which is largely attributed to the
ACT-ACT interface changes.35 The histidine bound structure of MthATP-
PRT shows the same conformational change, however such a change was not
observed in the AMP and phosphoribosyl-adenine bound crystal structures
of EcoATP-PRT. Therefore ATP-PRT long form enzymes adopt either an
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Figure 1.9: Histidine binding site. The histidine binding site of MtuATP-
PRT35 (PDB code: 1NH8) represented as sticks. Histidine (white) is bound at
the interface of two ACT domains (dark green and light green). Yellow dashed
lines indicate hydrogen bonding contacts. Hetero atoms are coloured according to
element: oxygen (red), nitrogen (blue).
“open” or a “closed” conformation depending on the presence or absence of
histidine.26
The position of the histidine binding site in the short form ATP-PRT is
still debated. Limited crystallographic evidence is given for TmaATP-PRT,
in which eight histidine molecules (two per ATP-PRT monomer) are placed
in two equivalent sites at the interfaces formed with HisZ.37 In contrast to
this observation stands the mutational analysis of LlaATP-PRT that suggests
the involvement of residues in a putative histidine binding site located solely
in HisZ.36 Whether one or both hypotheses are correct is still unclear.
1.2.7 Evolution
The evolutionary relationship of the separate units of both long and short
form ATP-PRTs have been examined, both to each other, and to other pro-
tein families. The catalytic core unit of domain I and II has been compared
to the family of the monomeric periplasmic binding proteins,35 which are
directly involved in the uptake of nutrients, such as sulphate and phosphate
as well as amino acids, in bacteria (reducing the need for de novo synthesis).
Periplasmic binding proteins, such as the E. coli HisJ,46 are composed of two
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domains that share a similar fold with the catalytic core of ATP-PRT with
an RMSD of 2.57 Å between the two E. coli proteins, suggesting a common
ancestry.36 The high specificity of the PRPP binding loop for negatively
charged ions could therefore be the evolutionary relic from an ancestral pro-
tein involved in sulphate and phosphate binding. Low sequence similarity
and the different function and motion35,47 of the two enzyme families on the
other hand stand in clear contrast to this theory.
The regulatory ACT domain of the ATP-PRT long form shares high
structural similarity with members of the PII protein superfamily, one of the
most widely distributed signalling proteins in nature.48 PII proteins act as
sensory devices for the metabolic state of the cell, a feature that they share
with the ATP-PRT regulatory domain. Furthermore, PII proteins adopt the
characteristic βαββαβ fold with a C-terminal β strand and assemble into
functional trimers near identical to the ACT domain of ATP-PRTs. The
main differences between the two structures are the elongated C-terminus
and the long T-loop of PII , which is inserted between the first and second
canonical βαβ unit. In ATP-PRT ACT domains both structural elements are
significantly shorter. Interestingly, both protein families bind their respective
ligand (ATP in PII , histidine in ATP-PRT) at the interface between two
neighbouring (ACT) domains. Consequently it has been proposed that an
ancestral PII or PII-like domain was recruited to create the long form of
ATP-PRT.49
A second gene product, HisZ, is essential for ATP-PRT short form
structure37 and function.45 HisZ is a class II aminoacyl-tRNA synthetase
paralogue that lacks the anti-codon binding domain of aminoacyl-tRNA syn-
thetases, but possesses an α-helical insertion domain, which is essential for
the formation of the hetero-octameric complex of short form ATP-PRTs.
Phylogenetic studies have shown that HisZ is only encoded in bacterial histi-
dine operons that also code for a short ATP-PRT gene. It has also been found
that short and long form ATP-PRTs generally do not co-exist, the Geobacter
clade forming the only known exception,50 dividing the histidine synthesising
species into two heterogeneous groups.51 The short form ATP-PRT, which is
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only found in bacteria, is believed to be the evolutionary older form, based
on its similarity with aminoacyl-tRNA synthetase, linking back to the early
stages of life. The long form ATP-PRT is believed to have evolved later in
either bacteria or archaea and was subsequently transferred into eukarya.52
In summary, all ATP-PRT enzymes are likely to have evolved from
a common ancestor and then diverged during early evolution into the two
forms present today (Figure 1.10). From the hypothetical precursor, that
is potentially related to periplasmic binding proteins, two co-evolutionary
pathways originate. The first used an aminoacyl-tRNA synthetase paralogue
as regulatory subunit for the formation of a hetero-complex (ATP-PRT short
form), while the second recruited a PII-like protein as a covalently linked
regulatory domain (ATP-PRT long form).
Figure 1.10: Evolution of ATP-PRT. Overview over the theoretical evolu-




The biochemistry of the cell is a vast network of enzymatic pathways by which
metabolites are generated, converted and degraded. Situated at key junc-
tions of these pathways are regulatory enzymes, which control the metabolic
flux. They are able to sense the metabolic needs of the cell and adjust their
catalytic activity accordingly. The diverse mechanisms that control these
enzymes ensure the efficient use of the available nutrient and energy pools
and consequently the survival of the cell.53
ATP-PRT is one of these key enzymes. Catalysing the reaction between
two important cellular metabolites, ATP and PRPP, it is situated at the
beginning of the energetically expensive histidine biosynthetic pathway.14
Cells that exhibit unregulated histidine biosynthesis have been shown to
dissipate up to 2.5 % of their metabolic energy.54 It is therefore essential to
regulate ATP-PRT, which is achieved by a multi-layered mechanism, mainly
concentrated on the modulation of the enzyme activity and to a lesser extent
the expression level of the protein.
1.3.1 Transcriptional regulation
The transcription level of bacterial operons can be regulated by attenuation.55
In amino acid biosynthetic operons attenuation involves a transcribed leader
region in the operon preceding the first structural gene. The essential part of
this leader region is a segment coding for a short polypeptide, which is rich
in the amino acid that is the end product of the corresponding biosynthetic
pathway. This segment acts as a sensory device for the abundance of the
relevant charged tRNAs and only allows the transcription of the operon to
proceed under amino acid starvation conditions.56
The histidine operon, encoding for all genes of the histidine biosynthetic
pathway, is controlled by attenuation and does not co-exist with a repressor-
operator system as seen for other amino acid operons, therefore making it
22
the only form of genetic level regulation for the abundance of ATP-PRT, and
consequently histidine, in the bacterial cell.12
1.3.2 Active site inhibition
One of the most common mechanisms for enzyme inhibition is the reversible
binding of a small molecule, the inhibitor, to (the active site of) an enzyme,
preventing the substrate binding by mere physical exclusion. This competi-
tive inhibition can be overcome by a high substrate to inhibitor ratio.57
Individually, AMP and ADP inhibit ATP-PRT with a clear competitive
character towards both substrates, ATP and PRPP.18 In the case of AMP,
this is strongly supported by the observed binding pose in the active site of
MtuATP-PRT and EcoATP-PRT (Figure 1.8C). The energy level of the cell
can generally be described by the ratio of ATP to AMP (and ADP). Since
ATP is the substrate and AMP and ADP inhibitors of ATP-PRT, the enzyme
is directly sensing the energy state of the cell and forced to adjust activity
accordingly. During starvation the ATP/AMP ratio will strongly decrease,
inhibiting the enzyme and stopping the metabolic flux into the energetically
expensive histidine de novo synthesis.21
Additionally, ATP-PRT has been reported to be inhibited by the prod-
ucts of the biosynthetic direction reaction, PR-ATP and PP. This logically
results from the fact that the ATP-PRT catalysed reaction is an equilib-
rium.17,28 Physiologically this would result in an arrest of ATP-PRT catal-
ysis in the biosynthetic direction only if the histidine pathway is blocked at
the second (irreversible) step, catalysed by PR-ATP pyrophosphohydrolase.
The effectiveness of AMP inhibition alone is based solely on the general
energy state of the cell, but a defining feature of ATP-PRT is the coupling
of this regulation mechanism with the inhibition by the allosteric feedback
inhibitor histidine, resulting in an overall synergistic effect.8,18
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1.3.3 Allostery
The term ‘allostery’ or ‘allosteric control’ describes the regulatory control
of an enzyme by the binding of a small effector molecule at a site other
than the protein active site. It is derived from the two Greek words ‘αλλoς’
(other) and ‘στερεoς’ (solid object) and is meant to express the ‘difference’
(allo-) in the (stereo-) specificity of the effector and substrate binding sites.58
Allostery can affect the catalytic properties of an enzyme positively (activa-
tion) or negatively (inhibition). It can be differentiated between homotropic
and heterotropic allostery. In homotropic allostery, typically known as co-
operativity, the substrate of an enzyme can also act as effector at the same
time. In heterotropic allostery the effector is not a substrate for the enzyme.
Generally the inhibition by pathway end products is achieved by heterotropic
allostery.
Principally, allostery can affect an enzyme’s conformation or dynamics.
Due to their intrinsic conformational flexibility, proteins are able to sample
a variety of different conformer populations. Effector binding interferes with
the equilibrium between those populations and alters the distribution of con-
former species, ultimately resulting in changes of the active site geometry
and consequently the catalytic efficiency.59 A change between structurally
distinguishable conformations is not always necessary. Changes in protein
dynamics can also contribute decisively to allosteric control.60,61
The evolution of allosteric models
The first allosteric effects were discovered at the beginning of the 20th cen-
tury. The observation of the sigmoidal behaviour of oxygen binding to
haemoglobin62 soon led to the formulation of the Hill equation,63 a fundamen-
tal instrument of enzyme kinetics. The next key observations were made in
the 1950s, when metabolic pathway end products (particularly amino acids)
were found to inhibit their own production by affecting an early enzyme
in the pathway (to which they are not a substrate), creating a negative
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feedback regulation.64,65 In 1963 the term ‘allosteric’ was introduced to de-
scribe these systems66 and in 1965 the concerted Monod-Wyman-Changeux
(MWC) model67 was postulated, which describes allostery as the transition of
(oligomeric) enzymes between two possible conformations. Soon afterwards
the sequential Koshland-Nemethy-Filmer (KNF) model68 was formulated to
address the ability of individual subunits in an oligomer to change confor-
mation independently. Most allosteric systems can be explained in broad
terms by these two models, such as the classic model proteins haemoglobin
and aspartate transcarbamylase.69 However, in recent years a third model
has arisen from the need to explain the behaviour of the enzyme porpho-
bilinogen synthase, which exists in an equilibrium between quaternary struc-
ture isoforms with different kinetic properties. This model has been named
the “morpheein” model after the words ‘protein’ and ‘to morph’ (to change
shape), describing the ability of a morpheein to assemble into structurally
and functionally distinct oligomers.70 The key features of the three models
are summarised below (Figure 1.11).
In the concerted MWC model multimeric enzymes are described to
exist in an equilibrium between two distinct symmetric states, R (relaxed)
and T (tense). The simplified assumption is made that all subunits exist in
the same state at any given time. To maintain the molecular symmetry, all
subunits must transform ‘in concert’ from one conformation into the other.
The allosteric effector shifts the position of the equilibrium by preferentially
binding and stabilizing one of the states (T). According to this model, even
low effector concentrations will have a large effect of the enzyme’s overall
conformation and function.
The sequential KNF model adopts the basic principle of the two equilib-
rium states and augments it by the proposal that the change in one subunit
of a protein does not necessarily induce the same change in any other sub-
unit. Based on the induced fit hypothesis71 each subunit is able to change
conformation independently upon effector binding, resulting in mixed con-
formational, asymmetric intermediate species.
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Figure 1.11: Models of allostery. Two dimensional schematic representa-
tion of the three allosteric models. Different conformations of the subunits are
indicated by colour (orange and blue). Effector molecules are highlighted in red.
A: The concerted MWC model.67 A symmetric multimeric protein can exist in
an equilibrium between two conformational states that differ in their affinity for
the effector. B: The sequential KNF model.68 Each protein subunit can change
its conformation independently. The allosteric binding site adjusts to accommo-
date the effector (“induced fit”). C: The morpheein model.70 A homo-oligomeric
protein exists in an equilibrium between different monomeric conformations, each
dictating a different, distinct oligomeric assembly. Oligomers must assemble their
interfaces symmetrically (fat line to dashed line). Effector molecules can shift the
equilibrium towards certain oligomers.
In contrast to the MWC and KNF models, where the oligomeric state
of the enzyme is fixed, the central postulate of the morpheein model is the
necessity for quaternary structure change. In this model, homo-oligomeric
enzymes can readily associate and dissociate under physiologic conditions.
The dissociated (monomeric) state exists in an equilibrium between differ-
ent conformational states (morpheeins) that each dictate the formation of a
different oligomeric assembly with defined multiplicity and different function-
ality. According to the model, the assembly of the morpheeins must preserve
the symmetrical contacts between the subunits in each oligomer. The mor-
pheein equilibrium can be influenced through the binding and stabilisation
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by morpheein-specific effectors, drawing the equilibrium towards a specific
oligomer.
Regardless of these models, allostery, in its general sense, can also be
applied to monomeric proteins.72,73
Allosteric control of ATP-PRT by the feedback inhibitor histidine
Both forms of ATP-PRT have been shown to be under allosteric control by
the pathway end product histidine by classic feedback inhibition.13,37 But
due to their vastly different oligomeric architecture, the molecular mecha-
nisms that underlie their regulation appear to be different.
In long form ATP-PRT the feedback inhibition by histidine is directly
associated with a conformational change between an open and a closed form,
which has been directly observed in the crystal structures of MtuATP-PRT
(Figure 1.12). The change is based on a large twist of the ACT domain,
relative to the domains I and II. Histidine binding occurs at the interface
of two neighbouring ACT domains, suggesting that direct interactions with
histidine, including a well ordered hydrogen bonding network, are causing
ATP-PRT to adopt the closed conformation.35
Only the binding of histidine results in the described conformational
changes. The crystal structure of EcoATP-PRT in the presence of AMP
(PDB code: 1H3D) shows the same overall conformation as described for
the apo form of MtuATP-PRT (PDB code: 1NH7), underlining that this
allosteric control mechanism is solely performed by the feedback inhibitor
histidine. Small differences in the positioning and the presented interfaces be-
tween the ACT domains of AMP bound EcoATP-PRT and the apo MtuATP-
PRT structures have been described though, presenting the ACT-ACT in-
terface of EcoATP-PRT in a marginally tighter position. These differences
have been attributed to the effect of AMP binding to the active site, which
could explain the synergistic inhibition of AMP and histidine described for
ATP-PRTs.26
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Figure 1.12: Allosteric mechanism of histidine feedback inhibition. Com-
parison of the open (left hand side) and closed (right hand side) crystal structures
of MtuATP-PRT (PDB codes: 1NH7 and 1NH8)35 in a cartoon representation.
Dimeric units are displayed in the same colour. Histidine is shown as green spheres.
Top: View on the trimeric arrangement of the ACT domains. Upon binding of
histidine the ACT domains twist, bringing their β sheets closer together in the
centre. Bottom: The open and closed hexamer labeled with their approximate
molecular dimensions in two axes. In the absence of histidine the holo-enzyme is
significantly wider and shorter.
According to the current models, long form ATP-PRT enzymes exist
in an equilibrium between active dimers and inactive hexamers. Although
all long form ATP-PRT crystal structures show hexameric arrangements, it
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is assumed that the hexamer is not a permanent state. The catalytic dimer
is believed to be the solely active species, whereas the hexameric state is
only adopted in solution upon histidine binding or at high protein concen-
tration.74 The binding of histidine at the ACT domain interfaces allows for
strong interactions and leads to hexamer formation, while the dissociation of
histidine also promotes the enzyme’s dissociation into dimers. The apo struc-
ture of MtuATP-PRT (PDB code: 1NH7) and the two EcoATP-PRT crystal
structures (PDB codes: 1Q1K and 1H3D) are therefore thought to present
loosely attached dimers forced together by crystal packing. This opinion
is justified by their relatively weak ACT domain interactions. The change
of oligomeric state, from dimer to hexamer, induced by histidine binding,
resulting in either altered topology or reduced access to the active site, is
consequently considered to be the main allosteric mechanism of long form
ATP-PRT enzymes.5,75
Comparative analysis of the short form ATP-PRT structures suggested
a potential role of the ATP-PRT dimer interface in the allosteric mechanism.
Upon binding of histidine, this interface is altered, causing the removal of po-
tentially catalytically relevant residues from the nearby active sites.36 Hereby
of special interest are conserved lysine and arginine residues, as they are
thought to create cross-dimer contacts and help in the binding or activation
of PRPP. K8 and K50 of LlaATP-PRT change their positioning in respect
to the neighbouring active site. Mutagenesis of both residues resulted in re-
duced catalytic properties of LlaATP-PRT, which supports their importance
for catalysis.27 These findings have also been related to the structures of the
long form enzymes MtuATP-PRT and EcoATP-PRT and interpreted as a
general mode of allosteric regulation in ATP-PRT enzymes.36
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1.4 Goals of this thesis
The main goal of this study is to gain a deeper understanding of the molec-
ular basis for the regulation of ATP-PRT enzymes, with a focus on the long
form and its characteristic regulatory domain. To obtain a wider perspective,
a new member of this enzyme group was chosen and its comprehensive char-
acterisation is presented, including detailed analysis of its crystal structure.
To extend the current knowledge of the ATP-PRT ligand interactions and
inhibitory synergy, the binding properties of this enzyme are also studied.
Furthermore the regulatory and catalytic role of the C-terminal regulatory
ACT domain are tested by separating it from the catalytic core structure and
studying the individual components in comparison to the wild type. Muta-
tional analysis is reported and reveals the involvement of crucial amino acid
residues in a potential allosteric communication pathway between the remote
inhibitor binding site and the active site. Finally, all gathered information
is discussed in regards to the regulatory mechanisms of long form ATP-PRT
enzymes.
The detailed objectives of this thesis were to:
• clone, purify and characterise a novel member of the ATP-PRT long
form from Campylobacter jejuni (CjeATP-PRT);
• investigate the oligomeric state of CjeATP-PRT in solution;
• produce and solve the crystal structures of substrate and inhibitor
bound CjeATP-PRT;
• generate a C-terminal truncation mutant, by removing the entire regu-
latory domain of CjeATP-PRT, and investigate its enzymatic proper-
ties and evolutionary implications;
• investigate a potential communication pathway between the binding







Characterisation of ATP-PRT began in the late 1950s and the pioneering
studies were carried out on the long form enzyme SenATP-PRT.13,16 The
kinetic characterisation of this enzyme led to a detailed understanding of its
kinetic properties and complex inhibition.18,28 The sedimentation behaviour
of EcoATP-PRT provided first insights into the oligomery of the ATP-PRT
long form.74,76 Decades later, the crystal structures of MtuATP-PRT35 and
EcoATP-PRT26 were solved, which, for the first time, enabled the exploration
of the relationship between structure and function of long form ATP-PRTs.
Based on this knowledge, the mutational analysis of Corynebacterium glu-
tamicum ATP-PRT (CglATP-PRT) resulted in the identification of crucial
residues for the interactions with histidine.77
Following on from these results, this study is aimed to consolidate a
general view on the overall properties and structure of the ATP-PRT long
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form, to establish some of the finer details of its regulation and to explore
the evolution of the enzyme. To widen the perspective, a new member of
this enzyme sub-family was cloned and characterised. C. jejuni was chosen
as the enzyme source.
C. jejuni is classified as a Gram-negative proteobacterium of the ε
clade78 and has a spiral rod-shaped appearance. It naturally colonises the
digestive tracts of many bird species79 but is also found in a variety of other
animal faeces including cattle, flies, and kangaroo. Despite its appearance
in other animals, C. jejuni causes serious infections in humans and is the
main cause of bacterial gastroenteritis in the developed world, although it is
rarely fatal.80,81 Given the increasing number of antimicrobial agent-resistant
strains worldwide,80 characterisation of the enzymes of the histidine biosyn-
thetic pathway might also provide the opportunity for new antibiotic treat-
ments in the future.
The genome of C. jejuni subsp. jejuni NCTC 11168, first sequenced in
2000,82 contains a single gene encoding for a putative ATP-PRT long form
as identified by sequence similarity. Cloning of this gene, as well as the
purification and characterisation of the encoded enzyme, CjeATP-PRT, are
presented in this chapter.
2.2 Multiple sequence alignment and phylo-
genetic analysis of the ATP-PRT long form
To obtain a systematic overview of the ATP-PRT long form sequences avail-
able, a large primary sequence alignment was created including 307 charac-
terised and putative ATP-PRT long form enzymes from the KEGG database.83
Sequences were chosen on the basis of length (≥ 270 amino acids) and genus
(not more than two species of the same genus). Therefore over-representation
of some taxonomic groups (e.g. enterobacteria) is due to the higher number
of complete or partially sequenced genomes available in these taxa. Plastidic
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signal peptides were ignored for the purpose of this alignment. A visual sum-
mary in the form of a phylogram is given in Figure 2.1. Protein sequences
with high similarity were identified and grouped in taxonomic clusters. A
consensus sequence was established for each cluster and subsequent alignment
of these consensus sequences was performed to produce a more representative
result (Figure 2.2).
Figure 2.1: Phylogram of selected ATP-PRT long form sequences. Align-
ment was performed using ClustalOmega84 and the resulting data is displayed as
a phylogram generated using FigTree.85 Scale of genetic distance is displayed be-
low. The colour of the clades corresponds to systematic grouping: plants (green),
cyanobacteria and chloroflexi (cyan), bacteria (red), proteobacteria (pink), archaea
(purple), fungi (orange and brown), other eukaryotes (blue). Positions of charac-
terised enzymes are indicated by black circles.
Following from the phylogenetic analysis, the ATP-PRT long form type
can be sub-divided into four main groups with various subgroups. The in-
ternal group sequence identity spans from 21 to 99 % whereas inter-group
identity is not higher than 38 %. Sequences encoding functionally char-
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acterised or putative long form ATP-PRTs are found in a large variety of
organisms including archaea, bacteria, fungi, plants, and lower eukaryotes, a
ubiquitous distribution with animals being the only exception. On a general
view the tree spreads according to the current opinions on systematics and
evolution.86 This supports the theory that the histidine biosynthetic path-
way along with many other amino acid biosynthetic pathways, as a basic
functionality, was established very early during evolutionary history.52
Figure 2.2: Phylogram of ATP-PRT long form consensus sequences.
Alignment was performed using ClustalOmega,84 resulting data is represented as
phylogram generated using FigTree.85 Genetic distance is displayed above the
branches. Clades were coloured according to Figure 2.1.
One of the most obvious findings is the similarity between the protein
sequences from plants and the mixed group of cyanobacteria and chloroflexi
(green non-sulphur bacteria), an observation that can be interpreted in two
ways. Either both groups have been under a very similar evolutionary pres-
sure, regarding their histidine biosynthesis, or plants have acquired the hisG
gene from a member of the cyanobacteria/chloroflexi group via lateral gene
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transfer early in evolution, most likely during an endosymbiotic event. Ac-
cording to the endosymbiotic theory, cyanobacteria are thought to be the
endosymbionts, which would be in accordance with the hypothesis of the
lateral gene transfer. This is further supported by the plastidic location of
the histidine biosynthetic enzymes in plants.9,87
To allow further comparison and identification of key residues for small
molecule binding and catalysis, a primary sequence alignment of CjeATP-
PRT with all structurally and/or biochemically characterised long form en-
zymes was performed. Following the previous alignments (Figure 2.1 and
2.2) that grouped CjeATP-PRT with the γ proteobacterial ATP-PRTs, a
somewhat unique positioning, the proteins with the highest sequence simi-
larity to CjeATP-PRT were EcoATP-PRT and SenATP-PRT with overall
identities of 66 % and 65 % respectively (Figure 2.3).
The ATP-PRT long form sequences show an overall low conservation.
Only 35 residues are conserved between the compared enzymes with the
majority being clustered in two areas: the α2-β4 fold of domain I and the
PRPP binding motif (β9-α7) of domain II, the PRT signature fold (Figure
1.4). The histidine binding loop in domain III is also found to be composed
of generally conserved residues. The sequence of this short motif is strictly
PGXXXPT, except for in the A. thaliana enzymes where the first proline
residue is replaced by a serine.
Figure 2.3 (following page): Multiple sequence alignment of charac-
terised ATP-PRT long form enzymes. The alignment was created with
ClustalOmega84 and edited using ESPript.88 Secondary structure elements of
MtuATP-PRT are depicted above as bolt arrows (β strands) and spirals (α helices).
Residues are coloured according to conservation: absolutely conserved (white, red
box), partially conserved (red) and not conserved (black). Residues known to in-
teract with histidine (red), 5’-phospho-ribose (green) and adenine (blue) groups
are highlighted below. Organism three letter code: M. tuberculosis (Mtu), M.
thermautotrophicus (Mth), C. glutamicum (Cgl), A. thaliana (Ath), S. enterica
subsp. enterica Typhimurium (Sen), E. coli (Eco) and C. jejuni (Cje).
35
36
2.3 Cloning and expression
Successful cloning of the C. jejuni hisG, locus tag Cj1597, was achieved us-
ing the Invitrogen Gateway R© Cloning system as described in section 6.1.16.
With the C. jejuni subsp. jejuni NCTC 11168 genomic DNA, supplied by
ATCC R© (ATCC strain identification: 700819), as the template, a linear DNA
construct of the estimated size (approximately 950bp), verified by agarose
gel electrophoresis, was generated in three consecutive rounds of PCR. This
construct included a tobacco etch virus (TEV) protease cleavage site imme-
diately upstream of the hisG gene. The linear fragment was inserted into
the shuttle vector pDONR
TM
221 using the Gateway R© BP Clonase
TM
and
transformed into TOP10 cells for selection, followed by plasmid propagation.
The purified plasmid was sequence verified and used in the LR Clonase
TM
reaction, which transferred the C. jejuni hisG gene into the expression vector
pDEST
TM
17 with an N-terminal poly-histidine tag (His-tag).
The resulting construct was used for heterologous expression in BL21*
(DE3) cells. SDS-PAGE of the induced crude lysate showed successful over-
expression, with one major band just below the 40 kDa molecular weight
marker corresponding to the estimated size of tagged CjeATP-PRT (approx-
imately 37.2 kDa), but situated mostly (>90 %) in the insoluble fraction.
In order to produce more overexpressed protein in the soluble fraction, the
pDEST
TM
17 CjeATP-PRT construct was transformed into the Chaperone
3 cell line. This resulted in an increase in the amount of soluble CjeATP-
PRT. ATP-PRT activity was detected in the soluble crude using the standard
ATP-PRT activity assay (section 6.1.33) and this final expression construct
was thus used for all protein purification.
2.4 Purification
A purification strategy was devised based on the removable N-terminal His-
tag. The enzyme was isolated from the crude lysate by immobilised metal
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affinity chromatography (IMAC) using Ni2+-charged nitrilotriacetic acid (Ni-
NTA), then desalted and freed of the His-tag by TEV protease treatment.
The tag-free enzyme was then to be reverse purified by a second IMAC step
and finally purified and desalted by size exclusion chromatography (SEC).
However, two major problems were encountered with this protocol. Firstly,
TEV protease was less efficient at removing the His-tag than expected. A
series of different incubation conditions, designed to test the influence of
TEV protease concentration, temperature, stirring speed, and time, were at-
tempted to improve the cleavage efficiency. An initial incubation at 37◦C and
agitation at 180 rpm, followed by a period without shaking or stirring at 4◦C
for 3 days gave the best improvement in tag cleavage efficiency. However,
even under these optimised conditions a small portion of tagged enzyme re-
mained. The removal of the tag had no adverse effects on enzyme activity
(Table 2.1). Secondly, CjeATP-PRT showed an unexpected strong intrinsic
affinity to the column. This was noticeable both in the initial IMAC, where
the elution occurred relatively late (at 250–300 mM imidazole concentra-
tion), but mostly the second IMAC passage when the tag-free CjeATP-PRT
bound the column instead of eluting in the loading buffer (containing 20 mM
imidazole) as expected. This led to changes in the purification protocol.
Table 2.1: Purification steps for CjeATP-PRT. Enzyme activity was mea-
sured at each purification step using the standard assay described in section 6.1.33.
Protein concentrations were determined according to section 6.1.29 to calculate the
specific activity. Recovery is a measure of the loss of the total activity of the whole
preparation.
Purification step Total activity [U] Specific activity [U mg−1] Recovery [%]
Soluble crude 334 ± 48 0.11 ± 0.02 100 ± 14
IMAC eluate 246 ± 8 1.70 ± 0.06 74 ± 2
TEV protease treated 237 ± 8 1.64 ± 0.05 71 ± 2
SEC eluate 171 ± 8 2.44 ± 0.12 51 ± 2
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To overcome the problems caused by the high affinity of the protein
to the Ni-NTA resin, a different column material was selected for the IMAC
purification steps. By using a HiTrap
TM
TALON R© crude column the elution
of the protein was shifted towards the earlier part of the elution gradient
suggesting a lower affinity. This also reduced the imidazole concentration
of the eluate significantly, which positively influenced the protein stability
and rendered the desalting step unnecessary. Since the protein was found to
bind to the IMAC column in the absence of the His-tag, the second IMAC
passage was removed from the purification protocol. During the experiments
Figure 2.4: CjeATP-PRT purification steps. Samples were taken after each
purification step and assessed for purity by reducing SDS-PAGE in 10 % Bis-Tris
gels using MES or MOPS buffer. Denaturation was performed by incubation at
95◦C for 2 min before sample loading. The main species in all preparations was
equivalent to the monomeric size of CjeATP-PRT, which consistently appeared on
the gel at an apparent higher molecular weight (tagged: 37.2 kDa, untagged: 33.7
kDa). The minor impurity carried through all purification steps (≈ 65 kDa) is most
likely dimeric CjeATP-PRT, appearing perhaps due to insufficient denaturation
time. The band at 30 kDa corresponds to TEV protease while the low molecular
weight band (≈ 4 kDa) is the cleaved tag. Lane labels correspond to: MWM -
Molecular weight marker, IC - Insoluble crude, SC - Soluble crude, IMAC - Eluate
from IMAC, TEV - TEV protease treated, SEC - Eluate from SEC.
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to improve the purification protocol it was observed that the overall yield was
dependent on the length of time the cell pellet had been stored. Generally a
fresh, unfrozen pellet gave a much higher yield than a frozen pellet and the
older the frozen pellet the lower the yield.
The final purification procedure was the following. The cells were lysed
immediately following harvest, when possible, and the CjeATP-PRT was
isolated from the soluble fraction by IMAC. The eluate underwent TEV
protease treatment and was purified and desalted by the final SEC step. The
pure protein was either kept at 4◦C for immediate use or concentrated and
flash frozen. All steps were performed as described in detail in chapter 6.
Figure 2.4 shows the purity of the CjeATP-PRT after each step and Table
2.1 lists the corresponding activities. With this protocol an overall yield of
15–20 mg pure CjeATP-PRT per litre of liquid culture was achieved.
2.5 Determination of molecular weight
The molecular mass of the purified CjeATP-PRT was determined to be
33695.2 g mol−1 by electrospray ionisation mass spectrometry. This value
is in close agreement with the theoretical value of 33696.2 g mol−1 calcu-
lated for the 300 amino acid sequence, which includes the complete native
CjeATP-PRT open reading frame and a single N-terminal glycine residue
left over from the truncated tag. A peak corresponding to a tagged version
of the enzyme was not detected.
2.6 Kinetic properties
Detailed kinetic characterisation of the pure CjeATP-PRT was performed as
it is essential to understand the functionality of the enzyme. The ATP-PRT
reaction is the reversible conversion of ATP and PRPP into PR-ATP and PP.
It is possible to follow the production of PR-ATP directly by the increase of
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absorbance at 290 nm due to the increased aromaticity of PR-ATP compared
to ATP. Using one of the substrates in excess (usually ATP) this increase
is also directly proportional to the consumption of the limited substrate.
All measurements of kinetic activity that are described here were performed
using a standard assay (section 6.1.33) following the comprehensive kinetic
analysis of the SenATP-PRT enzyme,17,18,28 with minor adjustments that
are described in the following sections.
2.6.1 Pyrophosphatase
The reaction catalysed by the ATP-PRT is an equilibrium (Figure 1.2). In
the conditions of the assay, this equilibrium lies at approximately 50–55 % in
the biosynthetic direction with a determined Keq of 0.9. To ensure the com-
plete turnover of all substrate and eliminate the possible effects on the initial
rate measurements, the assay was supplemented with an auxiliary enzyme,
inorganic pyrophosphatase (EC: 3.6.1.1). Pyrophosphatase catalyses the ir-
reversible hydrolysis of PP into phosphate removing all PP, which drives the
ATP-PRT reaction to completion.
For this study the E. coli inorganic pyrophosphatase wild type (EcoPPase)
was cloned using the Gateway R© Cloning procedure, expressed, and purified
using the introduced His-tag (section 6.2.2). The activity of the purified
EcoPPase was tested by adding it to the reaction after the equilibrium had
been established, which resulted in a second absorbance rise corresponding
to the complete turnover of the limiting substrate (in most cases PRPP).
It was also possible to follow the CjeATP-PRT reaction in the reverse
direction, where PR-ATP and PP are consumed to produce ATP and PRPP.
When CjeATP-PRT was mixed only with PR-ATP and PP a decrease in
absorbance was observed. After it had reached the equilibrium point the
addition of EcoPPase reversed the direction and led to an increase in ab-
sorbance corresponding to the production of PR-ATP (Appendix A).
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2.6.2 General behaviour
CjeATP-PRT retained catalytic activity over a long period of time when
stored at 4◦C. When stored at room temperature the first significant decrease
in enzyme activity (8 %) was seen after 48 hours, whereas rapid freeze/thaw
cycles had a strong negative effect with more than 60 % activity loss after the
second cycle (Figure 2.5). Together with the finding that fresh cell pellets
produce the highest protein yield it can be assumed that freezing adversely
affects the enzyme both in vitro and in vivo.
Figure 2.5: Activity decay over time. Relative activity was measured un-
der standard assay condition using 21.2 µg mL−1 CjeATP-PRT. The activity of
freshly purified enzyme was monitored over the course of a week while stored at
room temperature (green) or -80◦C being frozen and thawed once between each
measurement (red).
As for other kinetically characterised ATP-PRT enzymes, CjeATP-
PRT activity is dependent on the concentration of Mg2+ ions in the assay
solution, as well as the concentration of salt (NaCl and KCl) used.28,89 To
determine the optimal assay conditions these parameters were investigated
in more detail. The results are shown in Figure 2.6. CjeATP-PRT showed
increased activity over a concentration range of 20–250 mM for NaCl and
20–300 for KCl. The maximum activity measured in the presence of salt was
about 40 % higher than when no salt was added to the assay. Roughly 120
% activity was measured with 100 mM NaCl or 50 mM KCl. A mixture of
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50 mM of each salt had approximately the same effect, but was surpassed
by combinations of 100 mM NaCl or KCl with 50–100 mM of the other
salt. Above an overall salt concentration of 500–600 mM the activity slowly
decreased to a measured minimum of 41 % at 600 mM KCl and 500 mM
NaCl. The minor advantage of potassium over sodium is likely due to their
different position in the Hofmeister series. K+ is less chaotropic than Na+,
which might in turn increase the stability of the enzyme. As a result of this
analysis, the standard assay used in this work contained 100 mM NaCl and
50 mM KCl.
Figure 2.6: Influence of Na+, K+ and Mg2+ concentration on the activity
of CjeATP-PRT. Specific activity was measured under the conditions described
in section 6.2.3 and normalised against the activity in the absence of metal(s). The
magnesium dependence is shown as a scatter graph with lines directly connecting
the single measurements (green). Inset: three dimensional bar graph showing the
relative activity of CjeATP-PRT in the presence of 36 Na+ and K+ combinations.
With increasing K+ concentration, the bar colour changes gradually from green to
red.
The optimal concentration of Mg2+ for CjeATP-PRT in the assay was
determined in the presence of 100 mM NaCl and 50 mM KCl. After an initial
sharp rise maximal activity was reached at a concentration between 10 and 20
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mM. Further increasing the Mg2+ concentration, the relative activity slowly
levelled off to approximately 170 % of the initial activity at 0 mM Mg2+. The
optimal Mg2+ concentration for CjeATP-PRT was higher than the reported
value for SenATP-PRT28 (9–10 mM) in the presence of 5 mM ATP.
It is possible that the labile substrate PRPP is subject to hydrolysis
under assay conditions forming PP and ribose-5-phosphate (R5P). To confirm
that it was stable, PRPP (120 µM) was incubated for 1 h in a complete assay
mix, without the second substrate ATP, before the ATP-PRT reaction was
initiated with the addition of ATP. A second assay was prepared lacking
only the CjeATP-PRT and treated in the same manner. Both initial rate
and total turnover were measured and compared to an identical assay that
had been initiated without incubation time. Approximately 9 % of the PRPP
had been lost after 1 h in the reaction lacking ATP and over 18 % in the
reaction lacking CjeATP-PRT, showing an unexpected, stabilising effect of
CjeATP-PRT on PRPP under assay conditions.
2.6.3 Kinetic parameters
Michaelis-Menten constants (KM) for the substrates ATP and PRPP were
determined from non-linear fitting (2.7). Both KM values were found to
be in the micro-molar range with the KM(ATP) being about 6-fold larger.
The CjeATP-PRT showed consistently low turn-over rates. The obtained
Michaelis-Menten constants compare well to previously published data on
SenATP-PRT28 but are 3-fold and 6-fold lower than data reported for MtuATP-
PRT89 and AthATP-PRT87 respectively. A summary is given in Table 2.2.
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Figure 2.7: Determination of CjeATP-PRT kinetic parameters. Initial
velocity data for CjeATP-PRT was collected according to sections 6.1.33 using
the substrate concentrations described in section 6.2.3. Non-linear fitting was
performed using GraphPad Prism version 6.00 (GraphPad Software).
Table 2.2: Comparison of ATP-PRT kinetic constants. Kinetic constants of
CjeATP-PRT were determined under the conditions described in section 6.2.3 and
compared to values reported for SenATP-PRT,28 AthATP-PRT87 and MtuATP-
PRT.89
Organism KM (ATP) [µM] KM (PRPP) [µM] kcat [s
−1]
C. jejuni 97 ± 10 15 ± 1 1.8 ± 0.1
S. Typhimurium28 110 15 n.d.
A. thaliana87 600 130 n.d.
M. tuberculosis89 263 ± 63 49 ± 6 n.d.
45
2.6.4 Binding mechanism
Enzymatic reactions with multiple substrates (and products) can be classified
according to the sequence of substrate binding. Two main mechanisms can
be differentiated. In the sequential mechanism the enzyme binds substrate
molecules sequentially prior to turn over. The products are then released
from the active site one by one. Binding and release may either follow a
strict order (ordered sequential) or not (random sequential). In the alterna-
tive ping-pong mechanism the enzyme only binds and turns over one sub-
strate at a time, alternating between states with different substrate affinities.
The double reciprocal plots of the activity sets measured for an enzyme at
constant concentrations of one of the substrates either intersect (sequential
mechanism) or they are parallel (ping-pong mechanism).
CjeATP-PRT was tested for its binding mechanism in the biosynthetic
direction reaction by measuring a grid of non-saturating substrate concentra-
tions (6.2.3). The resulting data shows clear evidence for a sequential binding
mechanism as the theoretical extensions of the plots converge (Figure 2.8).
Figure 2.8: Sequential binding mechanism. Lineweaver-Burk plot of the ini-
tial rates measured for the biosynthetic direction reaction of CjeATP-PRT. Rates
were measured at PRPP concentrations between 1 and 200 µM and the plotted
ATP concentrations were: 40 µM (red), 80 µM (orange), 200 µM (green), 400 µM
(blue) and 2.0 mM (purple). The lines merge close to the X-axis, representative
of a sequential binding mechanism.
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This is consistent with previous findings for ATP-PRT from other
species.28 Further kinetic analysis concerning the type (ordered vs. random)
have not been made as neither the product PR-ATP nor a mimic of PR-ATP
were available (in sufficient quantities) for product inhibition studies.
2.6.5 Inhibition
In accordance with previous investigations on long form ATP-PRT enzymes,
CjeATP-PRT was found to be inhibited by AMP and histidine (Table 2.3).
Inhibition studies for these two inhibitors were performed against both sub-
strates and the resulting data was fitted with the equations for all four pos-
sible inhibition modes. The AMP inhibition data against both substrates
was consistent with a competitive model yielding values Ki(AMP) around
300–400 µM, indicating a relatively weak effect under assay conditions. A
non-competitive model produced the best fit for the histidine inhibition data
against both substrates with Ki values of around 40–50 µM (Appendix C).
Table 2.3: Inhibition constants of AMP and histidine. Ki values for AMP
and histidine on CjeATP-PRT were determined as described in section 6.2.3.
Inhibitor Inhibition mode KiATP [µM] KiPRPP [µM]
AMP Competitive 356 ± 22 382 ± 34
Histidine Non-competitive 44 ± 7 40 ± 1
While both histidine and AMP are inhibitors individually, their effect
is increased when both are present. This synergistic effect was clearly ob-
servable at low concentrations when both inhibitors only marginally affected
the activity. Addition of both inhibitors to the assay resulted in a significant
drop in activity that was larger than the theoretical additive value of both
inhibitors separately (Figure 2.9A). The synergy is also evident by plotting
the reciprocal initial velocities in the presence of different histidine concen-
trations against the AMP concentration (Figure 2.9B). The resulting graphs
47
are curved and not linear as would have been expected if histidine and AMP
were acting independently of each other.
Figure 2.9: Synergistic inhibition by AMP and histidine. Activity was
measured according to section 6.1.33 using 2 mM ATP and 0.3 mM PRPP. The
influence of the two inhibitors on each other is depicted as A: Bar graphs show-
ing the inhibitory response to the relative activity in the presence of no inhibitor
(none), 2 mM AMP (AMP), 20 µM histidine (his) and 2 mM AMP plus 20 µM
histidine (syn). The activity of the uninhibited enzyme reduced by both individual
inhibitor responses is given as a theoretical comparison (sum). B: Reciprocal plot
of initial velocity against AMP concentration at four different histidine concentra-
tions: 50 µM (blue), 30 µM (green), 20 µM (yellow) and 0 µM (red). Exponential
fits to the data points are displayed as black dotted lines.
2.7 Ligand binding
The binding interactions of the ATP-PRT with its natural ligands are largely
unknown. The structural information available features only the inhibitors
histidine and AMP,26,35 but there are at least eight natural ligands known
to bind to ATP-PRT, each of two substrates and products, Mg2+, and three
inhibitors. This creates a complex network of potential interplay between
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multiple ligands and the protein. Having kinetically characterised CjeATP-
PRT, the effects of ligands on the protein were investigated using calorimetry.
The stoichiometry, binding affinity and thermodynamics of ligand interac-
tions with CjeATP-PRT were studied. This was mostly achieved through
the application of ITC, which had not previously been reported for ATP-
PRT enzymes.
2.7.1 Isothermal titration calorimetry
To investigate the binding interactions of CjeATP-PRT with its ligands, ITC
was used to measure the dissociation constants of four natural ligands alone
and in the presence of a second ligand. All measurements were performed as
described in section 6.2.4 (Figure 2.10).
Binding of the substrates ATP and PRPP to CjeATP-PRT was mea-
sured individually, with Kd values, calculated from the fit to a one-site model,
of 158 ± 13 for ATP and 122 ± 8 for PRPP, which are respectively 1.6-fold
and 6-fold higher than the determined apparent KM values in the presence of
saturating concentrations of the corresponding second substrate. Contrary
to expectations, the enzyme bound PRPP with a dissociation constant in
the same order of magnitude as that determined for ATP (Table 2.4). The
large difference to the apparent KM therefore indicates that PRPP binding is
strongly affected by the presence of ATP. Unfortunately it was not possible
to study the direct influence of the substrates to one another as turnover
would have occurred in the cell when titrating one substrate into the cell
holding CjeATP-PRT saturated with the second substrate.
Figure 2.10 (following page): Ligand binding of CjeATP-PRT. ITC bind-
ing curves were measured under the conditions described in section 6.1.39 and
6.2.4, subtracted by their corresponding heat of dilution data series and fitted us-
ing OriginLab R© version 7.0. Single plots are showing the binding of A: ATP, B:
PRPP, C: AMP, D: Histidine, E: ATP in the presence of histidine, F: AMP in the




Table 2.4: Dissociation constants. Dissociation constants of CjeATP-PRT
ligands were determined by ITC according to section 6.2.4. A stoichiometry for
the histidine titration cannot be determined (ND) due to the type of fit used.
Ligand ATP PRPP AMP Histidine
Kd [µM] 158 ± 13 122 ± 8 51 ± 4 19.3 ± 0.2, 14.5 ± 0.2,
36 ± 1, 50 ± 1, 47 ± 1
Stoichiometry 1.07 ± 0.08 0.72 ± 0.05 1.00 ± 0.04 ND
The investigation of the inhibitor binding properties of CjeATP-PRT
showed two distinctly different results. AMP binding fits a standard one site
model but the resulting Kd is 6–8-fold lower than the Ki values measured ki-
netically. Histidine on the other hand consistently exhibited a complex bind-
ing behaviour that was only able to be fitted by applying a sequential model
with ≥ 4 binding events. This may suggest a strong cooperative effect of the
individual binding sites of the enzyme complex, a conformational change of
the enzyme, or both simultaneously. The Kd values determined from the fit
are close to the kinetic inhibition constants, confirming the strength of this
interaction.
To investigate the competitive relationship of AMP and ATP, AMP
was titrated into the enzyme in the presence of 1 mM ATP. The data was
still consistent with a one site model. The resulting change in the Kd of
AMP, about 3-fold higher than in the absence of ATP, confirmed that both
molecules are competing for the same binding site (Table 2.5). This explained
why the kinetically determined Ki value measured in the presence of 2 mM
ATP (around 400 µM), was a lot higher than the Kd value measured in the
absence of ATP.
Strong evidence for the synergistic effect of AMP and histidine was
found by titrating AMP into CjeATP-PRT completely saturated with his-
tidine, or vice versa. Not only did the affinity of the enzyme for each in-
hibitor increase significantly in the presence of the other (Table 2.5), but
the appearance of the histidine titration curve was altered notably. The ini-
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Table 2.5: Interference of CjeATP-PRT ligands. Interference of CjeATP-
PRT ligands was measured using ITC according to section 6.2.4. Dissociation
constants and stoichiometry were determined by fitting the data to a single site
model (AMP) or a sequential model (histidine). Abbreviations used are: no bind-
ing observed (NB), cannot be determined (ND).
Titrated ligand ATP AMP AMP Histidine
Ligand in cell Histidine ATP Histidine AMP
Kd [µM] NB 83 ± 8 8.3 ± 0.2 4.8 ± 0.7, 2.3 ± 0.1
Stoichiometry ND 1.1 ± 0.1 1.14 ± 0.01 0.9 ± 0.2
tial strong exothermic signal disappeared, leaving the distinctive cooperative
shape of two binding events. This demonstrates clearly that the presence
of AMP alters the binding interactions for histidine. It also confirms that a
bi-directional signal transduction exists between the active site, where AMP
binds, and the allosteric histidine binding site.
2.7.2 Influence on thermal stability
To further investigate the influence of ligand binding to the CjeATP-PRT,
thermal stability measurements were performed using differential scanning
calorimetry (DSC) and differential scanning fluorimetry (DSF) (section 6.1).
Limited success was achieved with the DSF experiments as an initial high
fluorescence signal was observed in all samples, with the exception of the
sample containing AMP and histidine (Figure 2.11). A high initial signal is
usually indicative of premature protein denaturation. In the case of CjeATP-
PRT, the signal decreased with increasing temperature prior to displaying a
typical melting behaviour.
Since the known ATP-PRT ligands are generally very polar and the
enzyme showed no sign of destabilisation prior to the experiment, the initial
high fluorescence was interpreted as nonspecific binding of the dye to the
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enzyme complex. Unfortunately information on possible specific site inter-
actions is lacking as the molecular structure of the SYPRO R© Orange dye is
proprietary. The high background reading may have altered the properties
of the melting event. Hence DSC experiments were performed to confirm the
DSF observations.
Figure 2.11: DSF analysis of CjeATP-PRT. Melting curves (solid lines) of
0.1 mg mL −1 enzyme samples were determined according to section 6.1.37 in the
presence of 5 mM MgCl2 and no ligand (green), 2 mM AMP (red), 1 mM histidine
(blue) and a mix of 2 mM AMP and 1 mM histidine (purple). A water blank is
given in black. The first derivatives (dotted lines) show the inflection points of the
melting curves, which represent the observed average Tm values.
According to the DSF results, pure, untreated enzyme is stable up to
57.5 ◦C in the presence of 5 mM MgCl2 prior to thermal denaturation. The
addition of AMP shifted the melting temperature (Tm) by 3
◦C upwards,
an effect that was enhanced even further with a mixture of AMP and his-
tidine seen as a shift of 5 ◦C, whereas the addition of histidine alone only
altered the melting temperature by 2 ◦C. The presence of the substrate ATP
on the other hand had no influence on the melting temperature. Most in-
terestingly, the AMP plus histidine sample showed low initial dye binding
leading to the conclusion that the binding of AMP and histidine must lead
to a change of enzyme shape or dynamics rendering the enzyme more rigid
and less susceptible to thermal denaturation.
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Very similar results were acquired from the DSC experiments (Figure
2.12), in which the stabilising effects of AMP and histidine were confirmed.
The thermal shifts measured by DSC are in close agreement with the DSF
values, althought the Tm values measured were consistently 3
◦ higher, which
is likely to be caused by the faster temperature ramping speed of the DCS
experiments (1 ◦C/min vs. 0.2 ◦C/20 s). A summary of all resulting Tm
values is given in Table 2.6.
Figure 2.12: DSC analysis of CjeATP-PRT. DSC measurements were per-
formed under standard assay conditions with a MgCl2 concentration of 5 mM. The
resulting melting curves were baseline subtracted (solid lines) and fitted against
a single melting event (dashed lines). Lines are coloured according to the ligand
present in the experiment: none (green), histidine (blue), AMP (red), histidine
and AMP (purple).
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Table 2.6: Thermostability of CjeATP-PRT. Melting temperatures were de-
termined by DSF and DSC (sections 6.1.37 and 6.1.38) in the presence of different
Mg2+ concentrations and known ligands. ND stands for not determined.
Additives DSF DSC
No ligand, no Mg2+ 54.4 ± 0.2 ◦C ND
No ligand, 0.5 mM Mg2+ 56.7 ± 0.1 ◦C ND
Mo ligand, 5 mM Mg2+ 57.5 ± 0.1 ◦C 60.7 ± 0.1 ◦C
2 mM ATP, 5 mM Mg2+ 57.8 ± 0.1 ◦C ND
2 mM AMP, 5 mM Mg2+ 61.1 ± 0.3 ◦C 64.4 ± 0.2 ◦C
1 mM histidine, 5 mM Mg2+ 57.6 ± 0.1 ◦C 62.5 ± 0.1 ◦C
2 mM AMP, 1 mM histidine, 5 mM Mg2+ 62.3 ± 0.1 ◦C 66.6 ± 0.1 ◦C
2.8 Oligomeric state analysis
2.8.1 Analytical size exclusion chromatography
The oligomeric state of purified CjeATP-PRT has been determined by an-
alytical size exclusion chromatography (section 6.1.26) at 1.0 and 0.05 mg
mL−1 enzyme concentrations at pH values of 8.5 and 7.5. The outcome was
identical in all cases. A single peak eluted from the column at 11.4 mL
corresponding to a mass of 204 kDa when subjected to linear regression ob-
tained from the protein standards, which is in very close agreement with the
theoretical mass of a hexamer (202 kDa).
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Figure 2.13: Low concentration analytical size exclusion chromatogra-
phy run of CjeATP-PRT. SEC was performed on 0.05 mg ml −1 CjeATP-PRT
using a Superdex
TM
200 10/300 GL column as described in section 6.1.26. The
absorbance of the protein sample was monitored at 280 nm (green, solid) and 214
nm (pink, dashed) due to the low extinction coefficient of CjeATP-PRT at 280
nm. Inset: Calibration curve. The molecular weight of the standards proteins
(Log(MW)) is plotted on a logarithmical scale against their normalised elution
volumes (VE/V0). The void volume (V0) was determined using Blue Dextran.
The calculated molecular weight of the CjeATP-PRT species is displayed as an
open circle.
2.8.2 Static light scattering
A similar technique used to probe the quaternary structure of an enzyme
is static light scattering (SLS). This method effectively combines size exclu-
sion chromatography with the measurement of refractive index (RI), light
scattering (LS), and viscosity (section 6.1.40). As observed in the analytical
size exclusion experiment, only a single species was detected corresponding
to a molecular mass of 188 kDa (Figure 2.14), which is slightly below the
theoretical molecular mass of the hexamer, 202 kDa.
56
Figure 2.14: Static light scattering of CjeATP-PRT. The refractive index
(solid green line) of 1 mg mL −1 CjeATP-PRT was determined as described in
section 6.1.40. The molecular weight of the mono-disperse species (black) eluting
between 10 and 12 mL was calculated, using bovine serum albumine (BSA) as
standard, and compared to the theoretical molecular mass of the CjeATP-PRT
hexamer (red dashed line).
2.8.3 Analytical ultracentrifugation
Due to the low extinction coefficient of CjeATP-PRT around 280 nm it was
necessary to perform all AUC experiments at 230 nm detection. An initial
run was performed with concentrations ranging from 1.2–0.13 mg mL−1 which
confirmed the results from SEC and SLS experiments. Only one species
was detected with a sedimentation coefficient of 7.8, which corresponds to a
molecular mass of 186 kDa.
The advantage of AUC over all other used methods is its high sensi-
tivity. To decisively confirm the presence of the hexameric species even at
very low protein concentrations another dataset was collected, at concentra-
tions ranging from 0.1 to 0.025 mg mL−1, with identical outcome. The un-
normalised size distribution data (Figure 2.15) shows only one major species
present in the sample. Using the SEDFIT parameters the obtained sedimen-
tation coefficient of 7.9 was converted to a molecular mass of 182 kDa. The
three minor peaks at 3.0 S, 4.8 S and 11.2 S were converted to molecular
masses 40 kDa, 87 kDa and 320 kDa accordingly, which would be closest to
the masses of a theoretical monomer (33.7 kDa), dimer (67.4 kDa) and de-
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Figure 2.15: Size distribution function of CjeATP-PRT. AUC experiments
were conducted according to section 6.1.41. The resulting data was analysed using
SEDFIT.90 The plot shows the data of all three used enzyme concentrations un-
normalised from highest to lowest signal: 0.1 mg mL −1 (green), 0.05 mg mL −1
(blue) and 0.025 mg mL −1 (red).
camer (337 kDa), but did not change in relation to the main peak. Since the
lowest measured concentrations is about two times higher than that used in
all kinetic assays, it is evident that the vast majority of CjeATP-PRT exists
as a hexamer in solution under the given conditions.
2.9 Crystal structure
2.9.1 Crystallisation
During the initial crystallisation trials (section 6.1.44) CjeATP-PRT did not
crystallise at high protein concentration due to the formation of heavy pre-
cipitate. Instead, the optimal protein concentration was found to be 2–4
mg mL−1 where small or thin crystals would form in multiple conditions
of both PACT and JCSG+ screens. Unfortunately none of the conditions
yielded crystals suitable for diffraction. Histidine was therefore added to the
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crystallisation conditions at a concentration of 1 mM, which resulted in the
formation of cuboid-shaped crystal in PACT screen condition F4 (section
6.2.5). Fine-tuning of this condition delivered the following crystallisation
condition: 100 mM BTP pH 6.5, 200 mM KSCN, 1 mM histidine and 13–
14 % w/v polyethylene glycol (PEG) 3350. Crystals formed overnight and
continued to grow for two days after the drops were put down (Figure 2.16).
The chosen cryoprotection procedure preserved the crystal appearance. All
diffraction data was acquired at the MX beamlines of the Australian Syn-
chrotron using the cryojet and a constant beam energy of 13000 eV.
Figure 2.16: CjeATP-PRT crystals. Photographs taken of drops containing
CjeATP-PRT crystals. A: histidine cocrystal, condition derived from PACT F4:
0.1 M BTP, 0.2 M KSCN, 13–14 % w/v PEG 3350, 1 mM histidine, pH 6.5. B:
ATP cocrystals, condition derived from Clear Strategy I A9: 0.1 M Na acetate,
0.1 M MgCl2, 13–15 % w/v PEG 4000, 10 mM ATP, pH 5.5.
After the initial success the screening for suitable crystallisation condi-
tions continued focussing on co-crystallisation with AMP and ATP as well
as a ligand-free form. Crystals were grown successfully from several addi-
tional conditions (section 6.2.5). Diffraction data was acquired for two of
these, featuring ligand density for ATP, and AMP and histidine (Table 2.7).
Promising diffraction data was also collected from a ligand-free crystal, but
unfortunately due to the low crystal symmetry and an error during collection.
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2.9.2 Molecular replacement strategy
The unit cell and symmetry (P1211) obtained were different from the pre-
viously published ATP-PRT structures of E. coli, M. tuberculosis, and M.
thermautotrophicus. As a result early attempts to solve the structure by
molecular replacement were unsuccessful. All attempts made to obtain a
heavy atom data set to solve the phases also failed. Neither the soaking
in bromide nor the use of a xenon pressure chamber resulted in suitable
diffraction from formed crystals and the substitution of thiocyanate in the
crystallisation condition with selenocyanate failed to generate crystals.
The phases were finally solved by applying a complex molecular replace-
ment strategy. It was expected from the unit cell dimensions of the initial
(Histidine bound) dataset that six complete chains were present. Initially
only domain I and II of the E. coli ATP-PRT structure (PDB code: 1H3D)
were used to find a suitable dimer. This dimer was then used as model in
a consecutive search resulting in a double circular arrangement of the six
truncated chains that largely resembled the hexameric structure published
previously.26 Starting from this solution, the ACT domains were manually
built into the density on all six chains through multiple refinement rounds
resulting in the first complete hexameric structure of CjeATP-PRT (PDB
code: 4YB5). While the completely refined hexamer was successfully used
as a search model for molecular replacement to solve the AMP and histidine
bound structure (PDB code: 4YB6), it was found unsuitable for the dataset
containing ATP in spacegroup P1. By applying the same strategy as above,
in this case 12 complete chains, ergo two whole hexamers (overall RMSD =
0.563 Å), were resolved (PDB code: 4YB7). Three effector molecules were
observed in the crystal structures of CjeATP-PRT. While both AMP and
histidine bound ATP-PRT long form structures have been described previ-
ously, the binding of ATP is unprecedented in the ATP-PRT literature. In
all cases, the ligand molecules were added last into the density maps during
refinement to avoid the introduction of model bias.
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Table 2.7: Crystal parameters, data collection, and refinement statistics.
Histidine Histidine/AMP ATP
Data collection
Crystal system monoclinic monoclinic triclinic
Space group P1211 P1211 P1
Unit cell parameters
a, b, c [Å] 91.14, 123.22, 95.70 91.87, 124.91, 92.81 91.67, 91.83, 154.90
α, β, γ [◦] 90.00, 110.66, 90.00 90.00, 115.86, 90.00 101.11, 95.21, 118.14
Resolution range [Å] 89.55–2.24(2.28–2.24) 50.00–1.98(2.01–1.98) 50.00–2.20(2.24–2.20)
Measurements 472477 493057 839825
Unique reflections 94235 127994 212958
Completeness 89.9 (89.7) 98.1 (96.9) 91.8 (97.3)
Redundancy 5.0 (4.5) 3.9 (3.9) 3.9 (4.0)
I /σ(I ) 9.9 (2.4) 14.6 (2.9) 9.8 (1.8)
Rmerge 0.093 (0.795) 0.059 (0.422) 0.076 (0.841)
CC1/2 0.997 (0.625) 0.998 (0.837) 0.982 (0.568)
Wilson B value [Å2] 43.8 21.3 36.8
Matthews coefficient 2.48 2.37 2.72
Refinement
Resolution [Å] 48.04–2.24 41.34–1.98 48.06–2.20
Rcryst 0.211 0.203 0.236
Rfree 0.241 0.220 0.259
Chain length 300 300 300
Observed residues 1753 1758 3531
Water molecules 128 714 365
Others 6 histidine, 8 SCN−,
5 K+, 3 PEG
6 histidine, 6 AMP,
9 Mg2+, 6 PEG
12 ATP, 12 Mg2+,
6 PO3−4 , 1 acetate
Mean B [Å2]
Protein 50.03 24.58 47.13
Water 38.62 26.94 35.20
Other 61.30 45.09 55.83
Ligand 34.64 13.06, 24.81 51.27
RMSD
Bond lengths [Å] 0.012 0.009 0.009
Bond angles [◦] 1.465 1.372 1.470
Chiral volumes [Å3] 0.075 0.077 0.073
Ramachandran
Preferred % 98.56 98.36 98.22
Allowed % 1.44 1.64 1.78
Outliers % 0.00 0.00 0.00
PDB entry 4YB5 4YB6 4YB7
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2.9.3 General fold
The crystal structures of CjeATP-PRT contain six or 12 identical protein
chains in the unit cell. Each chain shows the same fold as previously deter-
mined structures, composed of 10 α helices, 16 β strands and the connect-
ing loops arranged in three discrete domains: domain I, II, and III.26,35 A
schematic of the CjeATP-PRT topology is shown in Figure 2.17.
Domain I is composed of residues 0–103 and 191–225, which form an
α-β open twisted sheet structure, or Rossmann fold, commonly found for
nucleotide binding proteins.91 In detail it consists of a central twisted six-
stranded β sheet with four parallel (β1, β3, β4 and β5) and two anti-parallel
(β2 and β11) β strands, as well as four flanking α helices, two on one side
of the β sheet (α1 and α8) and two on the other (α2 and α3). The first few
N-terminal residues are unresolved in all three CjeATP-PRT structures and
the β5 strand appeared in some chains as a loop running in close proximity
along the β11 strand.
A similar fold is adopted by domain II, comprising residues 104–190,
but the central five-stranded β sheet (strands β7, β8, β9 and β10 parallel,
and β6 anti-parallel) are strongly curved and curled around α4 and α5 on
one side while α6 and α7 sit almost parallel next to each other on the other
side. Domain II is inserted into domain I at the primary sequence level into
the loop between β5 and β11 and consequently the β5-β6 loop and the β10-
β11 loop form the only two covalent connections of the two domains. These
loops also form one boundary of the active site.
Domain III is formed from the 74 C-terminal residues (225–299) and
possesses the distinctive features of an ACT domain, an anti-parallel four-
stranded β sheet (β12 and β13, β14 and β15) with two α helices (α9 and
α10) on one side. The special feature of the ATP-PRT ACT domain is
the last C-terminal β strand β16, which sits almost perfectly orthogonal to
β15 and is donated into the ACT domain of the adjacent chain, effectively
constructing a five-stranded β sheet. Each ACT domain also houses the two
faces of the allosteric binding site for the feed-back inhibitor histidine, α9-β13
62
Figure 2.17: Secondary structure of the CjeATP-PRT single chain. The
three domains of CjeATP-PRT as 2D cartoon representation. The size of α he-
lices and β strands is proportional to the number of incorporated residues while
loop/connection length is random. Secondary structure elements are coloured ac-
cording to domain association: domain I (green), domain II (yellow), domain III
(red). Image was created using Pro-origami.92
loop on one and β12/β15 on the other side. Its inter-molecular interaction
and allosteric binding site clearly define the CjeATP-PRT ACT domain as
a functional regulatory domain.41
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The CjeATP-PRT single chain is grossly shaped like a triangular wedge
with domains I and II positioned close together and the ACT domain sitting
aside on an angle relative to the domain I - domain II axis. The ACT domain
is connected to the catalytic domain I by the long α8 helix and the short α8-
β12 loop, allowing for a certain degree of flexibility. The large active site
is situated in the cleft between domains I and II and recruits residues from
both domains of one chain. The active site ligands found in the structures
4YB6 and 4YB7 revealed some detail about the CjeATP-PRT active site
architecture. The active site can be largely split into two regions: the ATP-
binding groove of domain I and the PRPP binding site of domain II (Figure
2.18), with each area sitting on the edge of the beta sheet of the corresponding
domain. The ATP-binding site the ATP bound CjeATP-PRT includes the
coordination site for a single Mg2+ ion between two aspartate side chains
(D55 and D56) and the β and γ phosphate of ATP.
Figure 2.18: The CjeATP-PRT active site. The active site of a CjeATP-
PRT (4YB7) chain (light green), adjacent to its dimer partner chain (dark green)
and the α1-β2 loop of a neighbouring chain (brown), is represented as a surface.
Domain I is to the left of the binding site and domain II to the right. Residue R16
has intentionally been removed for better visibility as it is positioned directly above
the adenine. ATP (pink) is displayed as sticks with the coordinated Mg2+ ion (grey
sphere) in the active site. The expected binding site of PRPP is represented by
red hatching. Hetero-atoms of ATP are coloured according to element: oxygen
(red), nitrogen (blue), phosphorous (orange).
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2.9.4 ATP bound structure
The structure of the ATP bound CjeATP-PRT (4YB7) contains 12 individ-
ual chains in the unit cell, forming two homo-hexameric assemblies (Figure
2.19). Two chains each form a dimer with an approximately 180◦ rotational
symmetry. The interdomain contacts are made between the catalytic do-
mains and are located on the opposite side to their intramolecular domain
connection (β5-β6 and β10-β11 loops). This effectively combines the two
active sites of the dimer into one large cavity. The dimer interface buries
an area of approximately 1000 Å2 in all six observed dimers, corresponding
to 7 % of the overall surface of a single chain. The main contacts at the
dimer interface are made between α6 and its flanking loops (domain II) of
one chain with β1 and the β3-α2 loop (domain I) of the other chain. The
interactions of α7 (domain II) with the α1-β2 loop (domain I) also make a
small contribution. Due to the rotational symmetry, these interactions are
inversely repeated on the other side of the interface.
Three dimers in turn come together to form the hexamer. The dimers
attach side by side along their ACT-to-ACT axes, with their active sites
on the inside of the formed complex. The hollow-centred core structure is
held together by two trimeric ACT domain units, one on each end. Two
neighbouring chains in such a unit bury approximately 850 Å2 of surface
area between them (6 % of their total surface), with the predominant con-
tribution made by the ACT-ACT interface. The main points of interaction
here are the tight contacts between the C-terminal β16 and β15 and α10
of the neighbouring chain, as well as contacts between α8 of one and α10
of the other chain. According to the analysis of the structure with PDBe
PISA93 this second interface, referred to as trimer interface, was classified as
essential for the complex with a higher complex formation significance score
(CSS) than the dimer interface (Table 2.8). This is a strong indicator for the
presence of the hexamer as permanent structural and functional entity.
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Figure 2.19: Structure and multimeric assembly of CjeATP-PRT. Crys-
tal structure of the histidine bound CjeATP-PRT complex (4YB5) in the cartoon
representation as example for the general multimeric assembly of CjeATP-PRT.
A single chain is structurally divided into domain I (green), domain II (yellow)
and domain III or ACT domain (red). A: Monomer B: Hypothetical dimer C:
Hexamer, view along the trimer axis D: Hexamer, view along the dimer axis.
There are six main triangular-shaped openings to the central cavity of
the hexamer, each between the β5-β6 and β14-α10 loops of one chain and
the α1-β2 loop of the neighbouring chain. The centre of each dimer interface
also contains a small opening.
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The binding of the substrate molecule ATP in structure 4YB7 (Figure
2.20) was observed in the nucleotide binding groove of domain I, involving a
complicated network of hydrogen bonding interactions with a small number
of residues that were in part found to be conserved (Figure 2.3). The most
obvious interactions can be seen for the binding of the triphosphate moiety
of ATP, which is flanked by two arginine side chains. R54 interacts with
the γ phosphate while R16 forms hydrogen bonds to the oxygens of the α
phosphate. Q12 also reaches into the active site, which places its side chain
nitrogen in an optimal position to interact with several of the triphosphate
oxygens. Interestingly Q12 is only conserved within the enterobacterial ATP-
PRTs. All other characterised enzymes possess a proline residue in this
position, making this interaction unlikely.
Another striking feature is the presence of a Mg2+ in an octahedral
coordination. It is coordinated by the side chains of the successive aspartate
residues D55 and D56 at the start of α2, two oxygen atoms, one each from
the β and γ phosphate, and two water molecules. This coordination both
embeds the Mg2+ into the binding site of CjeATP-PRT and provides strong
interaction with the ATP triphosphate.
N75 is the only residue found within hydrogen bonding distance to
the ATP ribose. The side chain of this functionally conserved residue forms
hydrogen bonding interactions to both ribose oxygens simultaneously. The
ribose ring itself is inserted into a small cavity created by the backbone
and short sidechains of L17, G73, G102, S191, R192 and A193. Despite
the relative hydrophobicity of this pocket, water molecules were observed
surrounding the ribose 2’ and 3’ oxygens.
The adenine portion of ATP forms a single hydrogen bond to S172,
which is part of the highly conserved PRPP binding loop. It is further
held in place by hydrophobic interactions with the side chain of R16, the
binding of which to the α phosphate has been described, on one side and
L170 and C104 on the other side. This “molecular clamp” is not as rigid
as the rest of the binding interactions, allowing the adenine to adopt two
different orientations in the active site (Figure 2.21). In each of the 12 active
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Figure 2.20: ATP binding site of CjeATP-PRT. Observed binding mode
of the ATP molecule found in 4YB7. A: Real space representation of the ATP
molecule (pink) surrounded by the observed electron density (Fo-Fc map - grey
mesh) and the active site residues (white) as sticks. B: Planar plot of all ATP in-
teractions created with LigPlot+.94 Hydrogen bonds are depicted as dashed lines
labelled with distances. Hydrophobic interactions are displayed as short radial red
lines. Water molecules are displayed as cyan spots. Hetero-atoms are coloured
according to element: oxygen (red), nitrogen (blue), phosphorous (orange), mag-
nesium (green).
sites the ATP-adenine was observed in either a catalytical relevant position,
placing the N1 nitrogen close to the expected PRPP binding site, or flipped
by a 180◦rotation. Overall the observed occupancy for ATP is comparatively
poor for the adenine ring portion in all 12 chains, reflecting its rotational
freedom. Although it appears very prominent, the importance of residue
R16 for ATP binding is undermined by the fact that it is only partially
conserved, implying an auxiliary role only.
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Figure 2.21: Alternative ATP binding modes in CjeATP-PRT. Superpo-
sition of the two observed ATP binding modes found in 4YB7 surrounded by the
active site residues (white), in stick representation. The catalytically relevant ori-
entation (pink) differs from the catalytically irrelevant position (cyan) by a flip of
the adenine portion of the molecule. A phosphate is found in chains displaying the
irrelevant ATP binding mode. Hetero-atoms are coloured according to element:
oxygen (red), nitrogen (blue), phosphorous (orange), magnesium (green).
2.9.5 Histidine bound structure
The histidine bound crystal structure of CjeATP-PRT contains six individual
chains in the unit cell forming a single hexameric assembly. Overall, the 2-
fold and 3-fold symmetry, as seen in each hexamer of 4YB7, is retained with
all active sites facing the inside of the holo-enzyme complex (Figure 2.19).
The dimer interface is, as in the ATP bound crystal structure, created
by cross-over contacts between the catalytic domains of the two involved
chains, but buries a larger surface area, 1200 Å2, approximately 8 % of the
total surface of a single chain. The main contacts involve residues of α6 and
its flanking loops, as well as β7 and β8 on one chain, and residues in β1, β2,
β3 and α2 on the other chain. Helix α7 is not involved in the dimer interface
in 4YB5 at all, but the C-terminal ends of α3 of both chains come together
in the centre of the interface. The trimer interface in 4YB5 buries about
the same area as the dimer interface (1200 Å2), underlining the importance
for both interfaces in the holo-enzyme. Each interface also includes a single
histidine and a conserved water molecule, which lend additional contacts to
the overall tighter interface.
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The six triangular openings into the central cavity found in structure
4YB7 are also present in 4YB5 and are only marginally smaller (10 ±1 vs. 12
± 1 Å in width). Due to rearrangements of the dimer interface (as described
in greater detail in section 2.9.7), the small opening between the two dimer
chains is completely closed.
Histidine binding in structure 4YB5 occurs at the interface between
two adjacent ACT domains in their trimeric arrangements. This means that
one histidine is bound per chain but each chain provides two different faces
for interaction with histidine. The histidine carboxy and amino groups are
nestled into a highly conserved binding loop with the consensus sequence
PGXXXPT between α9 and β13 of one ACT domain, while the imidazole
side chain is inserted into a small cavity created by the side chains on the β
sheet of the other ACT domain. This shared binding site allows the bound
histidine molecules to act like pins that pull the ACT domains together,
creating the conformational changes described later.
Looking at the histidine binding loop of CjeATP-PRT in closer detail
reveals the coordination of the histidine carboxy oxygen atoms by four back-
bone nitrogen atoms, three from the residues V248, E249 and R250 in the
conserved binding loop, and one contributed by residue V268 on the nearby
passing β strand β14. The amino group of histidine forms interactions with
the backbone oxygen of P251 and the side chain oxygen of T252 (Figure
2.22). This absolutely conserved threonine residue has been shown to be
crucial for histidine binding,77 but it is the two proline residues P246 and
P251 paired with the flexibility of G247, which provide this little loop with
the narrow twist that is required for the observed conformation.
The binding cavity on the other side is formed by residues M230, H232,
S288 and L290. It can be roughly split in two short motifs. The first is
situated on β12 and accommodating the residues M230 and H232 (AXB
motif) and the second is part of β16 and made up by residues S288 and L290
(CXL motif). Both motifs are structurally well conserved, as the overall fold
of the ACT domain β sheet is consistent in all deposited structures, but the
sequence allows a certain variability of the participating residues. In the AXB
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Figure 2.22: Histidine binding site of CjeATP-PRT. Histidine binding
mode found in 4YB5. A: Real space representation of the histidine molecule (pink)
surrounded by the observed electron density (Fo-Fc map - grey mesh) and the
residues of adjacent ACT domains (green and orange) as sticks. B: Planar plot of
all histidine interactions created with LigPlot+.94 Hydrogen bonds are depicted
as dashed lines labelled with distances. Hydrophobic interactions are displayed as
short radial red lines. Water molecules are displayed as cyan spots. Hetero-atoms
are coloured according to element: oxygen (red), nitrogen (blue), phosphorous
(orange), sulphur (yellow).
motif, positions A and B can be populated by valine, methionine, aspartate,
asparagine or histidine. The CXL motif on the other hand appears to be
more consistent throughout species with C always being a residue with a
short side chain (either glycine, alanine, serine or aspartate), and the leucine
being absolutely conserved.
Despite the changing residue environment, the binding mode of histi-
dine in CjeATP-PRT is identical to the binding mode presented in MtuATP-
PRT (1NH8) and MthATP-PRT (2VD3). Therefore a medium side chain
length and limited polarity appear sufficient to bind the imidazole side chain
of histidine, which is found stacking with the side chain of either aspartate,
asparagine or histidine, but specific functionalities are not required. The
importance of the mostly sterically conserved motifs AXB and CXL is sup-
ported further by the finding that the substitution of residue N215 and A270
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in CglATP-PRT (equivalent to H232 = “B” and S288 = “C” in CjeATP-
PRT) to lysine and proline respectively resulted in a lower sensitivity to
histidine, with 50 % and 35 % residual activity in the presence of 2 mM
histidine compared to 10% of the CglATP-PRT wild type.77
2.9.6 AMP and histidine bound structure
While equivalent to 4YB5 in conformation, arrangement and histidine bind-
ing, the structure 4YB6 features the inhibitor AMP, which was found to
interact almost entirely with residues of the PRT signature fold in specific
residues 169–176 (β9-α7 loop). Most residues of this highly conserved se-
quence surround the phosphate moiety in a half circle, presenting their back-
bone nitrogen atoms towards it. The short polar side chains of S172, S173
and T176 provide additional anchor points for the negatively charged phos-
phate (Figure 2.23). This arrangement allows for multiple (6–12) hydrogen
bonding interactions to be formed, which give this binding site its high co-
ordination strength. It is therefore unsurprising that it was found occupied
by inorganic phosphate in the ATP bound structure (4YB7).
The most interesting finding is the coordination of H33, and potentially
also H35, of the neighbouring subunit to the bound phosphate group of AMP.
Histidine H33, along with H35, is positioned on the flexible α1-β2 loop that
protrudes into the active site upon histidine binding and effectively “caps”
the phosphate binding site.
The AMP ribose 2’ and 3’ oxygens are in close proximity to the con-
served residues D169 and E156, with which they are likely to form hydrogen
bonding interactions. As described for ATP binding, the adenine ring system
is weakly coordinated by a hydrophobic stack between R16 and L170. The
only notable difference is the inverted orientation of the purine ring system,
which is a logical consequence of the 5’-phosphoribosyl (of AMP) and 5’-
triphosphoribosyl (of ATP) groups being located on opposite sides. The side
chain of R16 was unresolved in the experimental electron density likely due
to the absence of the negatively charged triphosphate to hold it in place.
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Figure 2.23: AMP binding site of CjeATP-PRT. Observed AMP binding
mode of the ATP molecule found in 4YB6. A: Real space representation of the
AMP molecule (pink) surrounded by the observed electron density (Fo-Fc map -
grey mesh) and the active site residues (white) plus H33’ of the adjacent subunit
(green) as sticks. B: Planar plot of all AMP interactions created with LigPlot+.94
Hydrogen bonds are depicted as dashed lines labelled with the real space distances
between atoms. Hydrophobic interactions are displayed as short radial red lines.
Water molecules are displayed as cyan spots. Hetero-atoms are coloured according
to element: oxygen (red), nitrogen (blue), phosphorous (orange), sulphur (yellow).
The crystal structure 4YB6 reveals AMP binding occurs in both, the
ATP and the PRPP binding region, of the active site. The 5’-phosphate
and ribose are closely coordinated into the PRPP binding motif, with the
adenine bridging across into the ATP binding site. The identical binding
mode was observed in the crystal structure of EcoATP-PRT (PDB code:
1H3D),26 the only difference being a closer coordination by E156 and R16
and the absence of the cap (side chains of H33 and H35). In MtuATP-
PRT (PDB code: 1NH8)35 the bound AMP is flipped by 180◦. The adenine
and phosphate groups are found in approximately the same position as for
CjeATP-PRT, but the ribose is turned around and out of the active site.
There it is making hydrogen bonding contact with the side chain of aspartate
D30 of the neighbouring chain, which is equivalent to H35 in CjeATP-PRT.
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2.9.7 Comparison of active and inhibited conforma-
tions
CjeATP-PRT exists crystallographically in two distinct forms as has been
described for MtuATP-PRT previously.35 The open, or active, conformation
is observed in the absence of histidine. In the case of CjeATP-PRT this
conformation is represented by the ATP bound crystal structure (4YB7).
The closed, or inhibited, conformation is found exclusively in the presence
of the allosteric inhibitor histidine, bound at the trimer interface. Both
remaining structures of CjeATP-PRT (4YB5 and 4YB6) show the inhibited
conformation (overall RMSD = 1.39 Å). The main difference between them
is the presence/absence of AMP in the active site. Although it is a potent
inhibitor, the binding of AMP to the active site alone does not induce the
same conformational changes as histidine binding, as shown in EcoATP-PRT.
Instead the enzyme stays in the open form, ready to bind histidine.26
The differences between conformations can be seen in both the individ-
ual chain and the holo-enzyme. Ultimately, all conformational changes are
facilitated by a rotational twist of the ACT domain connection by approxi-
mately 30◦ around the flexible α8-β12-hinge, in each chain (Figure 2.24A). As
it is performed simultaneously six times per hexamer, this small movement
restructures the entire complex.
Although the changes in a single chain are small (RMSD = 1.65 Å,
between single chains of 4YB6 and 4YB7) and appear to affect the catalytic
domains to an even lesser extent (RMSD = 1.22 Å, between residues 5–215
of 4YB6 and 4YB7 single chains), they significantly change the appearance
of the holo-enzyme. Structural comparison of the CjeATP-PRT hexamer in
open and closed conformation clearly shows large discrepancies with average
RMSD values of 35–40 Å between 4YB7 and 4YB5 or 4YB6, respectively.
The open hexamer of CjeATP-PRT (4YB7) is wider in the central catalytic
core (96 ± 1 Å vs. 92 ± 1 Å) and shorter when measured from one ACT-
trimer to the other (117 ± 1 Å vs. 122 ± 1 Å), compared to the closed
conformation (Figure 2.24B). The observed overall changes can be retraced
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to changes in the two interfaces presented in CjeATP-PRT hexamers. The
analysis of these interfaces of all three crystal structures revealed significant
differences (Table 2.8).
Figure 2.24: Conformational changes caused by histidine binding. A
series of superimpositions of the open (4YB7) (green) and closed (4YB5) (purple)
conformations of CjeATP-PRT are shown in the cartoon representation to high-
light the main differences between them. A: Superimposition of the single chain on
the catalytic core domains to visualise the relative ACT domain movement. The
α8-β12-hinge is highlighted in red. B: Superimposition of the complete hexamers
shows large discrepancies in chain arrangement. C: Superimposition of a dimeric
arrangement shows a “flex” of the dimer interface. D: The open and closed ACT
domain arrangements side by side. The trimeric structure rotates and compacts
in the presence of histidine.
75
Table 2.8: CjeATP-PRT interfaces. Interfaces presented in the three crystal
structures of CjeATP-PRT were analysed using PDBe PISA.93 Values are given
as average of all individual interfaces.
Structure Interface Buried area [Å2] [%] of total area CSS
4YB5 Dimer 1181 7.8 0.361
4YB6 Dimer 948 6.3 0.327
4YB7 Dimer 996 6.5 0.377
4YB5 Trimer 1220 8.0 0.598
4YB6 Trimer 1223 8.1 0.619
4YB7 Trimer 827 5.5 0.538
The trimer interface, which is directly influenced by the binding of
histidine, is significantly larger in 4YB5 and 4YB6 with an average buried
surface of 1200 Å2 compared to 830 Å2 in 4YB7. Histidine is positioned in
the centre of the interface interacting closely with residues V248–T252 on
one chain and H232 on the other, bringing those residues closer together.
This can be quantified by the distances between the α carbon atoms of E249
and H232’ (8.8 ± 0.1 Å vs. 11.6 ± 0.3 Å), and T252 and A264’ (6.9 ± 0.1 Å
vs. 10.6 ± 0.3 Å) in 4YB6 and 4YB7, respectively.
Additionally, a conserved water molecule was observed in all histidine
binding sites in both inhibited CjeATP-PRT structures (4YB5 and 4YB6).
It is positioned strictly beside the δ1 nitrogen atom of the bound histidine
molecule, able to form additional hydrogen bonding interactions with T252
and Y228 of one chain and H266 of the other. The three water molecules,
together with the terminal oxygens of the Y228 residues and all δ1 and ε2
nitrogens of the H266 residues, form a triangular hydrogen bonding network
in the centre of the histidine bound ACT domain trimer, which is connected
to the bound histidine. This network is absent in the ATP bound CjeATP-
PRT structure (Figure 2.25).
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Figure 2.25: Hydrogen bonding network in histidine bound CjeATP-
PRT ACT trimer. Central residues of one ACT trimer of 4YB5 (A) and 4YB7
(B) in stick representation. The binding of histidine (white) causes the formation
of a tight hydrogen bonding network (dashed lines) including three water molecules
(small spheres), residues Y228, T252 and H266. Residue labels are placed on one
chain only.
These interactions pull the two ACT surfaces together, which leads to
the obvious compaction and rotation of the ACT domain trimers relative
to the catalytic core in the inhibited conformation (Figure 2.24D). Similar
observations have also been reported for MtuATP-PRT crystal structures
(PDB codes: 1NH7 and 1NH8).35
The dimer interface also undergoes significant changes, which are most
prominent between 4YB7 and 4YB5, where the calculated surface area is
increased by approximately 200 Å. These differences are caused by a “flex”
of the dimeric unit. In 4YB7 the interface is constituted predominantly by
residue ranges T152–L163 (α6 and flanking loops) and T176–N180 (α7) of
the first chain and Q37–I40 (α1-β2 loop), R8 (β1), and R54 and D57 (α2) of
the second chain. In comparison to this, the two equivalent chains in 4YB5
are rotated relative to each other, retaining the contacts of α6 in the first
chain to R8 and the α1-β2 loop in the second chain. The contacts between
α7 and α1-β2 loop are lost entirely though, as α7 of both chains is shifted
towards the outside of the hexamer. New close contacts are made instead
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between residues N148–L151 (β8) of the first and D57–D64 (α2) of the second
chain, which are now located in close proximity. The C-terminal ends of the
α3 helices (L87) come significantly closer together (6.4 ± 0.3 Å vs. 13.8 ±
0.5 Å), which accounts in part for the large increase in surface area seen in
4YB5. The same rotational flex is observed in 4YB6 but to a lesser extent.
The neighbouring dimers of the inhibited hexamer also tighten their
interfaces in an interlocking motion, clearly visible by the relative position
change of the α7 helices in the inhibitor bound state compared to their di-
agonal side-by-side contact in the ATP bound structure (Figure 2.26).
Figure 2.26: Comparison of α7 positions. The two different orientations of
α7 at the contact point of two four neighbouring chains in the open (left hand
side) and closed (right hand side) conformation of CjeATP-PRT are displayed in
the cartoon representation.
Situated on the inside of the hexamer, the active sites are directly
influenced by the flex in the dimer interface. Following the twist of the
central beta sheet of domain I, the β1-α1 and β3-α2 loops are turned away
from the opposite chain. Or if examined from the perspective of domain I,
the central beta sheet of domain II turns, retracting the α7 helix from the
dimer interface. This is exemplified by the change in distance between the
α carbon atoms of N180 and S38, 6.7 ± 0.5 Å in 4YB7 and 13.3 ± 0.3 Å in
4YB6, respectively.
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This rearrangement of the interface affects the long basic side chain of
the conserved residue K13. It is able to reach into the opposite active site in
4YB7, where K13 is suspected to interact with the pyrophosphate group of
PRPP.27,36 In 4YB6 K13 is significantly further away. Its α carbon distance
to S154 is 10.7 ± 0.3 Å in 4YB6 compared to 7.7 ± 0.1 Å in 4YB7. On the
other side of the active site the positioning of the α1-β2 loop is also altered. In
4YB6, this loop is found closing over the active site of the adjacent chain (not
its dimer partner chain), coordinating the phosphate group of AMP sitting
in the PRPP binding loop (β9-α7 loop), with the two histidine residues H33
and H35 in hydrogen bonding distance. In 4YB7 this “capping” of the active
site loop does not occur, as the α1-β2 loop is far away from any possible
interaction with the neighbouring subunit (Figure 2.27).
Figure 2.27: Changes in the CjeATP-PRT active site between open
and closed conformation. A hexamer of 4YB7 (LHS, green) and 4YB6 (RHS,
purple) were superimposed on a single chain to compare the impact of the overall
conformational changes in the enzyme complex. Three chains each are shown in the
cartoon representation in variations of the ground colour with the superimposed
chain in the centre. The bound active site ligand in shown in white. Residues
K13’, H33” and H35”, representing the relative movement of structural motifs,
are shown as red sticks. Heteroatoms are coloured according to element: oxygen
(red), nitrogen (blue), phosphorous (orange).
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The active sites of 4YB5 and 4YB6 with all resolved side chains are
close to identical (RMSD = 0.45 Å). The main difference between the two
sites is the position of the α7 helix, which is shifted inwards (in respect to
the hexamer surface) by approximately 4 Å in the AMP bound structure
(4YB6). This is likely due to the presence of the 5’-phospho ribose moiety of
AMP in the PRPP binding loop (β9-α7 loop) directly preceding the α7 helix.
In the absence of AMP (4YB5), the PRPP binding loop possesses greater
conformational freedom and allows the helix to move outwards, while it is
held in place by the tight binding interactions of the PRPP loop in the
presence of AMP (4YB6).
2.9.8 Comparison to existing crystal structures
The chain structure and overall fold observed for CjeATP-PRT is identi-
cal to the folds described26,35 in all deposited structures of ATP-PRT long
form enzymes (PDB codes: 1NH7, 1NH8, 1H3D, 1Q1K, 2VD3). Due to the
higher symmetry in those structures, symmetry operations must be applied
to create hexamers of equivalent composition. As expected from the primary
sequence, the structure of CjeATP-PRT is most similar to the structure of
EcoATP-PRT, of which only the open form has been observed. Superimpo-
sition of EcoATP-PRT chain (PDB code: 1H3D) with a single CjeATP-PRT
chain (PDB code: 4YB7) resulted in a close fit (RMSD = 0.988 Å), while the
full length chain of MtuATP-PRT (PDB code: 1NH7) produced a weaker fit
(RMSD = 2.056 Å). This is caused mainly by the different angle and orienta-
tion of the ACT domain in all three structures. If only the catalytic domains
are considered, the superimposition of the two chains of CjeATP-PRT (PDB
code: 4YB7) and MtuATP-PRT (PDB code: 1NH7) consequently results in
a better fit (RMSD = 1.216 Å) (Figure 2.28).
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Figure 2.28: Comparison of ATP-PRT long form enzymes. Cartoon dis-
play of a single chain of all currently known long form ATP-PRT enzymes. A: Ac-
tive conformation. Superposition of CjeATP-PRT (4YB7) (green) with EcoATP-
PRT (1H3D)26 (cyan). B: Inhibited conformation. Superposition of CjeATP-PRT
(4YB6) (green) with MtuATP-PRT (1NH8)35 (red) and MthATP-PRT (2VD3)
(blue).
Another difference is the much shorter helix α3 in MtuATP-PRT, which
only includes eight residues compared to 14 residues for CjeATP-PRT and
EcoATP-PRT. This difference can also be easily retraced to the sequence
level (Figure 2.3). The same short helix was found in the inhibited form
of the archaean MthATP-PRT (PDB code: 2VD3), which overlays similarly
well (RMSD = 1.879 Å) with the inhibited CjeATP-PRT (PDB code: 4YB6).
2.9.9 Small angle X-ray scattering
Small angle X-Ray scattering was employed to compare the active and in-
hibited crystal structures of CjeATP-PRT with the shape of the enzyme in
solution. Data was collected in the presence and absence of an inhibitory
mix of 1 mM histidine and 2 mM AMP following elution from a SEC column
(section 6.1.42).
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The radius of gyration (Rg), determined by the Guinier analysis, was
43.5 ± 0.4 Å for the scattering profile of the ligand-free dataset and 42.0 ±
0.4 Å in case of the inhibited enzyme complex. Using the indirect Fourier
transform method95 the pair distribution function (P(r)) was established with
Rg being 43.5 ± 0.2 Å for the native and 42 ± 0.2 Å for the inhibited dataset.
The maximum scattering particle (Dmax) was calculated to 152 Å for the
ligand-free and 147 Å for the inhibited enzyme data (Appendix D). Following
this analysis the enzyme appeared almost unchanged in the uninhibited or
inhibited form.
The obtained scattering profiles are consistent with a hexamer in so-
lution as shown by the CRYSOL fits (Figure 2.29), with both data sets
being nearly identical. The theoretical scattering of the ATP bound crystal
structure (4YB7) shows marginal differences to the inhibitor bound structure
(4YB6), which was not observed experimentally.
The overall fit quality was poor. The better fits were observed against
the inhibitor-bound crystal structure with χ values of 4.4 (native) and 3.6
(inhibited). The fits against the ATP bound structure in turn produced χ
values of 5.7 (native) and 4.2 (inhibited). This observation is in line with the
previous results (section 2.8), suggesting that the only existing oligomeric
species of CjeATP-PRT is a homo-hexamer, but do not indicate a conforma-
tional change.
Figure 2.29 (following page): SAXS measurements of CjeATP-PRT.
Theoretical scattering profiles of the CjeATP-PRT crystal structures 4YB7 and
4YB6, representing the active (dotted line) and inhibited (dashed line) form of
the hexamer, were generated by CRYSOL96 and compared to the experimentally




2.10 Investigation of MtuATP-PRT
The ATP-PRT enzyme from M. tuberculosis has been studied in great detail
both kinetically89 and crystallographically35,75 and was therefore chosen to
serve as a comparison to CjeATP-PRT.
Soluble expression was achieved in pET24a(+). The MtuATP-PRT had
been altered to possess a short N-terminal non-removable His-tag, which was
used for purification via IMAC. The protein preparation was highly pure
(Figure 2.30) but unfortunately found to be inactive in all tested reaction
buffers tested (section 6.2.6).
Figure 2.30: Crystallisation of MtuATP-PRT. LHS: Assessment of the pu-
rity of the MtuATP-PRT preparation. RHS: Photograph taken of drop containing
MtuATP-PRT crystals. The crystallisation condition was 0.1 M MES pH 6.5, 1.8
M MgSO4 (section 6.2.6).
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Nonetheless, the protein was used for crystallisation making use of
the previously described condition.35 Small triangular prism-shaped crys-
tals formed readily over night. ATP was soaked into the crystals and several
diffraction data sets were collected at the Australian Synchrotron, one of
which showed density for an active site ligand. The structure was solved by
molecular replacement with the deposited ligand-free structure (PDB code:
1NH7) as starting model and revealed one ATP molecule bound in the cat-
alytic site of the enzyme, which is a novel finding for MtuATP-PRT (Table
2.9). MtuATP-PRT crystallised in a trigonal spacegroup with only one chain
in the unit cell, as in the previously published datasets 1NH7 and 1NH8. The
overall shape of the chain was unsurprisingly more like 1NH7 (RMSD = 0.45
Å) than 1NH8 (RMSD = 1.27). Therefore it was compared in detail to the
open, ATP bound, structure of CjeATP-PRT (4YB7).
The two structures superimpose well with an overall RMSD value of
1.89 Å (Figure 2.31A). The main differences are, as described before, the
shorter helix α3 and the missing β11-α7 and β13-β14 loops. The active site
of MtuATP-PRT appears more compact (Figure 2.31B). The observed chain
was leaning tightly against its dimeric counterpart, with the side chain of
residue K9 extending into the active site of the other chain. There are three
sulphate ions bound next to ATP in the active site that are interacting with
the residues of the putative PRPP binding site, including the β9-α7 loop
(residue range 157–161) and the conserved E141.
ATP adopts a similar binding mode in the active sites of MtuATP-
PRT and CjeATP-PRT, but the conformation and the interactions formed
are different (Figure 2.32) because of the protein environment. CjeATP-PRT
possesses a coordination site for a single Mg2+ ion, which in turn binds to the
triphosphate. In MtuATP-PRT, on the contrary, the functional Mg2+ is not
coordinated by any protein side chains but bound to all three phosphates,
giving the triphosphate group a different twist. A second Mg2+ ion is found
shared between the two ATP molecules in a dimer. It was coordinated by
the terminal oxygen atoms of both γ phosphates and both R49 side chains.
85
Figure 2.31: The MtuATP-PRT single chain and its active site.
A: Structural superimposition of the ATP bound MtuATP-PRT single chain (pink)
with a single chain of CjeATP-PRT (white) in cartoon representation. B: Surface
representation of the active site of MtuATP-PRT with the bound ATP (bright
yellow) and sulphur molecules displayed as sticks. Monomer contained in the
unit cell at the top (pink) and its symmetry mate at the bottom (cyan). Atoms
are coloured according to element: oxygen (red), nitrogen (blue), phosphorous
(orange), sulfur (yellow), magnesium (light green).
Additionally the interactions seen with CjeATP-PRT R16 and Q12
do not exist in MtuATP-PRT. The only conserved interactions are with
R54/R49, Asn75/Asp70 and L170/V155. Serine S191/S177 is another well
conserved residue that forms hydrogen binding interactions to the ribose ring
of ATP. In MtuATP-PRT this interaction is direct and not mediated by a
water molecule. Overall, the two enzyme active sites bind ATP in a similar
mode with a very limited number of essential interactions involving conserved
or similar residues, while the rest of the interactions have evolved differently
(Figure 2.32).
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Figure 2.32: Comparison of ATP binding mode. Observed binding mode for
ATP (dark green) in the active sites of MtuATP-PRT (pink) and CjeATP-PRT
(white) in a direct comparison. A and C: 3D stick representation of ATP with
surrounding electron density (Fo-Fc map - grey mesh) and active site residues
in close distance. The second chain of MtuATP-PRT is coloured in cyan. B
and D: Planar plots of all ATP interactions in both structures were created with
LigPlot+.94 Hydrogen bonds are depicted as dashed lines labelled with the real
space distance between atoms. Hydrophobic interactions are displayed as short
radial red lines. Conserved interactions are highlighted in red. Water molecules
are displayed as cyan spots. Hetero-atoms are coloured according to element:
oxygen (red), nitrogen (blue), phosphorous (orange), sulphur (yellow), magnesium
(light green).
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Table 2.9: Crystal parameters, data collection, and refinement statistics for




Space group H 32
Unit cell parameters
a, b, c [Å] 134.54, 134.54, 110.11
α, β, γ [◦] 90.00, 90.00, 120.00





I /σ(I ) 15.7 (2.6)
Rmerge 0.106 (0.805)
CC1/2 0.997 (0.793)















Bond lengths [Å] 0.007
Bond angles [◦] 1.303








CjeATP-PRT has been successfully cloned and purified using heterologous
expression in E. coli. An unusual feature was the intrinsic affinity of the
native CjeATP-PRT enzyme to immobilised metal ions that made reverse
IMAC purification impossible. This effect may involve the α1-β2 loop, which
houses two histidine residues (H33 and H35) in a good configuration to
chelate ions. In the active, ATP bound, structure this loop is found at
the periphery of the main opening into the central cavity, while it is close
to the active site (β9-α7 loop) in the inhibited conformation. This suggests
that conformational flexibility in the active form opens up the possibility
for the histidine side chains to bind particles at the outside of the hexamer.
This effect could potentially be circumvented by purifying the enzyme in the
presence of low concentrations of histidine (≤ 1 mM), which fully inhibit the
enzyme but do not reduce the IMAC binding affinity to the His-tag.
Overall, the kinetic parameters determined for CjeATP-PRT were in
agreement with those of other long form ATP-PRTs. Although the ATP-
PRT enzymatic reaction is well studied, extensive kinetic studies are rare. It
was therefore unsurprising that the acquired KM and kcat values were clos-
est to the data published for S. Typhimurium, which was grouped in the
same clade of the protein sequence alignments as CjeATP-PRT, even though
the work was performed using partially pure enzyme preparations.28 The
recently published kinetic data for MtuATP-PRT reports 3-fold higher KM
values than measured for CjeATP-PRT and can still be seen as a good com-
parison.89 Unfortunately the MtuATP-PRT preparation presented in this
thesis was inactive and could therefore not be compared. The inhibitory
behaviour of AMP was clearly competitive towards both substrates which
is in accordance with previous findings. The determined Ki values are also
very close to SenATP-PRT data (0.48 and 0.55 mM against ATP and PRPP
respectively).18 The competitive behaviour is evident by the binding modes
of AMP and ATP presented in the obtained crystal structures (4YB6 and
4YB7). AMP bridges over both binding sites covering the adenine ring po-
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sition of ATP, as well as the phosphate coordination site of PRPP in the
highly conserved PRPP binding motif, as has been previously described for
EcoATP-PRT.26 The inhibition mode of histidine was found to fit best to
a non-competitive model against both substrates, contrary to previous de-
scriptions of the histidine vs. ATP inhibition mode as uncompetitive.
The kinetic results were supported and largely confirmed by the affin-
ity constants measured with ITC, adding a new level of understanding and
confidence to the analysis. The binding curves followed a single site model
for all used ligands with the exception of histidine. Since this is the first
description of ITC experiments on an ATP-PRT enzyme, no comparison is
available and data interpretation is challenging. The complex curvature of
the histidine binding experiments clearly indicated a cooperative effect lead-
ing to the assumption that the binding of the first histidine molecule to a
hexamer influences all other binding sites in the complex. It was therefore
fitted with a sequential binding model in all cases. All resulting values should
be interpreted with care as the initial strong exothermic signal in the solely
histidine binding experiment was not observed when the enzyme was pre-
incubated with AMP. It appears possible that this strong exothermic event
is based on the rearrangement of the enzyme complex upon histidine binding,
adopting the inhibited state with close contacts at the ACT domain inter-
faces. It has been shown for EcoATP-PRT that AMP binding alone does not
cause the complex to change into the inhibited form,26 which could explain
why this effect is not seen for AMP titrations. On the other hand it is also
absent when the enzyme has been pre-incubated with AMP, suggesting that
AMP has an influence on the conformation of the complex or at least on the
energy required for the transition.
The determined Kd value for AMP was significantly lower than the
kinetically measured competitive Ki values, as well as the reported Ki val-
ues for SenATP-PRT. By measuring the binding of AMP to enzyme in the
presence of kinetically relevant concentrations of ATP (1 mM), it was shown
that this discrepancy is dependant on the ATP concentration in the ITC
experiment. Without the substrate competing for the active site, a tighter
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binding was observed than in the presence of 1 mM ATP. This conclusion
could apply equally to the differences of the measured substrate Kd and KM
values, which occurred most likely due to the absence of second substrate.
It was shown evidently that the kinetic mechanism of ATP and PRPP
to CjeATP-PRT follows a sequential model. Considering the difference in
the determined KM values and the relative instability of PRPP compared
to ATP it appears likely that ATP binds first, preparing the active site for
PRPP binding, which is then quickly turned over. This hypothesis is also
supported by the product inhibition and reverse reaction studies performed
on SenATP-PRT.17,28 However ITC experiments clearly showed that bind-
ing of PRPP is possible in the absence of ATP, although the affinity is low.
Together with the observation that the ATP Kd was lower than the deter-
mined KM for ATP (about half), this suggests that both substrate molecules
are able to bind the empty active site. It is therefore proposed that the
binding mode of CjeATP-PRT is random sequential. This is further sup-
ported by the observed stabilisation effect of CjeATP-PRT on PRPP under
assay conditions. It is plausible that PRPP adopts different binding modes
in the absence and presence of ATP, enabling the enzyme to secure this en-
ergetically expensive and labile metabolite without the risk of spontaneous
decomposition, until the more stable substrate ATP binds and the reaction
occurs.
It has been discussed that ATP-PRT long form enzymes exist in an equi-
librium between an active dimer and an inactive hexamer, which is driven by
protein concentration and the presence of inhibitor molecules. All data pre-
sented in this chapter is consistent with a single hexameric species under all
examined conditions, including kinetically relevant enzyme concentrations,
posing the question whether or not an equilibrium exists at all or if the
homo-hexamer is the only active and biologically relevant species. One of
the main arguments for the existence of the dimer-hexamer equilibrium is
the fact that all active sites lie on the inside of the hexameric arrangement,
apparently inaccessible to any substrate molecule. A comparison of the dimer
and trimer interfaces of both MtuATP-PRT and EcoATP-PRT revealed that
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the dimer interface is stronger and more important for complexation, ren-
dering the trimer interface auxiliary or even optional. This was further sup-
ported by the comparison to the short form enzymes, which contribute two
ATP-PRT dimers to the overall hetero-octameric complex highlighting the
importance of the dimer.37 The PISA93 analysis of the three CjeATP-PRT
crystal structures delivered a different result. The trimer interfaces of the
CjeATP-PRT ACT domains were found to be of equal or more importance
than the dimer interfaces, particularly in the absence of histidine, indicating
that the hexameric species is likely to be stable.
Furthermore the hexameric structures of all structurally characterised
ATP-PRT long form enzymes possess the same large openings between neigh-
bouring domains, which would likely permit access to the interior of the
complex at any time. Another possible entrance for substrate molecules is
present in the form of a small opening in the dimer interface, observed in both
ATP bound structures (4YB7 and 4YG9), that leads directly to the active
site and may function as a substrate channel. In the same way, the hexamer
could loosen and widen in a “breathing” motion, allowing substrate access
through the weak interfaces between the catalytical dimer cores. Limited
evidence for such movement comes from the thermal stability experiments
performed on CjeATP-PRT. Firstly the synergistically inhibited enzyme is
significantly more stable than the unliganded enzyme (thermal shift of 5◦),
which is commonly associated with increased rigidity. This observation goes
hand in hand with the crystallographic finding that the closed hexamer form
is narrower, tighter and generally more refined than the open form. This
increased rigidity was perhaps further evidenced by the findings of the DSF
experiments, when the fluorescent dye exhibited premature binding to the
ligand-free enzyme, but did not in the presence of both AMP and histidine.
The prior discussed metal affinity and the low symmetry of the APT bound
crystal structure also support the conclusion that the uninhibited hexamer
possesses a certain flexibility, allowing for substrate molecules to enter.
The observed changes between the open and closed conformations of
the CjeATP-PRT hexamer are a fine interplay between changes in the in-
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terfaces and the resulting shifts of functional structural motifs. The clearest
example here is the residue range G29–P47, which forms a long loop includ-
ing β2. While its C-terminal side is involved in the dimer interface formation
in the active hexamer, it is largely released upon histidine binding and al-
lowed to move inwards, where it then caps the phosphate binding site of
a neighbouring subunit with its N-terminal side. These rearrangements of
structure motifs between neighbouring chains are an additional indication
for the importance of the hexameric state for the function of CjeATP-PRT.
Although the most significant changes in the hexameric complex are
seen upon histidine binding, the two crystal structures 4YB5 (histidine only)
and 4YB6 (AMP and histidine) also show small differences. The described
active site flex is less prominent in 4YB6, resulting in a smaller calculated
dimer interface area, while the PRPP binding loop and helix α7 are signif-
icantly more flexible in 4YB5. These differences may be attributed to the
packing forces present in the alternative crystallisation condition. Alterna-
tively, these changes may be the result of the binding of AMP in the active
site. In the absence of active site ligands, histidine binding forces the hexamer
to adopt a very tight conformation, allowing only small functional motifs to
move freely. The binding of AMP, on the other hand, could release some of
the strain by reorienting the PRPP binding loop, causing the dimer interface
to relax. These small differences could potentially be part of the synergistic
effect of histidine and AMP inhibition, although the conditions presented in
the structures should both represent an absolutely inhibited enzyme, due to
the high inhibitor concentrations used.
The structural information presented in this chapter provides great de-
tail about the binding modes of two of the ATP-PRT ligands in the active
site. Convincing electron density for both ATP and AMP was found, which
led to the analysis of their binding interactions. PRPP binding in the active
site has not been shown experimentally. It is expected to occur in a similar
manner to the well established binding in type I and II PRTases,22 heavily
involving the residues of the β9-α7 loop assisted by an absolutely conserved
glutamate residue (CjeATP-PRT E156). The reported ATP binding, as seen
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in CjeATP-PRT as well as in MtuATP-PRT, has not been described pre-
viously. This enabled a detailed comparison of the binding sites in light of
this new ligand, highlighting the different architectures of both active sites
with only a few strictly conserved interactions: R49/R54 binding the triphos-
phate, D70/N75 and S177/S191 forming contacts to the ribose oxygens and
V155/L170 interacting with the adenine.
As the MtuATP-PRT protein was found to be inactive, it remains un-
clear whether the solved structure shows the correct orientation of ATP or
is merely an artefact of crystallisation. The high precipitant concentrations
could have allowed for the active sites to open up for ligand binding while they
were permanently blocked or misfolded in solution as a consequence of pu-
rification. As no further experiments have been performed on this enzyme, it
could also be possible that no suitable kinetic condition was found, although
the preparation was potentially active. The lack of activity may alternatively
be the result of an inability to bind PRPP. Overall it seems unlikely for a
large molecule like ATP to adopt a false conformation and interactions, given
the similarity to the ATP binding mode observed in CjeATP-PRT.
Significant differences were observed between the AMP binding mode
presented in crystal structure 4YB6 and its counterpart in MtuATP-PRT
(PDB code: 1NH8). Due to the absence of a large side chain (R16 in CjeATP-
PRT) “capping” the adenine binding site, the bound AMP possesses more
rotational freedom in MtuATP-PRT. AMP is able to flip upside down to in-
teract freely with the side chains of D30 and D33 of the α1-β2 loop, while the
longer side chains H33 and H35 in CjeATP-PRT coordinate the 5’-phosphate
bound in the β9-α7 loop. Although involving different residues and connec-
tivity both interactions have the same overall effect and could be seen as an
example of fine tuning of an enzyme active site by parallel evolution. Al-
ternatively it is possible that the density for AMP in MtuATP-PRT35 was
misinterpreted and not sufficient for the placement presented in 1NH8. This
would leave the binding mode of the AMP ribose as observed in EcoATP-
PRT (PDB code: 1H3D)26 as the only point of comparison, which is nearly
identical to the one presented for CjeATP-PRT.
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There was no observed difference between the SAXS profiles in the
presence and absence of the inhibitors mix. The maximum particle size and
radius of gyration calculated from the uninhibited data set were slightly larger
than in the data set containing the inhibitors. This is in accordance with the
tightening of the crystal structure in the presence of histidine. But both data
sets fitted better to the inhibitor bound X-ray crystal structure although
the expected scattering for the substrate bound structure was marginally
different. As the SAXS experiments have not been performed in the presence
of ATP it can also not be ruled out that the substrate has a determining
effect on the hexameric structure in solution, promoting the occurrence of
the expected open form. Aggregation might also have negatively affected the
outcome of the experiments and data recollection with an unfrozen enzyme










ATP-PRT enzymes are divided into members of the long or the short form.
The previous chapter described the detailed analysis of a new member of the
long form ATP-PRT from C. jejuni. This enzyme possesses a C-terminal reg-
ulatory domain characteristic of the long form, which is classified as an ACT
domain by fold and function.41 The CjeATP-PRT ACT domain facilitates
histidine binding and inhibition of the phosphoribosyltransferase reaction
resulting in a conformational change of the homo-hexameric enzyme com-
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plex. The short form ATP-PRT enzymes do not possess this mechanistic
feature. Instead a separate protein, HisZ, is employed for regulatory and
catalytic purposes, leading to the formation of a hetero-octameric complex.
The mechanism by which these complexes function has not been elucidated
in detail to date, but the central feature is thought to be the alteration of the
properties of the catalytic dimers36,97 by similar movements to those observed
in CjeATP-PRT and other long form enzymes.
Since the architecture of the catalytic domains of long and short form
ATP-PRTs is very similar and most important active site residues are con-
served, it is likely that they have evolved from the same precursor. Whether
the short form complex of contemporary proteins represents this precursor
is unclear, but it is likely that the long forms evolved subsequently from an
event that recruited an ACT domain to an ancestral ATP-PRT.37 This chap-
ter describes the creation of a truncated CjeATP-PRT mutant reversing this
evolutionary event on a modern long form ATP-PRT to study its properties
as an isolated catalytic domain species.
3.2 Selection of the truncation site
The choice of the truncation position is crucial to the outcome of a large scale
manipulation of a protein. For the removal of the regulatory ACT domain of
CjeATP-PRT the short α8-β12 loop (Figure 3.1) was chosen as it represents
the hinge by which the ACT-domain movement is facilitated. The presence of
exclusively polar residues made this position an excellent choice, considering
the properties of the newly created C-terminus. The minimal exposure of
new surface area to the environment, on the mainly polar outward face of
the α8 helix, was also an important aspect in its favour. The exact chain
termination position was chosen after residue E225, completely removing the
residue range 226–299.
The mutant was named Campylobacter jejuni adenosine triphosphate
phosphoribosyltransferase Core mutant (CjeATP-PRT Core or simply Core
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mutant), as it only possesses the catalytic domains I and II, which are posi-
tioned in the “core” of the CjeATP-PRT wild type hexamer.
Figure 3.1: Truncation site. The truncation site (bright red) on the full length
CjeATP-PRT chain (green) is shown. A: Cartoon representation of the entire
chain. The square box indicates the zoomed in area. B: Zoom on the truncation
site. All residues are displayed in the sticks representation. Atoms are coloured
according to element: oxygen (red), nitrogen (blue).
3.3 Cloning and purification
Cloning of the truncated mutant was performed following the procedure de-
scribed for the CjeATP-PRT wild type, but made use of an alternative reverse
primer (section 6.3.1) that introduced the artificial translation stop (Figure
3.2). Initial screens of the pDEST
TM
17 clone in BL21* (DE3) or Chaperone3
cells showed very limited solubility of the overexpressed protein. The gene
was therefore transferred into pDEST
TM
15, which adds a glutathione sulfur-
transferase (GST) solubility tag. This successfully increased the solubility
of the protein chain in BL21* (DE3) cells, which were grown at 37 ◦C for
4 hours after induction with 0.5 mM IPTG. The crude lysate was found to
be active under standard CjeATP-PRT assay conditions. Therefore these
conditions were used for all large scale expressions of CjeATP-PRT Core.
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Figure 3.2: Cloning of CjeATP-PRT Core. Agarose gel showing the am-
plified gene encoding for CjeATP-PRT Core from three selected clones, using the
colony PCR set up described in sections and 6.1.17. The gel was run according to
section 6.1.13.
The CjeATP-PRT Core mutant was observed to possess the same in-
trinsic affinity to IMAC columns. This fact was exploited in the development
of the purification protocol. Cells were harvested and lysed according to the
protocol described for the ATP-PRT wild type enzyme. An initial IMAC
run isolated the overexpressed enzyme from the soluble crude lysate. The
enzyme was then treated with TEV protease for 1 h at 37 ◦C and 180 rpm,
which removed the tag completely without adversely affecting the solubility
of the CjeATP-PRT Core. TEV protease treatment was followed by a reverse
purification step. Using GST affinity chromatography the free GST was re-
moved from the protein preparation, while the CjeATP-PRT Core eluted in
the flowthrough. SEC was employed as the final purification step, removing
the TEV protease and desalting the enzyme. After final assessment of the
protein purity by SDS-PAGE (Figure 3.3), the CjeATP-PRT Core contain-
ing fractions were concentrated to a stock concentration of ≥ 20 mg mL −1
and kept at 4 ◦C for immediate use, or flash frozen in liquid nitrogen and
stored at -80 ◦C.
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Figure 3.3: Purification of CjeATP-PRT Core. SDS-PAGE showing the en-
zyme preparation at its various purification steps. Electrophoresis was performed
according to section 6.1.31 in 10 % Bis-Tris gels using MES buffer. The theoretical
molecular weight of CjeATP-PRT Core is 53.9 kDa (tagged) and 25.3 kDa (tag re-
moved). Lane labels correspond to: CL - crude lysate, SC - soluble crude, MWM -
molecular weight marker, IMAC - eluate from IMAC, TEV - TEV protease treated,
GST FT/E - flow through/eluate from GST affinity chromatography, SEC - Eluate
from SEC.
3.4 Determination of molecular weight
The molecular mass of the purified CjeATP-PRT Core was determined to be
25307.7 g mol−1 by electrospray ionisation mass spectrometry. This value is
in close agreement with the theoretical value of 25308.2 g mol−1 calculated for
the 226 amino acid sequence derived from the first 225 amino acid residues of
the CjeATP-PRT open reading frame and a single N-terminal glycine residue
left over from the truncated tag.
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3.5 Oligomeric state analysis
3.5.1 Size exclusion chromatography
During the purification process CjeATP-PRT Core exhibited a different be-
haviour to the wild type enzyme. The relative ease with which the GST tag
was removed and a comparatively late elution of the protein from the size
exclusion column were indicative of a change in assembly or shape of the
truncated mutant compared to the CjeATP-PRT wild type.
Figure 3.4: Analytical size exclusion chromatography of CjeATP-PRT
Core. SEC was performed on 1 mg ml −1 CjeATP-PRT Core using a Superdex
TM
200 10/300 GL column as described in section 6.1.26. The absorbance of the pro-
tein sample was monitored at 280 nm (blue, solid) and 214 nm (pink, dashed) due
to the low extinction coefficient of CjeATP-PRT Core at 280 nm. Inset: Calibra-
tion curve. The molecular weight of the standards proteins (Log(MW)) is plotted
on a logarithmic scale against their normalised elution volumes (VE/V0). The
void volume (V0) was determined using Blue Dextran. The calculated molecular
weight of the CjeATP-PRT Core species is displayed as an open circle.
Analogous to the analysis of the wild type enzyme, analytical size exclu-
sion was employed to estimate the molecular weight of the purified CjeATP-
PRT species at a concentration of 1 mg mL−1. The main peak eluted from
the column after 15.1 mL of isocratic flow (Figure 3.4). This peak had an
expected mass of 52 kDa, which was very close to the theoretical dimer mass
of 51 kDa. A second much smaller peak eluted at 13.1 mL corresponding to
a size of 126 kDa, which may correspond to a pentamer or possibly hexamer.
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3.5.2 Static light scattering
Analysis of the CjeATP-PRT Core by SLS (section 6.1.40) was consistent
with the presence of a dimeric species. Only a single peak corresponding to
a single protein species with the molecular mass of 49 kDa was observed.
Figure 3.5: Static light scattering of CjeATP-PRT Core. The refractive
index of 1 mg mL −1 CjeATP-PRT Core (solid blue line) was determined as
described in section 6.1.40. The molecular weight of the mono-disperse species
(solid black line) eluting between 12 and 14 mL was calculated, using bovine
serum albumine (BSA) as standard, and compared to the theoretical molecular
mass of the CjeATP-PRT Core dimer (red dashed line).
3.5.3 Analytical ultracentrifugation
Sedimentation velocity experiments further supported the findings of SEC
and SLS. The main species detected had a sedimentation coefficient of 3.4,
corresponding to a molecular mass of 49.8 kDa (Figure 3.6). A secondary
peak at 5.4 S corresponding to a mass of 158 kDa was also observed with an
increased prominence at the highest tested concentration (1.2 mg mL −1).
This may correspond to a small amount of a hexameric species (theoretical
mass of 152 kDa) or a non-functional aggregate.
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Figure 3.6: Size distribution function of CjeATP-PRT Core. AUC ex-
periments were conducted according to section 6.1.41. The resulting data was
analysed using SEDFIT.90 The plot shows the data of all three used enzyme con-
centrations un-normalised from highest to lowest signal: 1.2 mg mL −1 (green),
0.4 mg mL −1 (blue) and 0.13 mg mL −1 (red).
3.5.4 Small angle X-ray scattering
Small angle X-ray scattering was also used to investigate the in solution be-
haviour of CjeATP-PRT Core. Static solution data was collected in the pres-
ence and absence of 2 mM AMP using the capillary set up (section 6.1.42).
The radius of gyration (Rg), determined by Guinier analysis, was 25.8 ± 0.1
Å for the scattering profile of the ligand free dataset and 24.8 ± 0.1 Å in the
case of the AMP containing sample. Using the indirect Fourier transform
method95 the pair distribution function (P(r)) was established with Rg being
26.2 ± 0.1 Å for the unliganded and 24.5 ± 0.1 Å for the AMP containing
dataset. The maximum scattering particle (Dmax) was calculated for native
and AMP containing data to 91.3 Å and 80.8 Å respectively. Overall data
sets appeared fairly similar showing no significant change in assembly.
The scattering profiles were compared to the theoretical scattering of
the PR-ATP bound CjeATP-PRT Core crystal structure (section 3.8), which
consists of two chains arranged as a dimer. Both datasets produced close
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fits against this crystal structure with χ values of 1.3 (ligand-free) and 0.4
(containing AMP). A comparison was also made to the data acquired for the
CjeATP-PRT wild type, showing the vast differences in scattering behaviour
between the two proteins. Fitting of the wild type data to the Core crystal
structure using CRYSOL96 resulted in χ values > 30, as would be expected.
These results are consistent with the presence of the CjeATP-PRT as a dimer
and support all previous results.
Figure 3.7: SAXS measurements of CjeATP-PRT Core. The theoretical
scattering profile of the PR-ATP bound CjeATP-PRT Core crystal structure (solid
black line) was generated by CRYSOL96 and compared to the experimentally de-
termined data of CjeATP-PRT Core in the absence (blue) and presence (red) of
2 mM AMP, and CjeATP-PRT wild type (green).
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3.6 Kinetic properties
The kinetic parameters of the CjeATP-PRT Core mutant were determined
under the conditions stated for the wild type enzyme (sections 6.1.33 and
6.3.3). The KM(ATP) value of CjeATP-PRT Core is comparable to the
CjeATP-PRT wild type, whereas the KM(PRPP) value increased about 3-
fold (Table 3.1) compared to the wild type enzyme. This suggests that the
substrate affinities of wild type and Core mutant are largely comparable.
The turn over rate on the other hand was heavily affected with a difference
of two orders of magnitude. CjeATP-PRT Core is therefore a very inefficient
catalyst.
Table 3.1: Kinetic constants of CjeATP-PRT Core. Kinetic measurements
were performed according to section 6.3.3. Equivalent values for CjeATP-PRT
wild type are given as a comparison.
Parameter CjeATP-PRT Core CjeATP-PRT wild type
KM (ATP) [µM] 94 ± 11 97 ± 10
KM (PRPP) [µM] 41 ± 5 15 ± 1
kcat [s
−1] 0.024 ± 0.003 1.8 ± 0.1
IC50(histidine) [µM] no inhibition 44 ± 1
IC50(AMP) [mM] 0.42 ± 0.05 2.1 ± 0.3
Due to the lack of the regulatory domain, the binding site for histidine
is absent in CjeATP-PRT Core. Consequently histidine showed no effect on
the catalytic properties exhibited by the mutant enzyme. AMP on the other
hand was still an effective inhibitor. CjeATP-PRT Core even showed a higher
sensitivity to AMP than the wild type when compared by their determined
half maximal inhibitory concentration (IC50) values. Taken together, these
findings suggest that the truncation of the regulatory domain interferes with
the catalytic properties of CjeATP-PRT, largely without altering the active
site ligand binding abilities. This compares well to the reported kinetic anal-
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ysis of partially and totally truncated CglATP-PRT mutants, which were
found to possess a largely decreased specific activity and turn over in the
crude cell extracts.98
The raw absorbency change of CjeATP-PRT Core, compared to the
CjeATP-PRT wild type data, showed an early retention of the reaction rate
before total turn-over was achieved. It was determined that this unexpected
behaviour is due to a inhibitory effect of the reaction product PR-ATP. The
(IC50) value for PR-ATP was determined to be 6.8 ± 0.7 µM in the presence
of 2 mM ATP (section 6.3.3), which shows the strong inhibitory potency of
the product.
3.7 Ligand binding
3.7.1 Differential scanning fluorimetry
DSF experiments on the CjeATP-PRT Core were performed as previously
described for the wild type CjeATP-PRT (section 6.1.37). For optimal com-
parison both enzymes were measured simultaneously on the same sample
plate. The Tm of the CjeATP-PRT Core mutant was determined to be 46.7
◦C in the presence of 5 mM MgCl2, which is 11
◦C lower than the measured
Tm of the wild type in the same condition. This finding shows that the
removal of the ACT domain has a negative influence on the thermostability.
As shown for the wild type enzyme (Table 2.6), the presence of Mg2+
ions stabilises the enzyme, providing an increase of approximately 2.5 ◦C
of the Tm value at 5 mM MgCl2 concentration compared to the MgCl2-free
sample. This underlines the importance of Mg2+ for the stability and function
of the enzyme. All other ligand samples therefore contained 5 mM Mg2+.
The presence of a saturating ATP concentration did not increase the
stability of the enzyme further. The resulting data (Figure 3.8) also shows
conclusive evidence for the conservation of the AMP binding ability in the
CjeATP-PRT Core mutant through an increase of its thermostability by
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4.5 ◦C. A stabilisation by histidine, as observed for the wild type enzyme,
does not occur, neither in the presence nor in the absence of AMP. This is
expected, as CjeATP-PRT Core lacks a histidine binding site (Table 3.2).
Figure 3.8: DSF analysis of CjeATP-PRT Core. Melting curves (solid lines)
of 0.1 mg mL −1 enzyme samples were determined by DSF according to section
6.1.37 in the presence of 5 mM MgCl2 and no ligand (green), 2 mM AMP (red), 1
mM histidine (blue) and a mix of 2 mM AMP and 1 mM histidine (purple). The
first derivatives (dotted lines) show the inflection points of the melting curves,
which represent the observed average Tm values.
Table 3.2: Thermostability of CjeATP-PRT Core. Melting temperature
values as determined by DSF. All samples contained 5 mM Mg2+, unless stated
otherwise. Samples were prepared and run according to section 6.1.37.
Additives Tm
No ligand, no Mg2+ 44.3 ± 0.1 ◦C
No ligand, 0.5 mM Mg2+ 45.3 ± 0.1 ◦C
No ligand, 5 mM Mg2+ 46.7 ± 0.1 ◦C
2 mM ATP, 5 mM Mg2+ 46.6 ± 0.2 ◦C
2 mM AMP, 5 mM Mg2+ 51.2 ± 0.1 ◦C
1 mM histidine, 5 mM Mg2+ 46.7 ± 0.1 ◦C
2 mM AMP, 1 mM histidine, 5 mM Mg2+ 51.1 ± 0.1 ◦C
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3.7.2 Differential scanning calorimetry
The collected DSF data was further supported by DSC experiments, which
were conducted as described (section 6.1.38). The sample buffer contained
5 mM Mg2+. Tm values were determined in the absence (52.5 ± 0.1 ◦C),
and presence of 2 mM AMP (54.6 ± 0.1 ◦C), 1 mM histidine (52.4 ± 0.1
◦C) and a mix of the latter two (55.0 ± 0.1 ◦C) (Figure 3.9). These melting
temperatures were 4–6 ◦C higher than the values obtained from DSF, which
is similar to the difference seen in the wild type experiments (section 2.7.2)
and can be reasoned by the faster temperature ramping speed of the DSC
experiments. The presence of histidine did not alter the Tm of CjeATP-
PRT Core, neither alone nor in combination with AMP, while 2 mM AMP
increased the Tm by 2–2.5
◦C.
Figure 3.9: DSC analysis of CjeATP-PRT Core. DSC measurements were
performed according to section 6.1.38 with a MgCl2 concentration of 5 mM. The
resulting melting curves were baseline subtracted (solid lines) and fitted against
a single melting event (dashed lines). Lines are coloured according to the ligand
present in the experiment: none (green), histidine (blue), AMP (red), histidine
and AMP (purple).
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3.7.3 Isothermal titration calorimetry
Further confirmation for the binding of AMP to the CjeATP-PRT Core mu-
tant was obtained by ITC experiments. Using 2 mM AMP as titrant, a Kd
value of 44 ± 2 µM was determined, which compares well to the wild type
Kd value of 51 ± 4 µM. As for the wild type enzyme, the binding followed
the expected single site model (Figure 3.10A) with a resulting stoichiometry
of 0.99 ± 0.04. With no significant difference in the binding affinity of AMP
to the macromolecule, it is evident that the active site is well suited for the
accommodation of the inhibitor molecule AMP even in the absence of the
regulatory domains and any cross-dimer contacts (α1-β2 loop “cap”).
Figure 3.10: Nucleotide binding of CjeATP-PRT Core. ITC binding
curves of 2 mM AMP (A) and 2 mM ATP (B) against 100 µM CjeATP-PRT
Core were measured under the conditions described in section 6.1.39, subtracted
by their corresponding heat of dilution data series and fitted using OriginLab R©
version 7.0.
ATP binding was also observed (Figure 3.10B) with CjeATP-PRT Core.
The binding was tighter than expected from the kinetic analysis (KM(ATP)
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= 117 ± 13 µM), which resulted in a very early saturation of the enzyme.
Principally it can be stated, that CjeATP-PRT Core is able to bind the
substrate molecule ATP. The Kd value obtained from the data fit was 10.0
± 4.3 µM, but should be disregarded as there were not enough suitable data
points available. Using a lower ATP concentration, it should be possible to
acquire a more accurate Kd value. Unfortunately this has not be achieved




Crystallisation procedures were performed as described in section 6.3.5. Dur-
ing initial screening, the condition A12 of the PACT premier
TM
HT-96 was
identified as yielding protein crystals of undesirable properties. The condi-
tion solution was rich in heavy, brown precipitate and the crystals formed
were of dark colour, small and grew as multiples. Due to the lack of other
suitable conditions, attempts were made to optimise this condition. By re-
ducing the precipitant concentration from 20 % to 7–10 % w/v and increasing
the initial protein concentration in the drop to ≥ 10 mg mL −1, large sin-
gle clear crystals were grown over night from heavy precipitate, that formed
immediately after the preparation of the drops. The shape of the crystals
was perfectly octahedral (Figure 3.11), unless crystal growth was stopped
by contact with a surface. Crystals grew consistently from either fresh or
frozen protein stocks and were suitable for ligand soaking. ATP, PRPP and
PR-ATP were soaked into the crystals by the addition of concentrated stock
solutions directly to the drop. Generally the crystals did not break up or dis-
solve during this treatment and were looped, cryoprotected and flash frozen
30–60 minutes afterwards.
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Figure 3.11: Octahedral crystal of CjeATP-PRT Core. Photograph taken
of a drop containing a single CjeATP-PRT Core crystal amidst left-over precip-
itate. The octahedral crystal was obtained from the adjusted PACT premier
TM
HT-96 screen condition A12: 0.1 M Sodium Acetate, 0.01 M ZnCl2, 7 % w/v PEG
6000, pH 5.0. The initial protein concentration in the drop was 11 mg mL −1.
It was not possible to combine AMP with the crystal condition, by
either ligand soaking or as a co-crystallisation agent. The condition solution
transformed into a gel upon addition of AMP, which was not able to diffuse
into the crystals. The cause of the gel formation was identified to be the
Zn2+ contained in the crystallisation condition, but Zn2+ was also found to
be crucial for the crystallisation process. Because of the excellent diffraction
quality of the crystals described above and the initial difficulties to find
appropriate crystallisation conditions, no further screening to introduce AMP
was attempted.
3.8.2 Crystal structure
The first X-ray dataset of CjeATP-PRT Core was collected on an apo crystal
with diffraction spots distributed out to 1.6 Å. The data was later cut back
to 1.9 Å and was integrated in space group P212121. A solution was found
by molecular replacement using a search model created from a single chain of
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a, b, c [Å] 65.70, 79.93, 91.01
α, β, γ [◦] 90.00, 90.00, 90.00





I /σ(I ) 22.9 (4.8)
Rmerge 0.050 (0.321)
CC1/2 0.999 (0.956)







Observed residues 220, 215
Water molecules 295






Bond lengths [Å] 0.013
Bond angles [◦] 1.582







the wild type structure 4YB5 that had the residue range 225–299 removed.
Two chains were found in the unit cell sharing one interface identical to the
described dimer interface of the wild type CjeATP-PRT. The entire helix
α8 of chain B showed significant variability compared to the rest of the
structure, which led to the assignment of a separate TLS group to it during
refinement. Later ligand bound structures were solved from the CjeATP-
PRT dimer (4YRX), again by molecular replacement.
3.8.3 Fold and arrangement
The descriptions and comparisons made in the following section largely corre-
spond to the CjeATP-PRT Core apo structure (4YRX) but all ligand bound
structures contain very similar features (Table 3.4). Although the two chains
resolved in the unit cell show the identical secondary structure arrangement
of domain I and II as described for the wild type (section 2.9.3), they present
two main differences with an overall RMSD between chains A and B of 0.38
Å. The more prominent of these is the shorter C-terminus of chain B when
compared to chain A. No electron density was observed for residues 220–225
in chain B. Therefore these residues were removed from the model.
Chain A shows an alternative conformation for the β9-α7 loop (the
PRPP binding loop), which was found stretched out, lacking the typical
narrow turn seen in chain B, and all other ATP-PRT structures. The sub-
sequent α7 helix is also effected by this change, being largely unwound with
only one helical turn remaining (residues 178–181). This conformation was
only observed in chain A of 4YRX, not in any of the ligand bound CjeATP-
PRT Core structures, where the loop is performing its binding function. It
is possible that this alternative conformation represents a “resting” position
of this important binding loop. A significant feature of the structure was
the coordination of several Zn2+ ions at the unit cell interfaces, interacting
mainly with residues H33 and H35 as well as E78 and E81, but also with
residues of the β9-α7 loop of chain A, which could in part be the reason for
its difference in conformation.
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Table 3.4: Comparison of the CjeATP-PRT Core structures. Compar-
ison of the dimeric subunit arrangements comprising residues 4–225 of all listed
CjeATP-PRT structures is given as RMSD value derived from their superimposi-
tion using PyMol.99 PDB identifiers are used for the structures of CjeATP-PRT
Core (4YRX), histidine bound CjeATP-PRT wild type (4YB5), AMP and histi-
dine bound CjeATP-PRT wild type (4YB6) and ATP bound CjeATP-PRT wild
type (4YB7).
Crystal structure 4YRX 4YB5 4YB6 4YB7
4YRX - 1.61 Å 2.17 Å 3.78 Å
PR-ATP bound CjeATP-PRT Core 0.47 Å 1.45 Å 2.14 Å 3.63 Å
ATP bound CjeATP-PRT Core 0.47 Å 1.54 Å 2.19 Å 3.70 Å
PRPP bound CjeATP-PRT Core 0.41 Å 1.55 Å 2.22 Å 3.80 Å
3.8.4 Comparison to the CjeATP-PRT wild type
When compared to the wild type CjeATP-PRT structures, several distin-
guishing features of the Core mutant are evident. Logically the resolved
chains entirely lack the regulatory ACT domain. Most importantly though,
the presented dimer interface closely resembles the dimer interfaces of the
histidine bound wild type structures (4YB5 and 4YB6). Superimposition
of the CjeATP-PRT Core crystal structures with the dimeric catalytic core
portions of the wild type structures (Table 3.4) shows the highest similari-
ties exist between all Core mutant structures the histidine bound wild type
structure (4YB5). In these structures the same close distance between the
C-terminal ends of α3 (3.4 Å between the peptide oxygen atoms of S86 and
S86’) and large distances between α8 helices and the α1-β2 loops (12.3 ± 0.4
Å between peptide oxygen of A179 and γ oxygen of S38’) are found, which
stand in stark contrast to the measurements made on the ATP bound wild
type structure (4YB7) (14.0 ± 0.7 Å between the peptide oxygens of S86
and S86’, and 5.2 ± 0.7 Å between peptide oxygen of A179 and γ oxygen of
S38’). This inverse relationship shows that the CjeATP-PRT Core mutant
114
exists in a similar conformation to the inhibited dimeric units of the wild
type (Figure 3.12). This was observed for the unliganded as well as for all
ligand bound crystal structures of CjeATP-PRT Core.
Figure 3.12: Structural superimposition of CjeATP-PRT Core and wild
type enzymes. Front (A + B) and side view (C + D) on the dimeric assemblies
of 4YRX (blue), 4YB5 (red) and 4YB7 (green) in their cartoon representation.
Overlays were performed using PyMol.99
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The structure also supports the existence of the mutant as a dimer,
as the dimers of neighbouring unit cells fail to arrange in a composition
resembling the CjeATP-PRT wild type hexamer.
3.8.5 Active site ligands
The ligand soaked crystals of CjeATP-PRT Core resulted in data sets of
comparable resolution to the apo structure (Table 3.5), featuring well re-
solved ligand density for the substrates ATP and PRPP, but especially for
the product PR-ATP (Figure 3.15A). A summary of their parameters and
refinement statistics can be found in Table 3.5. The position of the ligands
and the involved binding interactions in the active site are described in detail
in this section.
The substrate ATP is bound in a position nearly identical to its binding
mode in the wild type enzyme (Figure 3.13). Both orientations of the adenine
that had been observed in 4YB7 were also found in CjeATP-PRT Core, with
a phosphate ion bound in the loop next to the ATP in the catalytically irrele-
vant position. Consequently all interactions of ATP described in section 2.9.4
with active site residues are also present in CjeATP-PRT Core. Residues
Q12, R16 and R54 bind to the triphosphate, while N75 forms hydrogen bonds
to the ribose, and C104, L170 and R16 form hydrophobic interactions with
the adenine ring system. The metal in complex with ATP differs. Although
the binding site between D55 and D56 is equivalent, the high electron density
of the coordinated metal in CjeATP-PRT Core was attributed to the bind-
ing of Zn2+ from the crystallisation condition. The zinc ion substitutes the
magnesium ion, found in the wild type enzyme, and adopts an octahedral
coordination geometry uncommon for Zn2+. These results strongly support
the binding experiments performed by ITC and confirm that ATP binding
is not adversely affected by the removal of the regulatory domain.
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Table 3.5: Preliminary crystal parameters, data collection, and refinement statis-
tics for CjeATP-PRT Core ligand bound structures.
ATP PRPP PR-ATP
Data collection
Crystal system trigonal trigonal trigonal
Space group P212121 P212121 P212121
Unit cell parameters
a, b, c [Å] 66.17, 79.92, 92.25 66.00, 79.69, 91.12 67.46, 80.46, 92.73
α, β, γ [◦] 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Resolution range [Å] 46.12–2.00(2.05–2.00) 45.56–2.10(2.16-2.10) 44.55–1.90(1.94–1.90)
Measurements 264717 422010 439398
Unique reflections 33714 28897 40502
Completeness 99.8 (100.00) 99.9 (98.5) 99.8 (97.1)
Redundancy 7.9 (8.1) 14.6 (14.4) 10.8 (10.5)
I /σ(I ) 13.6 (3.3) 27.3 (3.7) 23.9 (3.2)
Rmerge 0.082 (0.549) 0.096 (0.803) 0.067 (0.910)
CC1/2 0.998 (0.948) 0.999 (0.896) 1.000 (0.769)
Wilson B value [Å2] 31.4 28.6 24.8
Matthews coefficient 2.41 2.37 2.49
Refinement
Resolution [Å] 40.00–2.00 40.00–2.10 40.00–1.90
Rcryst 0.208 0.209 0.196
Rfree 0.251 0.263 0.229
Chain length 226 226 226
Observed residues 222, 216 222, 218 222, 222
Water molecules 148 207 194
Others 2 ATP, 1 phosphate,
1 ribose, 3 Zn2+, 3 ac-
etate
2 PRPP, 3 acetate, 6
Zn2+, 2 Mg2+, 2 1,2-
ethylendiol
2 PR-ATP, 6 Zn2+
Mean B [Å2]
Protein 40.88 32.80 34.15
Water 39.35 34.00 32.12
Other 49.46 40.88 48.87
Ligand 52.55 54.78 31.20
RMSD
Bond lengths [Å] 0.013 0.012 0.008
Bond angles [◦] 1.710 1.504 1.430
Chiral volumes [Å3] 0.090 0.082 0.078
Ramachandran
Preferred % 98.38 97.13 97.93
Allowed % 1.39 2.87 1.84
Outliers % 0.23 0.00 0.23
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Figure 3.13: ATP binding in CjeATP-PRT Core. The binding mode of
the ATP molecules found in 4YB7 (A) and ATP bound CjeATP-PRT Core (B)
are compared by A/B: Planar plots of all ATP interactions in both structures cre-
ated with LigPlot+.94 Hydrogen bonds are depicted as dashed lines labelled with
the real space distances between atoms. Hydrophobic interactions are displayed
as short radial red lines. Conserved interactions are highlighted in red. Water
molecules are displayed as cyan spots. Metal ions are green. C: Superimposi-
tion of the three-dimensional structures of 4YB7 (backbone green, ATP pink) and
ATP bound CjeATP-PRT Core (backbone blue, ATP yellow) in cartoon and stick
representations. Hetero-atoms are coloured according to element: oxygen (red),
nitrogen (blue), phosphorous (orange), magnesium (white), zinc (grey).
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The substrate PRPP has not been observed in any ATP-PRT long
form crystal structure reported to date, but correlations can be made to the
short form structure of LlaATP-PRT, as the active sites are similar in long
and short forms. The binding mode of PRPP observed in the active site of
CjeATP-PRT Core (Figure 3.14) was different from the expectations based
on previous findings.36 The 5’-phosphate binds in the PRPP binding loop,
as expected, but the pyrophosphate bridges over to the metal coordination
site on domain I, instead of interacting with S154 and E156 of domain II.
Figure 3.14: Observed PRPP binding mode. A: PRPP (yellow) surrounded
by electron density (Fo-Fc map - grey mesh). Active site residues of CjeATP-PRT
Core (blue) are shown as sticks. Zn2+ (grey) and Mg2+ (green) ions are displayed
as spheres. B: Planar plot of all PRPP interactions created with LigPlot+.94
Hydrogen bonds are depicted as dashed lines labelled with the real space distances
between atoms. Hydrophobic interactions are displayed as short radial red lines.
Water molecules are displayed as cyan spots. Hetero-atoms are coloured according
to element: oxygen (red), nitrogen (blue), phosphorous (orange).
In the observed orientation, PRPP would cause steric clashes with ATP
bound in the conformation described above. Therefore this conformation may
not be catalytically relevant. Most of the interactions seen for the ribose-
5’-phosphate portion of PRPP are identical to the interactions described for
AMP in the wild type (section 2.9.4), mainly formed with the backbone and
short side chains of residues 169–176 (the PRPP binding loop). The py-
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rophosphate group forms interactions with Y131 and R16 and the bound
metal ions. R16 bends out of its ATP binding conformation to accommodate
the pyrophosphate group of PRPP, which reflects the importance of posi-
tively charged side chains for the binding of the phosphate-rich ATP-PRT
substrates.
As for the other ligand bound crystal structures, the PRPP bound
CjeATP-PRT Core contains zinc in the metal coordination site (D55, D56),
but an additional magnesium ion is observed binding between two oxygen
atoms of the PRPP α and β-phosphate. The presence of magnesium in
addition to zinc was unexpected, but is likely due to the use of Mg2+ saturated
PRPP solution for the crystal soak.
This is the first report of the large product molecule PR-ATP as a
complete entity in an ATP-PRT active site. The information about the
PR-ATP binding mode gathered from this structure is comparable to the
findings of the substrate binding modes. PR-ATP is accommodated in both
parts of the active site. It can be described roughly as “zig-zag”-shaped,
with the adenine in the centre and the ribose monophosphate and the ribose
triphosphate on either end facing in opposite directions (Figure 3.15).
This conformation closely resembles the superimposition of ATP and
AMP binding modes found in the CjeATP-PRT wild type structures. The
N1 linked phosphoribosyl group binds in the same position as seen for PRPP
and AMP, making contacts to residues of the PRPP binding loop. The
adenine is held between R16 and L170 in a position equivalent to the ones
seen for ATP and AMP. The ribose triphosphate part of the molecule sits in
a position again identical to that of ATP.
The only unoccupied area in each active site is situated next to the
phosphoribosyl moiety on domain II, formed by the β8-α6 loop and the
conserved residue E156 (of helix α8). This most likely represents the binding
site for PP, either free or as part of PRPP. The metal coordination site is
also identical to the other ligand bound structures of CjeATP-PRT Core and
contains a zinc ion.
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Figure 3.15: Phosphoribosyl-ATP in the active site of CjeATP-PRT
Core. A: PR-ATP (bright yellow) surrounded by the observed electron density
(Fo-Fc map - grey mesh). The CjeATP-PRT Core (blue) is shown in cartoon
representation and the Zn2+ ion as a sphere (grey). B: Surface display of the dimer
with the PR-ATP molecules bound in the active site cavities. C: PR-ATP and Zn2+
binding mode in the active site. Residues and water molecules in close distance are
displayed as sticks and spheres respectively. Hetero-atoms are coloured according
to element: oxygen (red), nitrogen (blue), phosphorous (orange), sulphur (yellow),
zinc (grey).
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PR-ATP showed a strong, well defined electron density with the av-
erage B factor of 31.2 Å2 well matched to the surrounding residues (25-35
Å2). This is indicative of a high affinity to the active site and low conforma-
tional flexibility. This finding strongly supports the determined inhibitory
properties of PR-ATP for CjeATP-PRT Core.
3.9 The CjeATP-PRT ACT domain
3.9.1 Cloning and purification
Alongside the CjeATP-PRT Core the second portion of the full length protein
chain, the regulatory domain, was cloned as a separate protein (Figure 3.16A)
denoted CjeATP-PRT ACT. The cloning followed the procedure described
in section 6.3.1, with two different forward primers, to generate a tagged




17, and an untagged con-
struct in pDEST
TM
14. As for the Core mutant, a desirable level of solubility
of the overexpressed protein was only achieved using the GST-tagged con-
struct (pDEST
TM
15), which was consequently used for all purifications of
CjeATP-PRT ACT.
The purification protocol for the CjeATP-PRT ACT protein followed a
sequence of chromatography steps. An initial GST affinity chromatography
step isolated the protein from the clarified supernatant. It was followed by
TEV protease incubation (1 h at 37◦) and a second GST affinity chromatog-
raphy to remove the free GST tag. After these steps the protein preparation
still contained TEV protease, which co-eluted with the CjeATP-PRT ACT
from a SEC run. Therefore the protein preparation underwent further pu-
rification by IMAC to remove the TEV protease before the final SEC step
(Figure 3.16B).
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Figure 3.16: Preparation of CjeATP-PRT ACT. A: Agarose gel showing the
amplified genes of CjeATP-PRT ACT (tagged and un-tagged) from three selected
clones each using the colony PCR set up described in section 6.1.17. The gel was
run according to section 6.1.13. B: Protein purity was assessed by SDS-PAGE,
ran according to section 6.1.31 using a Bolt R© 10% Bis-Tris Gel and MES buffer.
3.9.2 Characterisation
It was noted during its purification that the purified CjeATP-PRT ACT
species co-elutes with TEV protease (27 kDa) from a size exclusion column.
As the theoretical molecular mass of CjeATP-PRT ACT is 8.7 kDa. This
was taken as a first indication that it may exist as a trimer, analogous to the
regulatory trimer arrangement of the full length CjeATP-PRT enzyme. To
confirm the oligomeric state, SLS was performed, resulting in a calculated
mass of 23.4 kDa, which is closer to a trimer (26.1 kDa) than to a dimer (17.4
kDa). Consequently it was assumed that the protein exists in a trimeric form
in solution.
CjeATP-PRT ACT was tested for its thermostability using DSC. A
single run containing 0.35 mg mL −1 protein in the cell was performed fol-
lowing the description in section 6.138. The resulting curve showed a very
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late melting event for the protein sample around 94 ◦C (Figure 3.17), which
was confirmed by later repeats. This unexpectedly high melting tempera-
ture was interpreted as a measure of tight internal interactions of the ACT
domain trimer, which lead to a very stable conformation.
Figure 3.17: Thermostability of CjeATP-PRT ACT. DSC measurements
were performed according to section 6.1.38 with a MgCl2 concentration of 5 mM.
The resulting melting curve was baseline subtracted (solid line) and fitted against
a single melting event (dashed line).
To assess the function of the pure CjeATP-PRT ACT preparation it was
used in a kinetic assay with CjeATP-PRT Core (section 6.3.3) at CjeATP-
PRT Core to CjeATP-PRT ACT ratios of 1:1, 1:10, and 1:20. The outcome
was very clear. The ACT domain did not display any measurable activity
itself, nor did it enhance the activity of the CjeATP-PRT Core mutant at
any of the tested ratios. It also did not impose a sensitivity towards histidine
on the Core mutant (Figure 3.18B).
To test if the purified protein was functional as a histidine binding
module, an ITC experiment was performed. Under the given conditions
(section 6.3.4) binding of histidine to CjeATP-PRT ACT was not observed
(Figure 3.18A). Together the kinetic and ITC results indicate the protein
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does not appear to have retained the function of the covalently linked ACT
domain in the CjeATP-PRT wild type enzyme.
Figure 3.18: CjeATP-PRT ACT functionality. A: ITC binding curve of 1.5
mM histidine against 57 µM protein was measured under the conditions described
in section 6.1.39, subtracted by the corresponding heat of dilution data series and
fitted using OriginLab R© version 7.0. B: Kinetic data acquired for CjeATP-PRT
Core and ACT under the assay conditions described in section 6.3.3 in the absence
(blue) and presence (red) of 0.5 mM histidine. Data was normalised against the
CjeATP-PRT Core activity without additives.
Circular dichroism (CD) can be used to assess the secondary struc-
ture composition of a pure protein sample (section 6.1.36). The inconclusive
results for the CjeATP-PRT ACT protein led to comparative analysis by
CD. The resulting ellipticity curve showed that the isolated protein species
is at least partially unfolded, displaying a prominent peak in the CD spec-
trum around 204 nm (Figure 3.19). Peaks at 210 nm (α helix) and 220 nm
(β strand) are only weakly pronounced, compared to the theoretical spec-
trum100 for the CjeATP-PRT ACT trimer, which is consistent with a loss of
those secondary structure elements. Given its defined oligomeric state and
high melting temperature, this result was surprising.
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Figure 3.19: Folding of CjeATP-PRT ACT. Five point averaged ellipticity
was generated from the raw CD measurements according to section 6.1.36. The
curves for CjeATP-PRT wild type (green) and CjeATP-PRT ACT (red) are shown
in comparison. A predicted spectrum (black dashed) was generated from the PDB
coordinates of an isolated ACT trimeric unit using DichroCalc.100 Typically CD
peaks are associated with: β strand (220 nm), α helix (210 nm) and random coil
(200 nm).
3.9.3 Crystallisation
Crystallisation trials with CjeATP-PRT ACT resulted in a couple of initial
hits (section 6.3.5). All of these conditions were up-scaled and fine-screened
but failed to produce any crystals except JCSGplus premier
TM
HT-96 B9.
Crystals grown from this condition were of very poor diffraction quality,
resulting in weak diffraction patterns with resolutions ≥ 10 Å.
A single data set was collected from a crystal grown directly in the
JCSGpluspremier
TM
HT-96 screen in condition E1 (Figure 3.20). Diffraction
spots were visible out to approximately 4 Å, but the overall data quality was
too poor to resolve the structure by molecular replacement. If the protein is
in fact partially or completely unfolded, a solution by molecular replacement
with the CjeATP-PRT ACT domain as model is very unlikely.
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Figure 3.20: CjeATP-PRT ACT crystal. Crystal image of CjeATP-PRT
ACT crystal from JCSGplus premier
TM
HT-96 screen condition E1 taken during
diffraction collection on the Australian Synchrotron MX1 beam line.
3.10 Discussion
All results presented in this chapter are consistent with the formation of a
dimeric, functional, truncated species of the CjeATP-PRT enzyme by remov-
ing the regulatory ACT domain. The CjeATP-PRT Core mutant shows low
ATP-PRT activity and active site ligand interactions, but lacks the sensitiv-
ity to histidine, along with its entire regulatory apparatus. The presented
crystal structures contain high quality information about the ligand binding
properties of the CjeATP-PRT active site. This includes the presence of the
product molecule PR-ATP with high detail and resolution. Unfortunately
under the conditions used, an AMP bound crystal structure could not be
obtained, but all other results clearly show that AMP is still an effective
inhibitor to the enzyme.
Zinc has been found to replace the active site magnesium ion in all
ligand bound CjeATP-PRT Core crystal structures. As part of the crystalli-
sation condition, zinc is present during crystallisation in a 2:1 ratio with mag-
nesium that is present in all CjeATP-PRT buffers. The high affinity of zinc
to the metal site can therefore not be attributed to its excess alone. Activity
measurements with zinc in the absence of magnesium were not successful
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due to the immediate formation of precipitate of both CjeATP-PRT Core
and wild type enzyme. The same protein-destabilising effect of zinc was seen
during crystallisation. The fortunate exception here was that CjeATP-PRT
Core is able to refold and form high quality crystals from the precipitate.
This suggests that zinc does not have any biological function in CjeATP-
PRT. Nevertheless zinc can substitute for magnesium in the active sites of
CjeATP-PRT Core crystals, adopting the octahedral coordination of magne-
sium in the presence of ligand molecules. It is likely that this substitution and
the involvement of Zn2+ in the crystal packing provides stability to the com-
plex and allows for the high resolution of the structures and the observation
of the bound ligands.
PRPP was found to bind the active site in an unexpected way.36 This
is likely to be caused by the presence of zinc in the crystallisation condition,
which attracts the negatively charged pyrophosphate group of the bound
PRPP molecule. Similarly, a magnesium ion in the metal coordination site
(D55 and D56) could cause the observed conformation. The additional mag-
nesium ion bound to the α and β-phosphate supports this assumption. The
way in which PRPP binds obscures the binding site for the ATP triphos-
phate (Figure 3.21A), as both ligands individually coordinate to the bound
metal. This binding mode could represent the “safe keeping” of PRPP by the
enzyme, discussed in chapter 2 and explain the observed binding of PRPP
to the wild type enzyme in the absence of ATP. Upon the entrance of an
ATP molecule, the pyrophosphate group could be removed from the metal
by the electrostatic repulsion of the ATP triphosphate and shift PRPP into
the expected position for catalysis (Figure 3.21B).
The CjeATP-PRT Core preparation showed significant levels of activity
under the used assay conditions, but very high protein concentrations were
required. This is reflected in its low turn over rate of < 0.03 s−1. Recent
studies on CglATP-PRT have shown that the truncation of the regulatory
domain in the native enzyme leads to a comparable decrease in the catalytic
turnover rates of the resulting mutants,98 consistent with the results obtained
for CjeATP-PRT Core.
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Figure 3.21: Occupation of the CjeATP-PRT Core active site. A: ATP
(yellow), PRPP (pink) and PR-ATP (green) represented as sticks as observed
in the enzyme active site (blue), shown as surface. The three structures were
superimposed on their α-carbon chains. R16 is removed for better visibility B:
The two proposed binding states of PRPP in the active site. Individually PRPP is
able to bridge over and coordinate to the bound metal. As ATP enters the active
site, PRPP moves away and catalysis can occur, visualised by the product PR-
ATP. Zinc is displayed as a sphere (grey). Hetero-atoms are coloured according to
element: oxygen (red), nitrogen (blue), phosphorous (orange).
The sensitivity of the CjeATP-PRT Core to AMP is higher than for
the wild type protein. ITC experiments also indicate a significantly higher
affinity for ATP in the Core mutant. The substrate binding abilities are well
conserved, evident by both ITC and crystallography, and can therefore be
ruled out as the reason for the low catalytic turn over. It seems more likely
that the high ligand affinities cause the enzyme to be kinetically trapped,
making the dissociation of either ATP or PR-ATP the rate determining step.
This assumption is strongly supported by both the determined product inhi-
bition of PR-ATP and its high crystallographic resolution, as these indicate
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a very slow release of the product from the active site. Overall it appears
that the CjeATP-PRT Core dimer is not well suited to conduct catalysis and
merely provides a specific binding site.
The lack of the regulatory domain causes the catalytic domains to adopt
a conformation that is seen for the dimeric units in all histidine bound long
form ATP-PRT structures. SAXS analysis also confirmed the existence of
a single species in solution, which fits well to the obtained CjeATP-PRT
Core crystal structure. The existence of the CjeATP-PRT Core in this fixed,
“naturally inhibited” conformation is likely to be the rationale for the low
activity observed. The 3-fold increase in the KM value for PRPP can also
be accounted for by this fact, as the inhibited dimer interface causes changes
in the putative pyrophosphate binding site.36 Since CjeATP-PRT Core pre-
dominantly adopts this inhibited conformation, the assumption can be made
that it represents the lowest energy state or the most stable conformation for
any ATP-PRT dimer. The decreased catalytic properties of the truncated
long form mutants would therefore ultimately be caused by the disturbance
of the hexameric state of the enzyme, which provides either conformational
or dynamic control to the active sites by the way of ACT domain motion.
It could be concluded that the ACT domains are required for CjeATP-PRT
to adopt the active and not the inactive state, and that they are as much
required for effective catalysis as they are for feedback inhibition. This hy-
pothesis opposes all previously drawn conclusions about the existence of an
active dimeric long form ATP-PRT species,26,35 as it is unlikely that the ACT
domains on either end of the dimer cause significant changes in the dimer
interface on their own.
While the vast majority of CjeATP-PRT Core exists as a dimer, there
is limited evidence for a higher order species with the size of a potential
hexamer. Considering the distribution between the species by AUC, the
higher order species can not account for the total CjeATP-PRT Core activity
measured, but its contribution can not be ruled out entirely. The observed
peak may also correspond to a structurally undefined aggregate as a result
of slow decay in solution.
130
In contrast to CjeATP-PRT Core, the isolated CjeATP-PRT ACT ap-
peared to have conserved neither fold nor function of to the regulatory do-
main of the full length enzyme. Although it was expressed in a soluble form
and likely adopted a trimeric quaternary structure, the CjeATP-PRT failed
to possess any measurable histidine binding abilities. Furthermore CjeATP-
PRT ACT was unable to interact with the CjeATP-PRT Core in solution
to provide for enhanced activity or histidine sensitivity. These results can
be interpreted in different ways. The purified species could have been ei-
ther misfolded or the assembly misarranged, which is strongly supported by
the measured CD spectrum. Oligomeric state analysis on the other hand
supports the presence of a defined soluble trimeric species. Considering its
relatively high melting temperature, the isolated CjeATP-PRT ACT species
must have adopted a very stable and/or compact conformation. As crystal-
lographic evidence is missing, the structural details of this conformation can
only be speculated and it is questionable if it possesses any similarities to
the ACT domain of CjeATP-PRT. The majority of the ACT domain fold
consists of β strands and a small shoulder around 220 nm was observed in
the CD data. A possible conformation could therefore be composed of a
triple central beta sheet, similar to the tight histidine bound state of the
ACT domains in the CjeATP-PRT wild type, with the surrounding helices
being random coils. Whatever the actual adopted conformation is, the clear
change in 3D structure and/or multimeric assembly is the likely reason for
the loss of histidine binding abilities.
Apart from its role as an inhibitor binding module, which could not
be proven by a direct investigation of the isolated species, the ACT domain
trimer provides structural integrity to the hexamer. This is evident in the
lower melting temperature (approximately 11 ◦C) of the Core mutant com-
pared to the wild type CjeATP-PRT.
By removing the ACT domain the CjeATP-PRT was reduced to its
catalytic apparatus only and it adopted a dimeric state, like isolated short
form ATP-PRTs.101 This unregulated species, CjeATP-PRT Core, possesses
strong binding abilities but lacks an efficient catalytic turn over. Following
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the idea that both contemporary ATP-PRT subfamilies derive from the same
ancestor,37 the CjeATP-PRT Core could be viewed to be a precursor-like
intermediate species that could evolve in either direction, either by gene
fusion with an ACT domain or by recruiting a secondary protein chain. The
low catalytic capabilities of this intermediate clearly show that the modern
long form ATP-PRT enzymes are not simply the sum of their structural and









Allosteric signal transduction, the way by which ligand binding to a remote
site is communicated to the active site of an enzyme, occurs via a variety
of different mechanisms. Depending on the enzyme, large or subtle changes
in conformation or dynamics can occur, which rearrange domains, single
structural elements, interfaces or simply side chains. Often these changes are
communicated along a defined internal pathway by the formation or break
down of key interactions.
The existence of a signalling pathway in CjeATP-PRT that connects
the remote allosteric histidine binding site to the active site, and vice versa, is
conceivable due to the synergistic character of AMP and histidine inhibition.
While the removal of the regulatory ACT domain crudely and undoubtedly
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removed the regulation by the feedback inhibitor histidine, it also highlighted
the need for the regulatory apparatus for the maintenance of the active state
of the enzyme. It is clear that histidine binding causes a change in both
the ACT domain interface, which is directly involved in the binding process,
and the dimer interface, which influences the active sites. But other than
the gross conformational changes, no internal pathway by which the signal
is communicated has been identified.
An approach to segregate inhibitory response from enzymatic activity is
the mutational exchange of residues that are positioned along the inhibitory
pathway. If key interactions are broken or disturbed, the inhibitory trans-
mission could be disrupted without affecting the enzyme function. In the
following chapter approaches to delineate an exact pathway including the
partial characterisation of one such mutant of CjeATP-PRT are described.
4.2 Identification of potential residues of a in-
hibitory signal transduction pathway
The first step in the process of uncovering the signalling pathway was to
identify key residues that may play a role in the signal transmission. A first
idea about crucial interactions was obtained by inspecting the binding modes
of the active site ligands presented in the crystal structures of the previous
chapters. The search was focussed especially on changes that occur between
the two observed conformations of CjeATP-PRT.
Very pronounced changes were seen for the flexible α1-β2 loop, which
forms the only inter-molecular connection in the active site of the AMP
bound form (4YB6) via the side chains of the two histidine residues H33 and
H35 (Figure 4.1). The loop occupies the same position in the histidine bound
crystal structure (4YB5), while it is far away from any possible interaction
in the ATP bound structure (4YB7) (section 2.9.6). It seems likely that this
prearrangement of the loop is involved in the synergistic effect of histidine
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on AMP inhibition and it was therefore hypothesised to be part of an in-
hibitory signalling pathway. Consequently, H33 and H35 were targeted by
mutagenesis. Due to their close sequence proximity, it was decided to create
a double mutant altering both residues simultaneously, H33 to alanine and
H35 to serine. Serine was chosen to retain the hydrophilic character of the
loop, while removing its binding ability.
Figure 4.1: Double histidine motif of CjeATP-PRT α1-β2 loop. Cartoon
and stick representation of the CjeATP-PRT active site. A single AMP (pink) is
bound between chain A (green) and chain D (cyan). The two hydrogen bonding
interactions with H33’ and H35’ are highlighted (yellow dashed lines). Residues in
close distance to AMP are displayed as sticks. Atoms are coloured according to
element: oxygen (red), nitrogen (blue), sulphur (yellow), phosphorous (orange).
Two more residues for mutation were chosen after careful inspection
of the active and inhibited CjeATP-PRT crystal structures. When superim-
posed on a single ACT domain, the relative position change of the surround-
ing structural elements became visible. One of the most prominent differences
was found in the long α8 helix that connects domain I with the ACT domain
of each chain. The helix exhibits a relative angle change of approximately
30◦ between the superimposed chains. Two arginine residues were identified
that are seemingly involved in facilitating this movement, R216 and R224.
Upon the movement of α8, R216 changes not only its position but also its
connectivity (Figure 4.2). In the absence of histidine (4YB7) it interacts
strongly only with W275. This interaction is also maintained in the pres-
ence of histidine (4YB5), but a new connection is formed to N272, bridging
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the gap between the domains. This new connection was also one of the few
interactions that does not directly involve the histidine binding site. R224
maintains its connectivity to D100 in both structures, but is turned sideways
as the helix moves and the β5-β6 loop with D100 follows this motion. This
movement was thought to have an influence on the directly adjacent active
site. To abolish any possible side chain interactions, both arginine residues
were mutated to alanine.
Figure 4.2: Relative positioning of the α8 residues R216 and R224.
Environment of the arginine residues R216 (A and B) and R224 (C and D) in
cartoon representation compared between the active (green) and inhibited (purple)
CjeATP-PRT crystal structures. Hydrogen bonding interactions are highlighted
(yellow dashed lines). Hetero-atoms are coloured according to element: oxygen
(red), nitrogen (blue).
Histidine binding causes the dimer interface to undergoe significant
changes, as described in chapter 2. The individual chains rotate relative to
each other and form new contacts in close proximity to their active sites. One
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of these contacts includes R54, a highly conserved residue that is responsible
for the binding of the triphosphate group of ATP in the open CjeATP-
PRT conformation (4YB7). In the histidine bound crystal structure (4YB5)
R54 is interacting closely with its symmetric counterpart R54’ at the centre
of the dimer interface. To disrupt a potential communication across the
interface via this contact, R54 was chosen as a fourth target for mutagenesis.
Like R216 and R224, R54 was mutated to alanine. Figure 4.3 shows the
relative conservation of the chosen residues with respect to the structurally
characterised long form ATP-PRT enzymes.
4.3 Cloning and purification
The site directed mutagenesis (procedure described in section 6.4.1) was suc-
cessful for all three single site mutants, R54A, R216A and R224A, delivering
sequence verified clones in pDEST
TM
17 (Figure 4.4). While this approach
also produced successful amplification of constructs for the double histidine
mutant H33A/H35S it failed to generate the desired mutations. Multiple
colonies from different mutagenesis approaches with different annealing tem-
peratures were analysed by DNA sequencing without success. The mutations
were either not present, or the mutagenesis primer was inserted into the gene
multiple times (2x, 3x, and 4x). Amongst all sequenced clones, one contained
both the parental plasmid with CjeATP-PRT wild type sequence and a plas-
mid with the correct mutations, evident as a mixed read in the sequencing
chromatogram. Because of these difficulties, especially the multiple primer
Figure 4.3 (following page): Conservation of mutated CjeATP-PRT
residues. Multiple sequence alignment of all long form ATP-PRT sequences with
available structural information. Secondary structure elements of CjeATP-PRT
are displayed above as arrows (β strands) and spirals (α helices). Residues are
coloured according to conservation: absolutely conserved (white, red box), par-
tially conserved (red) and not conserved (black). Green triangles indicate the po-
sition of the mutated residues. Organism three letter code: M. tuberculosis (Mtu),
M. thermautotrophicus (Mth), E. coli (Eco) and C. jejuni (Cje). Alignment was
created with ClustalOmega84 and edited using ESPript.88
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inserts, the initial primer design and preparation were replaced with a primer
set containing a 7 base pair longer overlap on the forward direction 3’-end.
Unfortunately this did not yield any suitable amplification under the con-
ditions used either and this mutant was not pursued further due to time
constraints.
Figure 4.4: CjeATP-PRT mutagenesis. Agarose gel electrophoresis of the
site directed mutagenesis reactions generating the three single site mutants of
CjeATP-PRT. The reactions of R54A (left), R216A (middle) and R224A (right)
were performed at an array of different annealing temperatures according to section
6.4.1 using Pfu Ultra High-Fidelity Polymerase. Electrophoresis was performed
according to section 6.1.13
Test expression showed good solubility for all mutants in all strains
tested. Consequently, all large scale expression and purification was per-
formed with Chaperone3 strains, following the established protocol of the
CjeATP-PRT wild type. The purification results with respect to purity and
yield were comparable with the wild type enzyme (Figure 4.5). As seen for
the wild type, the highly pure mutant enzymes showed an additional band
around 66 kDa corresponding to the dimeric size of CjeATP-PRT, due to
insufficient denaturation time.
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Figure 4.5: Purification of the CjeATP-PRT R216A mutant. SDS-PAGE
showing selected purification steps of both wild type and R216A enzymes in com-
parison. 15 µL samples were taken from the preparations at each step, denatured
with 5 µL of sample loading dye for 2 minutes at 95 ◦C, loaded disregarding the
differences in protein concentration. Gel was run according to section 6.1.31. Lane
labels correspond to: MWM - molecular weight marker, CL - crude lysate, SN -
clarified supernatant, IMAC - pooled eluate fractions of the IMAC column, TEV -
sample during/after TEV protease incubation, SEC - pooled fractions after SEC.
4.4 Determination of molecular weight
The molecular masses of the purified CjeATP-PRT R54A and R216A mu-
tants were determined to be 33607.9 g mol−1 and 33609.4 g mol−1 respectively
by electrospray ionisation mass spectrometry. These values are in agreement
with the theoretical value of 33611.1 g mol−1 calculated for the 300 amino




To determine if the generated mutant enzymes adopted similar folds to the
wild type enzyme, CD experiments were performed. All curves were similar
in shape (Figure 4.6), showing the two main peaks for α helices (210 nm)
and β strands (220 nm). None of the mutants showed signs of unfolding (200
nm) as the CjeATP-PRT ACT protein did (section 3.9). These results are
consistent with a similar secondary structure composition and native folding
of the mutants analogous to the wild type protein.
Figure 4.6: Folding of CjeATP-PRT mutants. Five point averaged ellipticity
was generated from the raw CD measurements according to section 6.1.36. The
curves for CjeATP-PRT wild type (green), CjeATP-PRT Core (blue), CjeATP-
PRT R216A (red) and CjeATP-PRT R54A (purple) are shown in comparison.
Typically CD peaks are associated with: β strand (220 nm), α helix (210 nm) and




Neither crude nor highly pure CjeATP-PRT R54A exhibited any measurable
catalytic activity under standard assay conditions. Hence further kinetic
characterisation of this mutant was not pursued. As the protein showed
correct folding, the total loss of activity must be a direct consequence of the
mutated residue. This is not completely unsurprising, as R54 plays a role in
ATP binding (section 2.9.4).
4.6.2 CjeATP-PRT R224A
The crude preparation (section 6.4.2) of the CjeATP-PRT R224A mutant
showed an activity of approximately 10 % compared to the wild type enzyme
under standard assay conditions. It was also still responsive to histidine, be-
ing fully inhibited in the presence of 1 mM histidine (Figure 4.7). Due to this
wild type-like behaviour it was excluded from any further characterisation.
4.6.3 CjeATP-PRT R216A
Like the CjeATP-PRT R224A mutant, the CjeATP-PRT R216A mutant
showed a largely reduced activity, compared to the wild type enzyme. No
further activity loss was observed in the presence of 1 mM histidine though, a
concentration at which the CjeATP-PRT wild type is fully inhibited (Figure
4.7). This is a clear indication that the inhibitory response to histidine
is compromised in this mutant. A comparison of the kinetic parameters
determined for wild type and R216A mutant, as well as the Core mutant is
summarised in Table 4.1. It is evident from these results that the catalytic
properties of CjeATP-PRT R216A are closer to the CjeATP-PRT Core than
to the wild type enzyme, with an increased KM(PRPP) value and a two
orders of magnitude lower kcat value.
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Figure 4.7: Comparison of the CjeATP-PRT mutant activities. Specific
activity was measured under standard assay conditions (section 6.1.33) using sat-
urating substrate concentrations (2 mM ATP and 0.3 mM PRPP) in the presence
of 0 and 1 mM histidine and normalised against the wild type value. The Y-axis
break indicates a jump of 75 %. Colours correspond to: CjeATP-PRT wild type
(green), CjeATP-PRT R224A (blue), CjeATP-PRT R216A (red), CjeATP-PRT
R54A (purple).
To verify the initial results, the response of CjeATP-PRT R216A to
histidine was determined over three orders of magnitude (0.2–20 mM). The
results show very low variance in the overall activity that does not follow a
trend (Figure 4.8A), consistent with the absence of a histidine response.
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Table 4.1: Kinetic constants of CjeATP-PRT R216A. Measurements were
performed according to section 6.4.3. Equivalent values of CjeATP-PRT wild type
and CjeATP-PRT Core are given as a comparison.
CjeATP-PRT KM (ATP) [µM] KM (PRPP) [µM] kcat [s
−1]
R216A 133 ± 19 36 ± 4 0.033 ± 0.001
Wild type 97 ± 10 15 ± 1 1.8 ± 0.1
Core 94 ± 11 41 ± 5 0.024 ± 0.003
The CjeATP-PRT R216A mutant was furthermore found to be respon-
sive to the active site inhibitor AMP. The IC50 of AMP was determined
to 0.42 ± 0.05 mM and was found to be in good agreement with the IC50
value determined for CjeATP-PRT Core, 0.29 ± 0.02 mM, while it differed
significantly from the wild type value of 2.1 ± 0.3 mM (Figure 4.8B).
Like CjeATP-PRT Core, the R216A mutant was also inhibited by low
concentrations of the product PR-ATP. The IC50 of PR-ATP was determined
to be 3.2 ± 0.3 µM, which is very similar to the value determined for CjeATP-
PRT Core, 6.7 ± 0.7 µM (Figure 4.8C).
These findings confirm that the R216A single site mutation only affects
the inhibition by histidine. In contrast, the sensitivity and most likely the
binding affinity towards active site ligands, in accordance with the results for
CjeATP-PRT Core, is increased. Overall the kinetic properties of CjeATP-
PRT Core and CjeATP-PRT R216A are comparable, indicating that similar
processes may have been compromised in both mutants.
4.7 Isothermal titration calorimetry
Histidine binding experiments were performed (section 6.4.4) on the CjeATP-
PRT R216A mutant to determine whether or not the observed lack of inhibi-
tion was the result of direct interference with the histidine binding site. The
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Figure 4.8: Inhibitory response of CjeATP-PRT R216A. Dose response
curves of CjeATP-PRT R216A (red) to A: histidine, with the X-axis in logarith-
mical scale, B: AMP and C: PR-ATP. The response of the CjeATP-PRT wild type
(green) and CjeATP-PRT Core (cyan) are given as a comparison.
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resulting binding curve demonstrates that this is not the case. CjeATP-PRT
R216A is still able to bind histidine. (Figure 4.9).
Figure 4.9: Histidine binding to CjeATP-PRT R216A. Histidine bind-
ing curve was measured under the conditions described in section 6.1.39 and
6.4.4, subtracted by the corresponding heat of dilution data series and fitted using
OriginLab R© version 7.0.
The shape of the binding curve resembles the binding curve of histidine
binding to the CjeATP-PRT wild type in the presence of AMP (Figure 2.5D).
The dissociation constant was determined by fitting the data to a sequential
binding model with two binding events. The results presented in Table 4.2
are in good agreement with the Kd values measured for the wild type protein,
clearly showing that the histidine binding site has not been affected. With
both activity and allosteric binding confirmed, it is possible to conclude that
the R216A mutation disrupts the transmission of the inhibitory response.
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Table 4.2: Histidine dissociation constants. Kd values were determined by
ITC according to section 6.2.4. A stoichiometry for the histidine titration was
sometimes not determined (ND) due to the type of fit used.
CjeATP-PRT Kd [µM] Stoichiometry
Wild type 19.3 ± 0.2, 14.5 ± 0.2 ND
AMP bound wild type 4.8 ± 0.7, 2.3 ± 0.1 0.85 ± 0.20
R216A 1.0 ± 0.3, 14.5 ± 0.7 1.28 ± 0.02
4.8 Crystallographic analysis
4.8.1 Crystallisation
Crystallisation was successfully achieved for the R54A and R216A mutants
of CjeATP-PRT in co-crystallisation conditions following the procedure de-
scribed in section 6.4.5. Crystals formed in the presence of histidine, AMP
and ATP individually for both mutants. All crystals had similar shapes but
differed in size depending on the protein concentration and ligand used (Fig-
ure 4.10). Unfortunately all CjeATP-PRT R54A crystals failed to diffract
sufficiently for data collection up to this point.
Several datasets of CjeATP-PRT R216A were collected featuring the
different co-crystallisation conditions mentioned above. Overall the quality
of the diffraction was poor (3.5–4.5 Å) Only two datasets of comparable res-
olution were chosen for further processing featuring two different co-crystals,
the first one with histidine and the second one with ATP. The data was
cut to 3.4 Å and integrated in space group P1211. Employing a molecular
replacement strategy, a single solution was found for both data sets with a
search model generated from all six chains of the wild type crystal structure
4YB5. In both cases the initial solution contained the entire hexamer in the
unit cell. Analogous to the search model, both structures were in the inhib-
ited conformation. Later, during early refinement stages, the ATP co-crystal
structure was not further pursued as the solution had obvious flaws regarding
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Figure 4.10: Crystals of CjeATP-PRT R216A. Photographs taken of drops
containing CjeATP-PRT R216A crystals. Drop compositions were A: 0.1 M
Tris/HCl, 0.2 M KSCN, 15–16 % w/v PEG 4000, 1 mM histidine, pH 7.5, B:
0.1 M Tris/HCl, 0.1 M MgCl2, 13–15 % w/v PEG 4000, 5 mM AMP, pH 7.5, C:
0.1 M Tris/HCl, 0.2 M KSCN, 8 % PEG 1000/ 8 % PEG 8000, 10 mM ATP, pH
7.5.
density fit. The histidine dataset, on the other hand, was successfully refined
(Table 4.3).
4.8.2 Comparison of overall fold
Compared to the CjeATP-PRT wild type structure 4YB5, the CjeATP-PRT
R216A crystal structure was of more than 1 Å lower resolution. In all six
refined chains, approximately 40 % of the amino acid side chains had to be
removed, as well as entire residue ranges in areas of poor resolution. These
areas mostly include the more flexible parts of domain II, α6 and the PRPP-
binding loop (β9-α7), which underlines the importance of the mobility of
these structural motifs for CjeATP-PRT function.
No density was observed for the side chain of residue 216. Although
the low resolution of the data set may have caused the side chain of arginine
to be unresolved, the determined molecular weight for CjeATP-PRT R216A
is consistent with this observation. In some of the protein chains, the lack
of interaction with the arginine also led to a visible reorientation of the
tryptophan W275 side chain in the neighbouring subunit, which is another
indication for the presence of the single site mutation.
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The six chains in the unit cell arrange into the closed or inhibited
hexamer conformation, as seen for the wild type structures 4YB5 and 4YB6,
with the typical tight interactions between the ACT domain trimers. The
dimer interface hereby buries a surface of 529.5 Å2, approximately 4.7 %
of the total surface area of one chain, and the trimer interface 855.8 Å2,
equivalent to 6.2 % total chain surface area. The overall lower surface area,
compared to the wild type structures (section 2.9.7), is a direct consequence
of the missing side chain interactions due to the low resolution (3.4 Å). The
closed conformation of this structure becomes most clear by inspecting the
superimpositions with the open and closed wild type crystal structures, with
overall RMSD values of 1.16 Å to 4YB5 and 1.30 Å to 4YB6, but 40.6 Å to
4YB7 (Figure 4.11).
Figure 4.11: Conformation of histidine bound CjeATP-PRT R216A.
Superimposition of the CjeATP-PRT R216A crystal structure (red) with the three
wild type structures 4YB5 (blue, A), 4YB6 (cyan, B) and 4YB7 (green, C) in the
cartoon representation.
4.8.3 Histidine binding
Ligand density was observed in all six chains of CjeATP-PRT R216A at the
histidine binding site. Although the resolution was not sufficient to clearly
identify the bound molecule, it was assumed, based on the apparent site
specificity, that it is histidine (Figure 4.12C). As the ligand density was a lot
less defined, the binding modes of the modelled histidine molecules differ, but
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they appear to consistently form the same contacts as observed in the wild
type structures (Figure 4.12). The interactions with H226, Y228 and T252
were not observed in the mutant crystal structure, which is most likely due to
the conserved water molecule not being resolved. The presence of histidine
in the overall closed enzyme conformation is somewhat unsurprising, but
supports the previous findings on the conserved histidine binding function of
the CjeATP-PRT R216A ACT domains.
Figure 4.12: Histidine binding contacts. Observed binding mode of histidine.
A and B: Planar plots of all observed histidine interactions in the CjeATP-PRT
R216A (A) and CjeATP-PRT wild type (4YB5) (B) crystal structures created
with LigPlot+.94 Hydrogen bonds are depicted as dashed lines labelled with the
real space distances between atoms. Hydrophobic interactions are displayed as
short radial red lines. Water molecules are displayed as cyan spots. Conserved
interactions are highlighted in red. C: Stick representation of the histidine (pink)
between chain E (white) and chain D (pale green) in CjeATP-PRT R216A sur-
rounded by the observed electron density (Fo-Fc map - grey mesh). Hetero-atoms
are coloured according to element: oxygen (red), nitrogen (blue), sulphur (yellow).
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Table 4.3: Preliminary crystal parameters, data collection, and refinement statis-






a, b, c [Å] 92.09, 122.52, 99.31
α, β, γ [◦] 90.00, 107.84, 90.00





















Bond lengths [Å] 0.011
Bond angles [◦] 1.51







The results presented in this chapter demonstrated the uncoupling of the
allosteric inhibition and the enzymatic activity of CjeATP-PRT by mutating
a single residue, arginine R216. This mutation is centred in a pivotal point
of the motion of the regulatory ACT domain. As already observed for the
CjeATP-PRT Core mutant, the interference with the natural movement of
the regulatory apparatus caused a heavy catalytic penalty (approximately
90 % activity loss). In turn the sensitivity to the feedback inhibitor histidine
was completely removed, although histidine was evidently shown to still bind
to the enzyme.
The kinetic properties exhibited by CjeATP-PRT R216A were very
similar to the properties of CjeATP-PRT Core. The measured KM and kcat
values as well as the IC50 values of AMP and PR-ATP and the lack of any
detectable histidine inhibition are all consistent with this conclusion. In the
previous chapter it was argued that the Core mutant exists permanently in
the inhibited conformation, as determined by its crystal structures. Follow-
ing from this idea, it seems likely that the majority of the R216A mutant
hexamers also adopt the inhibited conformation, which would explain the
similarity in the kinetic behaviour of the two mutants. In contrast to the
CjeATP-PRT Core, crystallographic evidence for this assumption is weak
for CjeATP-PRT R216A. The two processed low resolution data sets were
in fact both solved with the closed hexamer conformation as a search model.
Only the histidine bound structure was refined though and shows the closed
conformation, as expected. At 3.4 Å resolution most molecular details are
missing, but the overall conformations of the open and closed wild type
hexamers are quite different, which makes this assumption possible. More
conclusive evidence in form of an ATP bound structure would be beneficial
to clarify this hypothesis.
The reason for the poor diffraction quality of the mutant crystals is
not entirely clear. All tested crystals showed a certain degree of fragmenta-
tion during cryoprotection and it is therefore likely that the cryoprotection
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strategy used was not appropriate. Working with the wild type CjeATP-
PRT crystals always posed difficulties because of the relatively high solvent
content. Together with the age of the protein solution used for crystallisa-
tion, this could also be a reason for the poor diffraction. Focussing on the
optimisation of these final steps should resolve the issue and result in higher
resolution data sets for the crystallised mutant proteins.
Clear evidence for the preserved histidine binding abilities of the Cje-
ATP-PRT R216A ACT domain was provided by ITC and to a lesser extent
by crystallography. The solved crystal structure supports the presence of
a small molecule in the histidine binding site of all six chains. Given the
presence of 1 mM histidine in the crystallisation condition and the low de-
termined Kd values for histidine (1 and 15 µM), this ligand is most likely
histidine. Additional candidates include Tris, SCN−, 1,2-ethylendiol, and
possibly phosphate or imidazole from previous purification steps, but none
of these molecules has ever been observed to bind the site. The ITC bind-
ing curve of the R216A mutant has the cooperative shape seen for histidine
binding to the wild type enzyme, but lacks the strong initial exothermic sig-
nal. Assuming that this early part of the curve is the result of the expected
conformational change of the CjeATP-PRT wild type hexamer, the loss of it
may be interpreted as the loss of the conformational change. This is an indi-
cation that the binding of histidine occurs, but has no effect on the enzyme
conformation.
Examination of the CjeATP-PRT wild type open and closed confor-
mations revealed a distinct difference in the connectivity of two neighbour-
ing ACT domains involving a newly formed hydrogen bonding interaction
between R216 and N276’ (and possibly E271’) in the inhibitor bound con-
formation. With the binding of histidine established in the R216A mutant
and the missing inhibitory response, it is clear that the communication of
the inhibitory signal flows along this intermolecular inter-domain contact,
underlining the importance of the hexameric quaternary structure for full
enzyme functionality. In the absence of this contact the enzyme behaves as
if the ACT domain has no regulatory function, similar to its removal.
153
How the inhibitory signal is further communicated can only be spec-
ulated at this point. If the inhibitory effect is indeed largely based on con-
formational changes around the active site, it is most likely that the motion
of the ACT domain leads to the consequent change of the dimer interface
arrangement, as seen in the wild type crystal structures. It is also possible
that the inhibitory response changes the dynamics of the active site, imped-
ing the necessary motions for effective catalysis. Indications that this might
be the case came from the thermal stability analysis of the wild type en-
zyme. The inhibitor bound CjeATP-PRT resisted higher temperatures than
unliganded samples, which is commonly correlated with a higher rigidity and
lower dynamic freedom. Equivalent studies on the R216A mutant should be
undertaken to support this theory. Whatever the exact mechanism of active
site inhibition may be, the results presented indicate that the effect of the
introduced mutation is based around the arrest of hexamer motion, causing
the CjeATP-PRT R216A mutant to largely exists in a low energy, “closed”
conformation. Though CjeATP-PRT R216A is capable of efficient histidine
binding, it has no further effect on the activity. This supports the conclusion,
that the ACT domain and consequently the hexameric arrangement of the
enzyme is crucial not only for the induction of the inhibitory response, but
also for the maintenance of an active enzyme state.
In contrast to the CjeATP-PRT R216A mutant, the R54A and R224A
mutations did not provide any further insight into the inhibitory signal trans-
duction. The removal of the highly conserved R54 side chain seems to be
detrimental for the CjeATP-PRT activity, most likely due to its role in the
binding of the ATP triphosphate moiety. This assumption is supported by
the wild type-like folding of the R54A mutant, but could not be explored
further due to the lack of crystallographic evidence. CjeATP-PRT R224A
showed comparable activity levels to CjeATP-PRT R216A, but no directly
observed influence on the histidine inhibition. The differences in histidine
sensitivity have not been examined in detail though, leaving the possibility
that this mutant might be receptive to much lower histidine concentrations.
The salt bridge formed between R224 and D100 is observed in both, the
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active and the inhibited complex, although their environment moves signifi-
cantly. R224 could therefore simply posses a structural function, anchoring
the ACT domain hinge, on which it is positioned, to the rest of domain I,
bestowing stability on the enzyme. A loss of this stabilising effect may have
been the reason for the low catalytic activity.
Overall, this chapter has provided evidence that the regulatory signal
transduction in CjeATP-PRT can be perturbed by targeting single amino
acids. Furthermore it appears that the inflicted penalties on the catalytic
properties of the enzyme are closely linked to the regulatory domain and its




5.1 Active hexameric state of CjeATP-PRT
The results presented in this thesis are consistent with the existence of an ac-
tive, homo-hexameric long form ATP-PRT species originating from C. jejuni.
Previous studies focussing on the crystal structures of EcoATP-PRT and
MtuATP-PRT had hypothesised that these enzymes exist in an equilibrium
between active dimers and inhibited hexamers.26,35 This hypothesis shows
strong parallels to the morpheein model of allostery, where a monomeric state
equilibrium determines the association into functionally different oligomers.
But this is not the case for CjeATP-PRT, which has been found to exist
entirely as a hexamer by all used methods even at concentrations as low as
0.025 mg mL −1 (742 nM monomeric concentration). Therefore the observed
activity must be exhibited by the hexameric species.
As reported for EcoATP-PRT26 and MtuATP-PRT,35 the crystal struc-
tures of CjeATP-PRT show the enzyme in two distinct hexameric conforma-
tions. It is important to compare the entire hexamer, as the details of the
conformational change lie mostly in the relative positioning of the six chains
to each other and only limited information can be gathered from a direct
superimposition of single chains. The active state, represented by the ATP
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bound structure 4YB7 differs from the inhibited state, represented by the
structures 4YB5 and 4YB6, by an approximately 30 ◦ twist of the regulatory
domain in each chain and by a flex of each individual dimer interface and the
resulting rearrangement of secondary structure elements. All changes taken
together, the active state appears more loose, shorter and wider than the
inhibited form, which is stretched, compact and tight in comparison.
The trimer interface that is formed by the interlocked β-sheets of three
ACT domains was found to be substantial in all observed crystal structures of
CjeATP-PRT, equally important or even stronger than the functional dimer
interface. This is in accordance with the high melting temperature found
for the CjeATP-PRT ACT protein on its own. Consequently, the removal of
the ACT domain caused the disruption of the hexameric enzyme complex.
The product of this truncation, CjeATP-PRT Core, exists as a functional
homo-dimer that is not feedback inhibited by histidine, but has also greatly
impaired catalytic properties. It is arguable if this impairment is caused by
the direct interference with the protein chain or the change in oligomeric
state, but all solved crystal structures of this mutant show the dimer in a
conformation very close to the histidine bound conformation of the wild type
protein. Given the consistently low binding constants and clear ligand density
in the CjeATP-PRT Core, a lowered substrate affinity can be excluded as a
potential reason for the activity loss. It may be possible that the inhibited
state of the enzyme binds the substrate and/or product molecules too tightly,
making the release of the products the rate-determining step. This theory
is supported by the introduced product inhibition to the CjeATP-PRT Core
enzyme and its PR-ATP bound crystal structure.
The existence of the ACT domain and its natural conformational mo-
tions in CjeATP-PRT appear to be crucial not only for the conformational
changes imposed on the enzyme during histidine binding, but also for the
preservation of the enzyme activity in the absence of histidine, which is in-
dicated by kinetic results from the CjeATP-PRT Core and CjeATP-PRT
R216A mutants. This suggests a much more important role of the ACT
domain for the enzyme than simply providing inhibitor binding properties,
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making the hexameric quaternary structure of the enzyme essential for reg-
ulation and effective catalysis.
5.2 Evolution of the ATP-PRT enzyme
The creation of the active truncated dimeric CjeATP-PRT brought with it
evolutionary implications. The truncation transformed the long form chain
into a ATP-PRT “short form-like” protein. While similar in chain length and
composition, as well as secondary and tertiary structure, it does not contain
the specific sites required for the interaction with HisZ, the essential second
component of functional short form holo-enzymes. The CjeATP-PRT Core
forms a dimer that resembles the two catalytic dimer units present in short
form ATP-PRT enzymes. These central units are the common feature of both
ATP-PRT forms and it is likely that the large contemporary homo-hexameric
and hetero-octameric complexes have evolved from a common ancestor.37
The recruitment of a member of the PII signalling protein family and
later gene fusion seems to be the most likely event that created the long
form ATP-PRT enzymes.48 A very similar, but not covalent, interaction
with a PII protein was identified to exist for N -acetyl-L-glutamate kinase,
which represents a similar evolutionary development to the formation of the
long form ATP-PRT enzymes.49 The short form ATP-PRT complexes, on
the other hand, are believed to have developed from the association with a
histidyl-tRNA synthetase gene product that originated from a gene duplica-
tion event and later evolved into the HisZ protein.45 Extensive phylogenetic
studies showed that HisZ only exists in genomes that encode for a short form
ATP-PRT gene, underlining the tight evolutionary relationship of those two
genes.51 The common ancestor of both ATP-PRT forms was most likely also
a catalytic dimer, as this structure has been preserved throughout evolution.
The artificial creation of CjeATP-PRT Core could therefore be regarded as
a successful evolutionary regress into a ancestor-like state.
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The very slow catalytic turn over of the CjeATP-PRT Core implies that
the catalytic properties of the ancestral ATP-PRT enzymes could have been
comparably poor as well. The development of large complexes consequently
suited two purposes, an improvement on the catalysed reaction kinetics and
the installation of the feedback inhibition by the end product of the (evolving)
pathway. Essential for this development was the introduction of a mecha-
nisms by which the active sites of the dimer could be altered between an
active and inhibited state27,36 and the coupling of this change to effector
binding. The recruitment of the regulatory domain by the later long form
added a structural element for histidine binding, the ACT trimer. This led
to the formation of the hollow hexameric ellipsoid structure, which was then
able to modulate the contained dimers by twisting and stretching (Figure
5.1A). A similar process can be imagined for the octameric short form com-
plex. A change in the HisZ conformation at the central hinge point, widening
the angle between the two HisZ dimers like scissors, would cause a rotational
stretch of the peripherally bound ATP-PRT dimers (Figure 5.1B). Following
this hypothesis both parallel evolutionary paths led to similar result using
different molecular mechanisms.
Figure 5.1: Mechanisms of dimer rearrangement. Schematic depiction of
the observed and hypothetical movements of the catalytic ATP-PRT dimer units
(green) facilitated by their corresponding regulatory apparatus (red and pink). A:
The catalytic sites (blue) are arranged almost parallel to each other in the active
conformation of the long form ATP-PRT. Histidine binding causes a twist of the
ACT domains (red) to form the tight trimer interface (not shown), which pulls the
active sites in the catalytic core apart. B: A widening of the angle between the
HisZ dimers (pink) at their hinge point (black cross) might cause similar changes
to occur in the short form ATP-PRT dimers.
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5.3 The inhibitory signal transduction
Mutational analysis of CjeATP-PRT identified one particularly interesting
mutation site, arginine R216. The mutation to alanine resulted in a mutant
enzyme that lacks the allosteric regulation by histidine. The mutated residue
is positioned at the interface between helix α8, of its own chain, and helix α10
of the neighbouring chain. This interface undergoes significant changes upon
binding of histidine, moving closer together and forming new contacts includ-
ing hydrogen bonding interactions with R216. The lack of these contacts in
the R216A mutant has been shown to not adversely affect histidine binding.
R216 must therefore play a crucial role in the molecular communication of
the inhibitory signal.
The kinetic properties of the CjeATP-PRT R216A and CjeATP-PRT
Core mutants are in very close agreement. The very similar catalytic turn
over rate and the strongly increased sensitivity to AMP and the reaction
product PR-ATP are indicative of this fact. The binding of histidine to the
R216A mutant was confirmed by ITC, but lacks the initial strong exother-
mic signal observed for the wild type, which may be associated with a re-
arrangement of the enzyme complex altering the properties of the histidine
binding sites. This conformational or energetic change is absent in CjeATP-
PRT R216A. Preliminary crystallisation results also indicate that the R216A
mutant structure might adopt the histidine inhibited conformation in the
presence of ATP, unlike the wild type enzyme. Taken together these findings
imply the existence of a permanently or predominantly inhibited conforma-
tion of the catalytic core of CjeATP-PRT R216A, as seen for the CjeATP-
PRT Core dimer. It is therefore hypothesised that the mutation of R216 has
detached the ACT domain motion from the catalytic dimer motion, which
effectively broke the transmission of the regulatory signal along this path-
way resulting in a fixed “false” signal. The catalytic core is receiving a
constant histidine binding signal, resulting in permanently reduced catalytic
efficiency, while the “disconnected” ACT domain still allows for effect-less
histidine binding.
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With only limited crystallographic evidence from the generated mu-
tants, little can be inferred about the exact nature of the ATP-PRT inhibi-
tion. The AMP bound structure of EcoATP-PRT (1H3D) clearly adopts the
open hexamer conformation, leaving doubts about whether the inhibitory ef-
fect is solely conformational. The inhibitors AMP and histidine both increase
the Tm of CjeATP-PRT, while the substrate ATP does not. This leads to the
conclusion that the inhibitory signal rigidifies the complex, which supports a
change in dynamics. More evidence was brought about by the direct compar-
ison of the ATP bound structures of CjeATP-PRT wild type and Core. The
conformations of the single chains are very similar and ATP adopts the same
binding mode, but the activity of both species is undoubtedly different. This
is indicative of the alteration of essential enzyme dynamics by the removal
of the ACT domain and consequently also by the break of the R216 contact
point.
However, the crystallographic observations on the wild type enzyme
support a conformational driven regulatory signal transmission, which in-
volves large domain movements that are communicated via hinge points.
These movements in turn force the dimer interfaces into different arrange-
ments altering the catalytic properties of the ATP-PRT active sites. R216
sits on one of the crucial connection points between domains and a hypo-
thetical communication pathway focussing on similar connections is shown
in Figure 5.2). The pathway naturally includes the residues of the histidine
binding site in the ACT domain and travels along inter-subunit interactions.
The α1-β2 loop is thought to be another important connection point.
In the histidine bound, closed conformation the loop protrudes into the active
site of a neighbouring chain. Therefore the loop may serve as a “sensor” for
the binding of the active site inhibitor AMP. This interaction could be the
reason for the increased AMP binding affinity of the wild type enzyme in the
presence of histidine and thereby explain the synergistic inhibitory effect.
Regarding the effects of AMP binding on histidine binding, the presence of
AMP enables loop interactions, which might lower the energy required for
the conformational change of the hexamer. The C-terminal side of the α1-
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Figure 5.2: Hypothetical inhibitory signal communication pathway. Car-
toon representation of three adjacent chains in the CjeATP-PRT crystal structure
4YB6 with the third chain (dark green) only partially shown. A schematic pathway
(solid red lines) between the allosteric and active sites (black circles) is superim-
posed onto the three dimensional image, highlighting potential key contacts in
the transmission of the regulatory signal. The dashed red line depicts the lost
interactions between the α1-β2 loop and helix α7 at the dimer interface.
β2 loop in turn is part of the open dimer interface interacting closely with
residues of helix α7. A connection that is completely removed in the closed
conformation. This might also direct the inhibitory signal flow from the
dimer interface to the active site.
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This is not the first report of uncoupled activity and feedback regulation
in a long form ATP-PRT. The complete truncation of the regulatory domain
of CglATP-PRT generated a mutant that is not responsive to histidine and
also has a reduced specific activity. These results are largely consistent with
the findings on the CjeATP-PRT enzyme presented in this thesis and vali-
date that similar mechanisms for the inhibitory signal transmission exist in
all long form ATP-PRT enzymes. Furthermore the debilitating effect of the
ACT domain removal was able to be partially compensated by a single site
mutant, S143F. This mutation did not only increase the specific activity of
the CglATP-PRT truncation mutant, but it also removed the feedback in-
hibition of histidine in the full length CglATP-PRT enzyme.98 The site of
this randomly generated mutation, and the equivalent CjeATP-PRT residue
A158, is positioned in the α6 helix at the dimer interface. From a crystal-
lographic view point this mutation site has no obvious involvement in any
regulatory pathway other than its position close to the dimer interface. The
change to a large hydrophobic side chain most likely disrupts the position-
ing of the two chains relative to each other. This leads to the assumption
that this conformational change positively alters the catalytic abilities of the
enzyme by “fixing” the dimer interface in the active conformation, directly
opposite to the effect caused by the CjeATP-PRT R216A mutation.
Overall the presented results strongly support a simple physical mech-
anism for the allosteric regulation of long form ATP-PRT enzymes by histi-
dine. Two different hexamer conformations exist that differ greatly in their
exhibited catalytic properties. In the absence of histidine, the equilibrium
between the two states favours the active conformation, whereas histidine
binding stabilises the inactive conformation and drives the equilibrium in
the other direction. Due to the architecture of the enzyme and the nature
of the ACT domain interfaces, the conformational change always affects the
entire hexamer, with all chains adopting the same conformation. These de-




5.4.1 What is the nature of the PRPP binding?
Contrary to previous reports, PRPP was shown to be able to bind CjeATP-
PRT in the absence of ATP. Unfortunately, the analysis of the active site
binding abilities is limited by the equilibrium character of the ATP-PRT reac-
tion. The use of substrate mimics such as the carboxylic PRPP analogue 1-α-
pyrophosphoryl-2-α,3-α-dihydroxy-4-β-cyclopentane-methanol-5-phosphate
(PCP) could be very beneficial to kinetic and ITC experiments, as it would
eliminate or largely reduce catalytic turn over, while preserving the binding
event. The use of the comparatively stable PCP for crystallography may
also provide more insight into the binding behaviour of PRPP in ATP-PRT
enzymes analogous to results on type I PRT enzymes.
5.4.2 Are there more key interactions in the inhibitory
signal communication?
The rational mutagenesis of CjeATP-PRT has led to the discovery of a
residue crucial for signal transmission through the enzyme. Thereby a first
success has been achieved in unravelling detailed information about the trans-
mission mechanisms. By placing a strong focus on the crystallographic anal-
ysis and comparative computational modelling, the involvement of single
residues and crucial contacts in the domain movements and interface re-
arrangements should become clear and allow for further identification and
characterisation of these key interactions.
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5.4.3 Can an ATP-PRT long form be converted into a
fully functional short form?
Preliminary experiments have shown that the truncated CjeATP-PRT Core
is not able to interact with separately purified HisZ in vitro. While this
analysis is far from complete, it opens the opportunity to investigate what
truly distinguishes long and short form ATP-PRT chains. Combinations of
truncation mutants and HisZ proteins from several different organism sources
should provide a deeper insight into essential components of the interaction
site between ATP-PRT and HisZ in the hetero-octameric complexes. Another
promising approach would be the rational design of CjeATP-PRT Core to
be more short form-like, by adjusting or replacing structure motifs or residue
ranges with their short form equivalents. The most likely starting points
hereby are the helix α8 and the strand β5, which form large parts of the in-
terface with HisZ. If successful, this experiment would provide more evidence
for a dimeric common ATP-PRT ancestor.
5.4.4 Can the evolutionary recruitment of the ACT
domain be simulated?
The catalytic portion of CjeATP-PRT, the Core mutant, on its own has
shown to be a relatively ineffective catalyst. By creating an artificial fusion
protein with a contemporary PII protein, it might be possible to restore
its full catalytic efficiency, thereby re-creating the evolutionary event that
led to the contemporary ATP-PRT long form enzymes. Depending on the
choice of the fusion partner, this could potentially also replace the allosteric
effector. Many common PII proteins, like GlnB or GlnK, are known to
bind ATP, which could be disruptive to the ATP-PRT activity. The ligand
binding sites of PII protein involve long loops though, which are not present
in ATP-PRT ACT domains. Consequently it needs to be carefully considered






6.1.1 Multiple sequence alignments
Amino acid sequence alignments used in this thesis were generated using ei-
ther ClustalW2102 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) or Clustal
Omega84 (http://www.ebi.ac.uk/Tools/msa/clustalo/). For visual output
the alignments were modified using ESPript88 3.0 (http://espript.ibcp.fr/
ESPript/ESPript/).
6.1.2 Phylogenetic trees
To generate the dendrograms displayed in this thesis the distance matrices
created by Clustal Omega were visualised with the program FigTree.85
6.1.3 Protein structure figures
All figures of protein structures were created using the PyMOL Molecular
Graphics System (version 1.7.4.0, Schrödinger, LLC).99 Shown ligand density
166
maps represent the unbiased expected ligand density (Fo-Fc) contoured at
3.0 sigma.
6.1.4 Water
Water used in all experiments was purified by a Millipore Milli-Q R© system.
If required for molecular biology or cell culturing the water was sterilised by
autoclaving prior to use.
6.1.5 Metal ion removal
When required, divalent metal ions were removed from solutions by treatment
with Chelex R© 100 resin, 100–200 mesh (Bio-Rad). After addition of the resin
the solution was stirred over night and the resin was removed by filtration
(0.22 µm membrane) afterwards. The pH of all Chelex R© treated solutions
was re-adjusted according to the requirements.
6.1.6 pH measurements
All pH measurements were performed using a Mettler Toledo SevenCompact
TM
pH/Ion meter S220 (Global Science) with a InLab R© Expert Pro-ISM pH
probe. The pH of solutions was adjusted by using HCl (1 M or 10 M) or
glacial acetic acid, and NaOH (1 M or 10 M).
6.1.7 Antibiotics
1000-fold concentrated antibiotic stocks of ampicillin (100 mg mL−1), Kana-
mycin (50 mg mL−1), and chloramphenicol (25 mg mL−1, solvent ethanol)
were prepared in batches, filter sterilised, and stored at −80◦C. For any appli-
cation requiring antibiotics these stocks were thawed and diluted accordingly.
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Spectinomycin was used at an effective concentration of 0.1 mg mL−1 and
always prepared immediately prior to use.
6.1.8 Cell lines
The E. coli cell lines used in all experiments were as follows. High-copy
number strains for plasmid propagation were either TOP10 (Invitrogen) or
Stellar
TM
(Clontech). For protein expression BL21* (DE3), BL21* (DE3)
pLysS, or BL21* (DE3) pBB540 + pBB542 (referred to as Chaperone3) cell
lines were used.
6.1.9 Glycerol stocks
Cell stocks of all plasmid-containing strains were prepared by mixing 250 µL
of 60% glycerol (sterile) with 750 µL of an overnight culture in a 1.7 mL
screw-top tube. Stocks were flash frozen in liquid nitrogen and stored at
−80◦C.
6.1.10 Chemically competent cells
For the preparation of competent cells a 100 mL LB culture containing the
appropriate antibiotics was inoculated from a 5 mL overnight culture of the
desired strain and grown until an optical density of just over 0.4 was reached.
The cells were then centrifuged at 4000 g for 15 minutes in two sterile con-
ical 50 mL centrifuge tubes. After decanting the LB media the cells were
resuspended in 25 mL freshly prepared sterile CaCl2 per tube by gentle vor-
texing and left to incubate on ice for 30 minutes. The cell suspension was
centrifuged again at 4000 g for 15 minutes and the supernatant decanted.
The cells were resuspended in 2.5 mL sterile CaCl2 per tube by gentle vor-
texing and left on ice for 2–4 hours thereafter. Glycerol was added to a final
concentration of 15 % v/v and the suspension was quickly aliquoted (50 or
100 µL) and flash frozen in liquid nitrogen.
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All centrifugation steps were performed in pre-chilled centrifuges at 4◦C
and all equipment used in the process was kept cool at all times.
6.1.11 Transformation
Chemically competent cell aliquots (50 or 100 µL) were slowly thawed
on ice prior to the addition of 1–2 µL purified plasmid (50-100 ng µL−1).
The cell suspension was gently mixed and kept on ice for 30 minutes prior
to heat shock. The tubes were then placed in a warm water bath (42◦C) for
1 minute and cooled down on ice for 1 minute afterwards. The cells were
regenerated by addition of 250–500 µL super optimal broth with catabolite
repression (SOC) medium and incubated at 37◦C and 180 rpm for 1 hour. A
portion of the cell suspension was then spread on LB-agar plates containing
the appropriate antibiotics and incubated overnight at 37◦C.
SOC medium: 2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM
NaCl, 2.5 mM KCl, 10 mM MgSO4, 20 mM glucose. Filter sterilised in
aliquots.
6.1.12 Plasmid extraction and purification
Plasmids were purified using one of the following kits: High Pure Plas-
mid Isolation Kit (Roche), ChargeSwitch R© Pro Filter Plasmid Miniprep Kit
(Invitrogen), or NucleoSpin R© Plasmid EasyPure (Macherey-Nagel). Cells
were grown as 5 mL overnight cultures in glass test tubes containing the
appropriate antibiotics and harvested by centrifugation. The extraction and
purification was performed according to the manufacturer’s instructions.
The concentration of the purified plasmid was measured by absorption
at 260 nm using an appropriately blanked NanoDrop R© ND-1000 spectropho-
tometer.
6.1.13 Agarose gel electrophoresis
Per gel 0.7–1.0 % (w/v) agarose was dissolved in 30 mL Tris-acetate-
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EDTA (TAE) buffer using a microwave and equilibrated in a 60◦C oven
before the addition of 3 µL SYBR R© Safe DNA gel stain. The mixture was
then poured into a sealed gel tray including a comb and left to set. The
samples were mixed 5:1 with a sample loading dye prior to loading. Typically
20 µL of sample were loaded per well. One well on each gel held 12 µL of
DNA ladder (1.2µL of 1 kb Plus DNA ladder (Invitrogen) diluted to 10
µL mixed with 2 µL sample loading dye) to estimate the sample fragment
size(s). The electrophoresis was performed for 45 min at 85 V in TAE buffer
in a Mini-Sub R© Cell GT (Bio-Rad) and the resulting gel was visualised and
photographed under UV (302 nm) using a Molecular Imager R© Gel DocTM
XR (Bio-Rad).
TAE buffer: 50 mM Tris, 1 mM EDTA, 20 mM acetic acid
Sample loading dye (6x): 60 mM Tris-HCl, 60 mM EDTA, 0.2% (w/v)
orange G, 0.05% (w/v) xylene cyanol ff, 60% (v/v) glycerol
Alternatively pre-cast 1.2% E-Gel R© or 0.8% E-Gel R© CloneWell
TM
aga-
rose gels (Invitrogen) were loaded and run according to manufacturer’s in-




system which also allowed the
real-time monitoring of the sample separation and safe band excision via blue
light (480 nm).
6.1.14 Polymerase chain reaction (PCR)
All PCR was performed in a Veriti R© 96-well Thermal Cycler (Applied
Biosystems) or an iCycler (Bio-Rad) using Phusion R© High-Fidelity DNA
Polymerase (Thermo Fisher Scientific), if not stated otherwise. Primers were
synthesised by Invitrogen and dissolved in either autoclaved water or TE
Buffer (10 mM Tris/HCl, 0.1 mM EDTA, pH 8.0) to a stock concentration
of 100 µM. A 10 µM working stock was prepared prior to use for most
applications. All reactions were performed in a 50 µL volume.
6.1.15 Site-directed mutagenesis (SDM)
For mutagenesis Pfu Ultra High-Fidelity Polymerase (Agilent Technolo-
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gies) was used according to instructions with 30 repeats in the cycling pro-
tocol. Complementary mutagenesis primers were designed to a length of ap-
proximately 40–50 base pairs with the point of mutation in the centre leaving
sufficient overlap (15–20 base pairs) on both sides. The methylated template
DNA was digested using the restriction enzyme DpnI supplied by either Life
Technologies or New England BioLabs afterwards and the resulting product
verified by agarose gel electrophoresis.
6.1.16 Gateway R© Cloning
The Invitrogen Gateway R© Cloning system makes use of the site-specific
recombination properties of bacteriophage λ Integrase and Excisionase to-
gether with the E. coli Integration Host Factor to facilitate the transfer of
heterologous DNA sequences between vectors.103 It features the two highly












All genes cloned by this method were amplified from genomic DNA by
PCR in two steps (nested PCR). Whilst the first step amplified the gene
itself, specific recombination sites (attB sites) were added in the second step
using generic primers. The second step also introduced a N-terminal tobacco
etch virus protease cleavage site between the attB1 site and the start-codon.
Primers used for nested round one were designed by the same method for
all genes. Design scaffold for the first round primers and the generic second
round primers used are listed below. XXX symbolises a 15–18 nucleotide
long sequence of the beginning or end of the cloned gene including start or
stop codon.
1st R nested FWD 5’ GGCAGCGGCGCGXXX 3’
1st R nested REV 5’ GAAAGCTGGGTGXXX 3’
2nd R nested FWD 5’ GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACC
continued TGTATTTTCAGGGCAGCGGCGCG 3’
2nd R nested REV 5’ GGGGACCACTTTGTACAAGAAAGCTGGGT 3’
The linear DNA construct is then transferred into pDONR
TM
221 by
performing the BP Clonase
TM
reaction according to the manufacturer’s in-
structions. During this recombination the original insert in pDONR
TM
221
encoding for a ccdB gene is replaced by the gene of interest. The resulting
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entry clone is transformed into chemically competent TOP10 cells and plated
on LB-agar containing kanamycin for selection. As the protein encoded by
the ccdB gene terminates cell growth it acts as a negative selection and only
correctly recombined vectors will produce colonies.
Colonies were picked and grown for plasmid extraction. The purified
entry clone is sequence verified before proceeding to the second recombina-
tion step using LR Clonase
TM
mix according to the instructions provided.
Here the desired gene is transferred out of the pDONR
TM
221 vector into a





creating the final expression construct. The reaction mixture is transformed
into TOP10 cells and plated on LB-agar containing ampicillin for selection.
Again only correctly recombined vectors produce colonies due to the cell
growth inhibiting properties of the ccdB casette contained in the parental
pDEST
TM
vectors. One or two of the resulting colonies were picked and
grown over night to prepare both a glycerol stock and purified expression
clone, which was transformed into E. coli expression strains and used for
heterologous expression thereafter.
6.1.17 Colony PCR
Whenever a newly created construct was transformed into a plasmid
propagation strain the presence of the desired gene in the resulting clones was
verified by PCR. A fraction of each picked colony from the overnight plate
was placed into a PCR reaction as the template. Usually the reaction mixture
contained a gene specific forward primer and a plasmid specific reverse primer
and amplification was performed using Taq DNA Polymerase (Roche) with an
elongated initial denaturation step (5 min). After agarose gel electrophoresis
showed the expected construct size the remainder of the colony was used to
inoculate an overnight culture (5 mL) for plasmid preparation.
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6.1.18 DNA sequencing
All DNA sequencing was performed at Canterbury Sequencing and
Genotyping using an Applied Biosystems 3130xl Genetic Analyzer with BigDye
Terminator 189 v3.1 (Applied Biosystems) sequencing chemistry. 300 ng of
purified double-stranded plasmid and were supplied for each sample while
sequencing primers, either M13 (pDONR
TM
221 vector) or T7 (pDEST and
pET expression plasmids), were diluted to 3.2 µM and supplied as 50 µL
aliquots.
M13 FWD 5’ GTAAAACGACGGCCAG 3’
M13 REV 5’ AACAGCTATGACCATG 3’
T7 FWD 5’ TAATACGACTCACTATAGGG 3’
T7 REV 5’ CTAGTTATTGCTCAGCGGTG 3’
6.1.19 Culture media
Lysogeny broth (LB) media for bacterial growth were prepared by dis-
solving tryptone (10 g L−1), yeast extract (5 g L−1), and NaCl (5 g L−1)
in water and sterilised by autoclaving. Antibiotics were added as required
before use.
For solid media LB-agar (Miller’s) (37 g L−1) was dissolved in water,
sterilised by autoclaving, and stored at room temperature until use. The
LB-agar was heated to a boil using a microwave oven until all solid was
dissolved. The solution was then allowed to cool down before the addition
of the required antibiotics and the plates were cast in circular petri dishes.
6.1.20 Cell culturing and protein expression
Expression strains were cultured in 1, 2, or 3 L baffled conical flasks
in an Ecotron shaker/incubator (INFORS HT) or an Innova R©44 stackable
incubator shaker (New Brunswick Scientific) at 180 rpm. In general not
more than 30% of the flask’s volume was filled for optimal aeration. The
sterilised medium was inoculated with an overnight culture of the desired
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strain to an optical density of 0.1 and the cells were left to grow at 37◦C
until the mid-logarithmic growth phase was reached before isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 0.1 to
0.5 mM. After induction the culture was left to grow either at 180 rpm and
37◦C for 2–4 hours or at 180 rpm and 23◦C overnight before harvest.
All expression vectors (pDEST or pET) used are under the control of a
T7 promotor and all expression strains used contain the T7 RNA polymerase
gene under the control of a inducible lac promotor. IPTG binds to the lac
repressor and induces the expression of the T7 RNA polymerase which in
turn leads to the over-expression of the desired gene from the expression
vector. This basic expression system can be further modified. In the case
of BL21*(DE3) pLysS the additional plasmid pLysS contains the gene for
the T7 lysozyme which acts as a repressor of the basic T7 RNA polymerase
activity (in a non-induced culture) allowing the fine-tuning of the protein
expression via IPTG. The pBB540 and pBB542 plasmids of the Chaperone3
strain produce the chaperone proteins GroEL/GroES which counter misfold-
ing and aggregation of the over-expressed protein of interest.
6.1.21 Cell harvesting
Liquid cultures were harvested by centrifugation in a Fiberlite
TM
F9-6 x
1000 LEX Fixed-Angle rotor (Thermo Scientific) in either 1 or 0.8 L bottles,
or 0.4 L bottles in the appropriate adaptors at 12000 g for 15 minutes at
4◦C. The supernatant liquid was decanted and the pellet was scraped into
sterile 50 mL falcon tubes. Small cultures were directly harvested in sterile
50 mL tubes using a Fiberlite
TM
F14-14 x 50cy Fixed-Angle rotor (Thermo
Scientific). Harvested cell pellets were either immediately lysed or frozen and
stored at −80◦C.
6.1.22 Cell lysis
Cell lysis was performed by one of three different methods. In all three
cases the cell pellets were thawed on ice and dissolved in chilled lysis buffer
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to a more or less viscous (depending on the methods requirements), homo-
geneous suspension.
Most commonly cells were lysed by sonication using an Omni-Ruptor
4000 Ultrasonic Homogenizer (Omni International). The cell suspension was
kept in a glass beaker in a tightly packed ice bath. Sonication was performed
in multiples (usually three to four repeats) of 5 minutes at 70 % power
and 30 % pulsation until the suspension cleared or its viscosity significantly
decreased.
Small cultures were typically lysed by chemical detergent using Bug-
Buster R© Protein Extraction Reagent (Novagen). 10 mL of 1x BugBuster R©
solution (in lysis buffer) were used per gram of cell pellet. Benzonase R©
Nuclease (Novagen) was added (≤ 1 µL) to the mixture and the resuspended
cells were incubated at RT for an hour with gentle shaking/rocking.
The third method, cell disruption, made use of a M-110P Microfluidiser R©
(Microfluidics). The cell pellet was resuspended in a Benzonase R© (≤ 1 µL)
containing lysis buffer and left for approximately 10 minutes before dis-
ruption. The suspension was passed three times through the well-cooled
pressure-chamber at 18000 psi and monitored to avoid overheating.
Removal of the cellular debris was achieved by centrifugation at 40000
g and 4◦C for 30 minutes in a Fiberlite
TM
F21-8 x 50y Fixed-Angle Rotor
(Thermo Scientific).
6.1.23 Protein purification
All protein constructs were engineered to have either a poly-histidine
or a glutathione S-transferase tag. The first step of all purifications there-
fore was affinity chromatography, followed by the optional removal of the tag
using TEV protease and a final size exclusion chromatography step. All chro-
matography was performed on Bio-Rad Biologic DuoFlow and GE Health-
care ÄKTApurifier
TM
10 machines. All buffers used for chromatography were
filtered (0.22 µm) and degassed under vacuum.
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Samples were pre-filtered using a 0.8 µm filter and then loaded into
either a 10 mL, 50 mL, or 150 mL Superloop
TM
(GE Healthcare) while si-
multaneously being filtered (0.22 µm). The eluate was collected in 96-well
plates (2 mL fractions). Elution from the columns was monitored at 280
nm and 260 nm wavelength, and also 214 nm when possible. Elution peaks
were analysed by SDS-PAGE and for ATP-PRT activity the first time any
purification step was performed or when major changes where made to the
protocol. Verified ATP-PRT fractions were pooled and prepared for the next
chromatographic step.
6.1.24 Immobilised metal affinity chromatography
Throughout all IMAC purifications either 5 mL HiTrap
TM
TALON R©
crude (Co2+) or 5 mL HiTrap
TM
HP (Ni2+) columns (GE Healthcare) were
used. The column was washed with at least 3 column volumes of water prior
to equilibration with 5 column volumes of washing buffer (50 mM phosphate,
500 mM NaCl, 5 mM MgCl2, 20 mM imidazole, pH 8.0). The clarified su-
pernatant was then loaded onto the column and the column was washed
with another 5–10 column volumes of washing buffer. A gradient increasing
the concentration from 20 to 250 (Co2+) or 500 mM (Ni2+) imidazole over
7 column volumes was applied to elute the bound protein of interest before
washing the column with 3 column volumes of elution buffer (50 mM phos-
phate, 500 mM NaCl, 5 mM MgCl2, 250 or 500 mM imidazole, pH 8.0) and
a final 5 column volumes of washing buffer. The flow rate was kept constant
at 3 mL min−1 throughout the run except for the injection of the protein
solution which was held at 1 mL min−1. All steps mentioned above were
routinely performed using a pre-programmed method and only changed oc-
casionally. The sodium chloride concentration was altered for some proteins
but was kept at a minimum of 300 mM for optimal protein-column interac-
tion. For storage purposes the column was first washed with water to remove
all salt and then transferred into 20 % v/v ethanol and kept at 4◦C.
During solubility tests disposable His SpinTrap
TM
columns (GE Health-
care) were used according to the instruction manual to allow for the isola-
176
tion of the his-tagged protein from the separated soluble and insoluble crude
lysate. The protein was then identified by consecutive SDS-PAGE and ATP-
PRT activity assays.
The CjeATP-PRT has an intrinsic affinity to the IMAC columns, which
means it bound even when it did not contain a poly-histidine tag and eluted at
approximately 100 mM (Co2+) or 200 mM (Ni2+) imidazole. It was therefore
unfavourable to use IMAC for purification other then the initial separation.
6.1.25 Glutathione sulfur-transferase affinity chromatog-
raphy
GST affinity chromatography was performed in a very similar fashion to
the IMAC. The columns used for this purification step were 5 mL GSTrap
TM
HP columns (GE Healthcare) and column handling and protocol were iden-
tical to IMAC with the buffers being the only difference. Wash (and lysis)
buffer in this case was 1x phosphate buffered saline (140 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) and the elution buffer was
50 mM Tris/HCl pH 8.0 with 10 mM reduced glutathione.
Besides the first step of purification GST affinity chromatography was
also used later on as reverse purification step to remove the GST tag, es-
pecially in the case of the CjeATP-PRT Core mutant. When used as a
downstream purification step buffer exchange of the protein solution into 1x
phosphate buffered saline was performed directly before the run.
6.1.26 Size exclusion chromatography
Fractions containing the desired protein were pooled and concentrated










75 prep grade column (GE Healthcare), at 4◦C in 10 (or 50)
mM Tris/HCl, 100 (or 150) mM NaCl, 5 mM MgCl2, pH 8.0. The elution
flow rate was usually kept at 1–1.2 mL min−1. All fractions containing the
pure protein of interest were pooled and concentrated afterwards.
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For the purpose of molecular weight determination a Superdex
TM
200
10/300 GL column (GE Healthcare) was used. The column was equilibrated
and then calibrated by running through standard proteins of known sizes in
the range of 29 to 669 kDa and Blue Dextran (Gel Filtration Calibration
Kit HMW, (GE Healthcare), Molecular Weight Marker Kit MW-GF-1000
(Sigma)) in above stated buffer at a flow rate of 0.2 mL min−1. The sample
was analysed using the same buffer and flow rate. Samples and standards
(usually at a concentration of 1 mg mL−1) were injected in 500 µL volume
using a static loop (either 0.5 or 1 mL volume). Elution times were normalised
by the void volume (Blue Dextran).
6.1.27 Tobacco etch virus protease treatment
Frozen stocks of TEV protease were thawed and added directly to the





of that of the tagged protein. The mixture was then incubated
for 1 hour at 37◦C and 180 rpm and either used immediately in the next
purification step or left at 4◦C over night before advancing in the purification.
In the case of the CjeATP-PRT wild type enzyme this 4◦C incubation had
to be prolonged to 2–3 days for optimal cleavage of the tag.
6.1.28 Protein concentration and buffer exchange
Protein solutions were concentrated using 10000 Da (or 5000 Da) molec-
ular weight cut off (MWCO) devices Vivaspin R© Turbo 15, Vivaspin R© 20, or
Vivaspin R© 500 (Sartorius). 5000 Da MWCO devices were only used for
CjeATP-PRT ACT preparations. All filters were rinsed with water prior to
use. Buffer exchange was achieved by repeated concentration and dilution
cycles, using the desired buffer, in these filtration units.
Large quantities of concentrated protein solution were buffer exchanged
by using either a HiPrep
TM
26/10 Desalting column (GE Healthcare) or a 50
mL Bio-Scale
TM
Mini Bio-Gel R© P-6 desalting cartridge, equilibrated with at
least 3 column volumes of the desired buffer. The protein sample was then
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loaded and eluted by applying a continuous flow rate. Any salt and buffer
remaining on the column were removed afterwards by thoroughly washing
the column with water (2–3 column volumes) before running it into 20 %
ethanol (2 column volumes) for storage.
6.1.29 Determination of protein concentration
For all purposes protein concentrations were measured by absorption
at 280 nm with an appropriately blanked Nanodrop R© ND-1000 spectropho-
tometer using 1.5 µL of purified protein solution for each measurement. The
concentration was calculated from the absorption using the molar extinction
coefficient values calculated from protein sequences using the ProtParam tool
on the ExPASy Proteomics Server. Used extinction coefficients were:
CjeATP-PRT wild type and single site mutants 14440 M−1 cm−1
CjeATP-PRT Core 7450 M−1 cm−1
CjeATP-PRT ACT 6990 M−1 cm−1
MtuATP-PRT wild type 19940 M−1 cm−1
EcoPPase 22920 M−1 cm−1
6.1.30 Protein storage
All enzymes were generally kept at 4◦C if they were intended for immediate
(up to 3 days) use to decrease losses due to the freeze and thaw processes. For
long term storage proteins were concentrated to 5–20 mg mL−1, aliquoted in
either 50 or 100 µL aliquots in 0.6 mL micro-centrifuge tubes, flash-frozen
in liquid nitrogen, and kept at −80◦C. Frozen samples were rapidly thawed
before use.
6.1.31 Sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis
SDS-PAGE was performed using either NuPAGE R© 10% Bis-Tris Gel
1.0 mm 12-well (Invitrogen) pre-cast gels in NuPAGE R© MOPS SDS Running
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Buffer (Invitrogen) or Bolt R© 10% Bis-Tris Gel 1.0 mm 12-well (Life Tech-
nologies) pre-cast gels in Bolt R© MES SDS Running Buffer (Life Technologies)
or Bolt R© MOPS SDS Running Buffer (Life Technologies). Electrophoresis
was performed using a XCell SureLock
TM
Electrophoresis Cell (Invitrogen)
at 200 V for 50 min for NuPAGE R© gels and a Bolt R© Mini Gel Tank (Life
Technologies) at 165 V for 35 min (MES) or 45 min (MOPS) when Bolt R© gels
were used. Samples were mixed with 4x NuPAGE R© LDS Sample Buffer or
4x Bolt R© LDS Sample Buffer (Life Technologies) respectively. To allow for
complete denaturation samples were mixed with dithiothreitol (DTT) and
boiled at 95◦C for 2–3 minutes prior to loading. To estimate protein size
Novex R© Sharp Pre-Stained Protein Standards (Invitrogen) was run in one
lane of each gel.
6.1.32 Visualisation of PAGE gels
All PAGE gels were stained in square petri dishes with hot stain solution
(0.1% (w/v) Coomassie brilliant blue R-250, 10% (v/v) glacial acetic acid,
40% (v/v) methanol) for a minimum of 5 minutes before being destained with
hot destaining solution (10% (v/v) glacial acetic acid, 40% (v/v) methanol)
for another 5 minutes to remove excess dye. Gel and solution were heated
each time in a microwave oven until almost boiling and rocked gently during
the incubation time. Best resolution was achieved by destaining the gel after-
wards in water over night with gentle rocking. Photographs of the destained




6.1.33 Standard kinetic assay
The standard assay for ATP-PRT activity monitored the production of
PR-ATP directly by gain of absorbance at 290 nm, based on the method of
Morton and Parsons.28 All kinetic measurements were made using a Varian
Cary 100 UV-visible spectrophotometer. All reactions were measured in
stoppered 1 cm pathlength quartz cuvettes in a total assay volume of 1
mL. Standard assays were carried out at 25◦C and all assay solutions were
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equilibrated to temperature and baseline absorbance before initialisation with
PRPP, or occasionally ATP-PRT.
Standard reaction mixtures contained variable concentrations of PRPP
and ATP in 50 mM Tris/HCl, 100 mM NaCl, 50 mM KCl, 10 mM MgCl2,
pH 8.5 as well as the enzymes ATP-PRT and EcoPPase, with the EcoPPase
always being in at least 5-fold excess. Assay buffers and all assay stock solu-
tions were prepared with Chelex-treated water to remove divalent metal ions.
ATP stock solutions were mixed 1:1 with MgCl2 in order to saturate the sub-
strate with Mg2+ without significantly altering the free Mg2+ concentration
of the assay buffer.
Initial rates of reaction were measured as a least-squares fit of the initial
rate data using Cary WinUV Kinetics Application (version 3.00, Varian). A
unit of enzyme activity was defined as the production of 1 µmol min−1 of PR-
ATP (ε = 3.6·103 M −1 cm−1) at 25◦C, and was calculated from the measured
gain of absorbance at 290 nm using Beer’s Law. The values of the kinetic
parameters were determined by fitting data to the Michaelis-Menten equation
using the software GraFit (version 5.0.13, Erithacus Software Limited).
6.1.34 Determination of ATP and PRPP concentra-
tion
The concentrations of the substrate solutions (ATP and PRPP) were
determined each time before other kinetic measurements were performed us-
ing the standard assay for ATP-PRT activity. The concentration of the
substrate not being measured was used in excess (usually 20x KM) and the
substrate for which the concentration was being measured was used at a
limiting concentration. The secondary substrate saturation was checked by
addition of more of the limited substrate after the reaction had reached com-
pletion. The change in absorbance, between that before initiation of the
reaction and that at completion, was measured as ∆A1. A control reaction,
absent in enzyme, was used to measure the change in absorbance due to the
addition of PRPP for reaction initiation (∆A2). The total change in ab-
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sorbance (∆A1 + ∆A2) was converted to the concentration of the limiting
substrate in the cuvette using Beer’s Law. From this the stock substrate con-
centration was calculated. All concentration measurements were performed
in duplicates or triplicates.
6.1.35 Mass spectrometry
Protein molecular mass was determined by electrospray ionisation us-
ing a Micromass LCT Classic, Bruker maXis 3G. Highly concentrated protein
samples were diluted with water to a final concentration of 1 mg mL−1 to
minimise the effect of buffer components during the measurements. Alter-
natively the protein samples were buffer exchanged into 5 mM ammonium
bicarbonate.
6.1.36 Circular dichroism
All CD experiments were performed using a JASCO J-815 Spectropo-
larimeter. CD spectra were recorded from 250 nm to 190 nm at 25◦C using a
1 nm data pitch, 1 s response, and 1 nm bandwidth. 2 mL of protein solution
(0.03 mg ml−1) in a 3 mL quartz cuvette with 1 cm path length were used for
each measurement. All measurements were taken in water and blank spectra
of water were recorded before each experiment. The buffer-subtracted data
were smoothed by performing a five-point moving average.
6.1.37 Differential scanning fluorimetry
Melting temperatures in the presence of different water soluble addi-
tives were determined by DSF using an iCycler iQ5 Multicolour Real-Time
PCR Detection System (Bio-Rad). The method used was based on that of
Nordlund et al.104
For each condition 100 µL of buffer (50mM Tris/HCl, 150 mM NaCl,
pH 8.5) including the desired additive(s) was prepared, to which 5 µL of 250x
SYPRO R© Orange dye was added. One fifth (21 µL) was mixed with 4 µL
of water, representing the blank. To the remaining 84 µL of the condition
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solution 16 µL of protein (0.6 mg mL−1) were added and 25 µL each were
dispensed into three replicate wells followed by the blank in a fourth adjacent
well of a 96-well microplate (vide infra). After all samples and blanks were
loaded the plate was sealed with a self-adhesive transparent seal.
The plate was set up and checked for initial protein denaturation which
was commonly seen for all CjeATP-PRT samples. The melt proceeded in
0.2◦C increments from 20 to 95 ◦C, with a 20 s dwell time after each temper-
ature rise. Measurements of the fluorescence were made at the end of each
dwell time. An Excel spreadsheet with custom VBA-scripted macro was
used for data analysis to toggle and dynamically display melt and derivative
curves for each sample. The melt temperatures were calculated as the tem-
perature of maximum inflection of the melting curve after subtracting the
reading of the blank well. Additives used were: L-histidine (1 mM), ATP (2
mM), AMP (2 mM), and MgCl2 (0, 0.5, and 5 mM)
6.1.38 Differential scanning calorimetry
For DSC experiments protein samples (0.3 to 1.0 mg mL−1) were buffer
exchanged into 50 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, pH 8.5 con-
taining either no ligand, 1 mM histidine, 2 mM AMP, or the mixture of the
latter two. All prepared solutions were degassed prior to the experiments.
Samples were analysed against their identical buffer using a Nano DSC dif-
ferential scanning calorimeter (TA Instruments). The sample and reference
chamber were thoroughly cleaned with detergent (Decon 90) and water before
the chambers were washed with buffer. Cells were loaded by gently pipetting
the solutions in, and up and down to remove any residual air bubbles.
The temperature was increased from 20 to 100◦C in increments of 1◦C
per minute under a constant pressure of three atmospheres. Data anal-
ysis was performed with the NanoAnalyze
TM
software version X.1.2 (TA
Instruments). The baseline corrected data was fitted using the provided
TwoStateScaled model if not stated otherwise.
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6.1.39 Isothermal titration calorimetry
Dissociation constants were determined using a VP-ITC microcalorime-
ter (MicroCal, GE Healthcare) operating at 298 K. All protein solutions (50
to 100 µM) were buffer exchanged into and ligands were made up in binding
buffer (10 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, pH 8.5). Solutions
were filtered and degassed under vacuum and the protein concentration was
measured by UV absorption prior to the experiments. The syringe and cell
were washed multiple times with binding buffer and degassed binding buffer.
For all experiments the cell was loaded with the protein and the syringe
contained the ligand (titrant). Titrations were performed with 56 injections
(one 2 µL injection followed by fifty-five 5 µL injections) or 29 injections
(one 2 µL injection followed by twenty-eight 5 µL injections) of ligand. Heat
of dilution experiments were measured independently and subtracted from
the integrated data before curve-fitting in Origin (version 7.0, OriginLab R©).
The initial point (2 µL injection) was routinely deleted to allow for diffusion
of ligand across the needle tip during the equilibration period and the used
binding model was chosen according to the experiment performed.
6.1.40 Static light scattering
Static light scattering was used to determine the molecular weight and
hydrodynamic radius of proteins in solution. Measurements were performed
using a Superdex
TM
200 10/300 GL column directly coupled to a Viscotek
TDAmax multidetector system (Malvern) at constant flow rate of 0.5 mL
min−1. Typically only UV/Vis, Refractive Index (RI) and Right angle light
scattering (RALS) detections were used.
Before every experiment the system was equilibrated with one column
volume of running buffer (10 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2,
pH 8.5). For each sample a total amount of 100 µL of protein solution at 1
mg mL−1 was injected and run through with one column volume of running
buffer. A bovine serum albumin (BSA) standard was run before and after
every set of samples and used to calibrate the OmniSEC software (Malvern)
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for analysis of the recorded sample peaks.
6.1.41 Analytical ultracentrifugation
Sedimentation velocity experiments were performed in a ProteomeLab
TM
XL-I analytical ultracentrifuge equipped with UV–visible scanning optics
(Beckman Coulter). Protein samples were prepared by dialysis in the refer-
ence buffer (10 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, pH 8.5) over
night and then diluted, in sets of three, to different concentrations ranging
from 1.2 mg mL−1 down to 0.025 mg mL−1 using the identical reference
buffer in which the dialysis had been performed. High range: 1.2 mg mL−1,
0.4 mg mL−1 and 0.13 mg mL−1. Low range: 0.1 mg mL−1, 0.05 mg mL−1
and 0.025 mg mL−1.
Reference buffer (400 µL) and samples (380 µL) were loaded into 12-
mm double-sector cells with quartz windows, and the cells were then mounted
in an An-50 Ti eight-hole rotor. Proteins were centrifuged at 50000 rpm and
20◦C, and radial absorbance data were collected at 230 nm wavelengths, due
to the low absorbance of CjeATP-PRT at 280 nm, in continuous mode every
8 min without averaging.
AUC data was fitted to a continuous distribution c(s) model using
SEDFIT.90,105 The partial specific volume (v) of the proteins, buffer den-
sity (0.7482 g mL−1 for the CjeATP-PRT wild type, 0.7434 g mL−1 for
the CjeATP-PRT Core) and buffer viscosity (1.00618 cp) were calculated
using the program SEDNTERP.106 The ratios of the frictional coefficients
( f
f0
) calculated by SEDFIT from fitting the c(s) models were 1.27 for the
CjeATP-PRT Core and 1.29 for the CjeATP-PRT wild type.
6.1.42 Small angle X-ray scattering measurements
Measurements were performed at the Australian Synchrotron SAXS/
WAXS beamline equipped with a Pilatus detector (1 M, 170 mm x 170 mm,
effective pixel size, 172 x 172 µm). The wavelength of the X-rays was 1.0332
Å. The sample-detector distance was 1.6 m, which provided an s range of
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0.0126 to 0.6014Å−1. s is defined as the magnitude of the scattering vec-
tor, which is related to the scattering angle (2Θ) and the wavelength (λ) as
follows: s = (4π
λ
)sinΘ.
Protein samples (∼ 10 mg mL−1) filtered (0.22 µm) prior to use to
avoid aggregation. For the capillary set-up of the beam line samples were
buffer exchanged and diluted (to 0.5 mg mL−1, 1 mg mL−1, and 2 mg mL−1)
using the appropriate buffer, transferred into 96-well plates, and degassed by
centrifugation (10 min at 4000 g). Scattering data was collected either fol-
lowing elution from a SEC column (Superdex
TM
200 5/150), pre-equilibrated
(50 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, pH 8.0) with or without
effectors PRPP (1 mM), AMP (2 mM), or L-histidine (1 mM) or directly
from a sealed 96-well plate containing the desired conditions.
Data were collected from a 1.5 mm glass capillary at 27◦C at 2 s in-
tervals. Two-dimensional intensity plots from the top of the size-exclusion
chromatography peak (column set up) or the sample conditions (plate set up)
were radially averaged, normalised to sample transmission and background
subtracted using ScatterBrain (www.synchrotron.org.au/index.php/aussync
beamlines/saxswaxs/software-saxswaxs).
6.1.43 Small angle X-ray scattering data analysis
Scattered intensity (I) was plotted versus s. All samples were checked
for non-linearity in the increase of intensity at low s (indicative of aggrega-
tion). Guinier plots were linear for s ·Rg < 1.3 as calculated by PRIMUS.107
Indirect Fourier transform was performed using GNOM95 to provide the pair
wise distribution function P(r), which determines both the relative probabil-
ities of distances between scattering centres and the maximum dimension of
the scattering particle (Dmax). Theoretical scattering curves were generated
from atomic coordinates and compared with experimental scattering curves
using CRYSOL.96 To assess and compare the quality of the fits in CRYSOL
χ values for the fits were compared.
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6.1.44 Crystallisation
Initial screening was performed using a mosquito R© Crystal robot (TTP






I HT-96 and Clear Strategy
TM
II HT-96 crystallisation screens (Molecular
Dimensions), and 96-well sitting drop iQ plates (TTP Labtech). For each
condition drops of 400 nL concentrated pure protein and 400 nL of reservoir
solution were mixed and placed next to the 40 µL reservoir by the robot.
Plates were sealed, incubated at 20◦C, and checked regularly for crystal for-
mation. After a suitable condition had been identified the crystallisation was
scaled up and fine screened in 24-well VDX plates (Hampton Research) at
20◦C using hanging-drop vapour diffusion. Protein solutions were mixed 1:1
(v/v) with the reservoir solution. Here the drop size was 2 µL or 4 µL and
the reservoir solution volume 500 µL. Typically crystals were fully formed
after 1–3 days.
Co-crystallisation was achieved by mixing the desired ligand with the
crystallisation condition prior to mixing with the protein solution. This
generally required further screening either manually or using the mosquito R©
Crystal robot. In some cases the ligand was soaked into previously formed
crystals. This was achieved by the addition of the ligand (dissolved or diluted
in the condition) to the drop containing the crystal and incubation for a set
amount of time. Crystals for collection were mounted on loops, transferred
briefly into the appropriate cryoprotectant, flash frozen in liquid nitrogen
and stored in Australian Synchrotron Pucks for transportation.
6.1.45 X-ray data collection and structure determina-
tion
All X-ray diffraction data was collected at the Australian Synchrotron
(AS). Pre-mounted crystals stored in AS Pucks were transported in a dry
shipper (Taylor-Wharton CX100) and transported as checked-in luggage.
Data collection at the Australian Synchrotron used either the Macromolec-
ular Crystallography (MX1) or Micro Crystallography (MX2) beamlines108
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and were processed using X-ray Detector Software (XDS),109 Aimless and
Truncate110 (CCP4 suite111).
For novel structures initial phase estimates were calculated by molecular
replacement with MolRep112 or Phaser113 (CCP4 suite) using the available
MtuATP-PRT and EcoATP-PRT structures (PDB codes: 1NH7, 1H3D).
The Rfree set (5 %) was chosen automatically. Structures of CjeATP-PRT
Core were solved by molecular replacement, using the catalytic domains of
wild-type CjeATP-PRT (PDB accession code 4YB5) as starting model with
all non-protein molecules removed. 10 rounds of rigid-body refinement were
performed using Refmac5114 and the same set of reflections for calculation of
Rfree was carried through.
Structural refinement was performed using RefMac5 with iterative mo-
del building using Coot.115 NCS was included in the initial rounds of refine-
ment and waters were gradually added in the later rounds. TLS refinement
was included in the later rounds of refinement. Structures were validated and
adjusted using the validation tools of Coot and the MolProbity116 as well as
the wwPDB deposition servers before deposition.
6.2 Methods for Chapter 2
6.2.1 Cloning of CjeATP-PRT
Cloning proceeded as described (section 6.1.16) with a minor change in the
primer design strategy. To avoid the relatively long generic primers of the
second nested PCR a set of three forward and two reverse primers was used
instead.
cjeAPRT0 FWD 5’ GGAATGCAAGAAAACACTCGTTTACGC 3’
cjeAPRT1 FWD 5’ GGCTTCGAAAACCTGTATTTTCAAGGAATGCAAGAAAAC 3’
2R GERD 5’ GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAAC 3’
cjeAPRT0 REV 5’ GGGTGTCACTTTAACATTTTTTCTATAG 3’
cjeAPRT1 REV 5’ GGGGACCACTTTGTACAAGAAAGCTGGGTGTCAC 3’
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These were used in three consecutive PCR steps as follows:
Step 1: cjeAPRT0 FWD and cjeAPRT0 REV
Step 2: cjeAPRT1 FWD and cjeAPRT1 REV
Step 3: 2R GERD and cjeAPRT1 REV
This resulting construct differed to the one that would have been created by
the standard method only by the absence of a short linker sequence (AGCG-
GCGCG) between the TEV cleavage site and the start codon.
6.2.2 Cloning and purification of E. coli PPase
Cloning of the E. coli ppa gene (locus names: b4226, JW4185) followed the
general Gateway R© Cloning procedure using the following primers in the first
round of nested PCR:
Gerd Ecoppa FWD 5’ GGCAGCGGCGCGATGAGCTTACTCAACGTCCCT 3’
Gerd Ecoppa REV 5’ GAAAGCTGGGTGTTATTTATTCTTTGCGCGCTCG 3’
The pDEST
TM
17 construct was cloned into the expression strain BL21*
(DE3) and usually expressed overnight at 23◦C and 180 rpm after induction
with 0.5 mM IPTG.
In most cases EcoPPase was found to be exclusively in the insoluble
fraction after lysis. A basic resolubilisation was performed by dissolving the
entire pellet in lysis buffer containing 8 M urea. The solution was centrifuged
again at 40000 g and 4◦C for 30 minutes in a Fiberlite
TM
F21-8 x 50y Fixed-
Angle Rotor (Thermo Scientific). The resulting supernatant contained more
than 95 % of the EcoPPase and was diluted 10 fold with lysis buffer to reduce
the urea concentration. It was then filtered to remove remaining insoluble
particles and DNA.
The protein was purified in a one step protocol using IMAC (5 mL
HiTrap
TM
HP column). Resolubilised EcoPPase always eluted in two peaks,
a first peak around 250 mM imidazole and a second peak at 500 mM imi-
dazole. All fractions of the second peak precipitated immediately after the
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column passage and were discarded. Fractions of the first peak were com-
bined, desalted, concentrated, aliqoted, flash frozen in liquid nitrogen and
stored at −80◦C until use.
The activity of the resulting enzyme was tested in standard ATP-PRT
assay conditions. When added after the ATP-PRT reaction had come to
the equilibrium point (first absorbance rise) a second rise in absorbance was
observed. The total absorbance change was identical to the change measured
in an equivalent reaction where the EcoPPase had been added prior to start.
6.2.3 Kinetic measurements
Deviations from the described standard assay (section 6.1.33) occurred only
during adjustment of the Mg2+ and salt concentration. In this case a metal
free buffer was used (50 mM Tris/HCl, pH 8.5) and the salts (metal chlorides)
were added from Chelex-treated stock solutions at the desired concentration
for each measurement. The Mg2+ concentration was held constant at 10 mM
while determining the Na+ and K+ dependence. While determining the Mg2+
dependence Na+ and K+ concentrations were held constant at 100 mM.
For determination of the kinetic parameters and the binding mechanism
initial rate measurements were taken in a grid of PRPP (0.001 mM, 0.0025
mM, 0.005 mM, 0.0075 mM, 0.01 mM, 0.025 mM, 0.05 mM, 0.075 mM, 0.1
mM and 0.2 mM) against ATP (0.05 mM, 0.1 mM, 0.25 mM, 0.5 mM and
2.5 mM) concentrations. The protein concentration used in the cuvette was
50 nM. Results were plotted using Microsoft Excel and Graph Pad Prism.
Similar grids of concentrations (listed below) were used for the inhi-
bition studies with the second substrate at saturating concentrations and a
constant enzyme concentration of 267 nM. The resulting data was plotted
and analysed by global fitting using pre-programmed inhibition type tem-
plates in GraFit (version 5.0.13, Erithacus Software Limited).
KiATP (AMP) ATP (0.08 mM, 0.2 mM, 0.4 mM, 0.8 mM)
AMP (0 mM, 0.5 mM, 1 mM, 2 mM)
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KiPRPP (AMP) PRPP (0.03 mM, 0.06 mM, 0.09 mM, 0.12 mM)
AMP (0 mM, 1 mM, 2 mM, 3 mM)
KiATP (his) ATP (0.1 mM, 0.2 mM, 0.4 mM, 1 mM)
histidine (0 mM, 0.02 mM, 0.04 mM, 0.07 mM)
KiPRPP (his) PRPP(0.045 mM, 0.09 mM, 0.135 mM, 0.18 mM, 0.3 mM)
histidine (0 mM, 0.01 mM, 0.02 mM, 0.03 mM)
6.2.4 Ligand binding experiments
All ITC experiments were performed as described in section 6.1.39 with the
following concentrations used:
Ligand Enzyme concentration Secondary ligand in cell
4 mM ATP 150 µM -
3 mM PRPP 150 µM -
3.5 mM AMP 100 µM -
1.5 mM histidine 100 µM -
10 mM AMP 100 µM 1 mM ATP
4 mM ATP 150 µM 2 mM histidine
2 mM AMP 100 µM 1 mM histidine
1 mM histidine 100 µM 1 mM AMP
AMP and histidine titrations were performed with 56 5 µL injections,
while 28 10 µL injections were used for ATP and PRPP titrations.
All data was fitted with a single site model except the histidine titra-
tions which were done using the sequential site model with either 5 sites
(histidine alone) or 2 sites (histidine in the presence of AMP).
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6.2.5 Crystallisation conditions
Initial crystal screens were performed as described above (section 6.1.44).
The usually used protein concentration ranged between 2 and 5 mg mL−1
for all crystallisation trials. Three screen conditions were identified that
produced crystals of desired quality. All three conditions were scaled up
and fine screened for optimal crystal growth. The resulting mixtures are
listed below. Histidine co-crystals were put down as 2 µL drops and the
cryoprotectant was composed of 20 % v/v PEG 400 and 80 % reservoir
solution. For ATP co-crystals the total drop size was 4 µL and 40 % glycerol
was added slowly in a 1:1 ratio to the whole drop prior to crystal-looping for
cryoprotection.
Screen condition Ligand Refined condition
PACT premier
TM
HT-96 1 mM histidine 0.1 M BTP pH 6.5
F4 0.2 M KSCN
13–14 % w/v PEG 3350
Clear Strategy
TM
I HT-96 5 mM AMP 0.1 M Tris pH 7.5
E9 1 mM histidine 0.1 M MgCl2
13–15 % w/v PEG 4000
Clear Strategy
TM
I HT-96 10 mM ATP 0.1 M Na acetate pH 5.5
A9 0.1 M MgCl2
13–15 % w/v PEG 4000
6.2.6 MtuATP-PRT
The cloning of MtuATP-PRT made use of the In-Fusion R© HD Cloning Kit
(Clontech R© Laboratories Inc.) which is designed for the fast and direct
cloning of genes into any vector. It was chosen to insert the hisG gene from
the M. tuberculosis strain H37Rv (gene locus: Rv2121c) into pET24a(+) be-
tween the NdeI and XhoI restriction sites. For this purpose primers were
192
designed according to the user manual instructions to generate 5’ 15 bp ex-
tensions on the Mtu hisG for the purpose of the In-Fusion R© recombination.
The forward primer also included an additional short insert coding for a
non-removable 6x histidine tag and the original start codon was mutated





The gene was amplified in 30 cycles using Phusion R© High-Fidelity
DNA Polymerase with an annealing temperature of 50 ◦C. Both the lin-
ear PCR product and the pET24(+) vector were then digested at 37 ◦C for 1
h with NdeI and XhoI (New England BioLabs R© Inc.) and cleaned using the
NucleoSpin R© Gel and PCR Clean-up kit (Macherey-Nagel) before perform-
ing the In-Fusion reaction according to the manufacturer’s instructions. The
product was then transformed into Stellar
TM
competent cells. The plasmid
was extracted from a single cell colony and sequence verified before trans-
forming it into the BL21* (DE3) pLysS expression strain.
The construct was expressed for 4 h at 37◦C and 180 rpm after in-
duction with 0.5 mM IPTG and harvested normally. The frozen cell pellet
was resuspended in lysis buffer (50 mM Tris/HCl, 100 mM NaCl, 5 mM
MgCl2, pH 8.0) and spiked with Benzonase
R© Nuclease (Novagen) and lysed
by sonication (3 x 5 min).
The supernatant contained the majority of the overexpressed MtuATP-
PRT. Purification was performed by IMAC (5 mL TALON R© crude column)
applying a gradient from 5 mM imidazole to 250 mM imidazole over 35 mL.
The wash buffer (50 mM Tris/HCl, 100 mM NaCl, 5 mM MgCl2, pH 8.0)
only contained 5 mM imidazole since the initial binding test had shown a
large portion of the enzyme in the flow through when 20 mM imidazole was
used. The second purification step was a SEC run using the combined elution
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peak fractions from the IMAC.
Kinetics were performed using the standard assay for CjeATP-PRT in
50 mM Tris/HCl, 100 mM NaCl, 50 mM KCl, 10 mM MgCl2, pH 8.5 as well
as 50 mM phosphate, 500 mM NaCl, 10 mM MgCl2, pH 8.5 and 20 mM
triethanolamine, 200 mM KCl, 10 mM MgCl2, pH 8.5.
Crystals were grown in the condition described by Cho et al.35 7–9 mg
mL−1 highly pure MtuATP-PRT was mixed 1:1 with 0.1 M MES pH 6.5, 1.8
M MgSO4. Crystals grew over night and were soaked by adding 1 µL of 10
mM ATP to the crystal drop 30 minutes prior to flash freezing. A mixture
of 50 % saturated sucrose and 50 % reservoir served as cryoprotectant.
6.3 Methods for Chapter 3
6.3.1 Cloning of the CjeATP-PRT Core and CjeATP-
PRT ACT mutants
The truncation mutants of CjeATP-PRT were created using the same Gateway R©
Cloning protocol as described for the wild type (sections 6.1.16 and 6.2.1)
using the following primers.





HisG ACT FWD GGCAGCGGCGCGTCTAAATACATTATGC
HisG ACT2 FWD GCTTCGAAGGAGATAGAACCATGTCTAAATACATTATGC
cjeH trunc REV GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATTCTC
TTGCTTGCATTAC
2R GERD GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAAC
2nd R nested FWD GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACC
TGTATTTTCAGGGCAGCGGCGCG
2nd R nested2 FWD GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAG
ATAGAACCATG
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These were used in three consecutive PCR steps for each construct as follows:
CjeATP-PRT Core
Step 1: cjeAPRT0 FWD and cjeAPRT0 REV
Step 2: cjeAPRT1 FWD and cjeH trunc REV
Step 3: 2R GERD and cjeH trunc REV
CjeATP-PRT ACT
Step 1: cjeAPRT0 FWD and cjeAPRT0 REV
Step 2: HisG ACT FWD and cjeAPRT0 REV
Step 3: 2nd R nested FWD and cjeAPRT1 REV
The CjeATP-PRT ACT was also amplified alternatively without a tag for
the consecutive cloning into pDEST
TM
14:
Step 1: cjeAPRT0 FWD and cjeAPRT0 REV
Step 2: HisG ACT2 FWD and cjeAPRT0 REV
Step 3: 2nd R nested2 FWD and cjeAPRT1 REV







17 expression plasmids via LR-reaction,
and into pDEST
TM
14 in case of the tagless CjeATP-PRT ACT. All constructs
were transformed into BL21* (DE3) and Chaperone3 cell lines.
6.3.2 Expression conditions
Large scale expressions were performed using the BL21* (DE3) clones con-
taining the pDEST
TM
15 constructs of CjeATP-PRT Core and ACT mutants.
Cells were grown to the exponential phase at 37 ◦C and 180 rpm before the
addition of 0.5 mM IPTG for induction. Cells were left to grow for an ad-
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ditional 4 hours at 37 ◦C and 180 rpm before harvest. Lysis was performed
according to general methods (section 6.1.22).
6.3.3 Kinetic measurements
Apparent Michaelis-Menten constants and turn over rates for CjeATP-PRT
Core were measured under standard assay conditions (section 6.1.33) altering
the PRPP concentration (0.01 mM, 0.02 mM, 0.03 mM, 0.05 mM, 0.075 mM,
0.1 mM, 0.15 mM and 0.2 mM) and ATP concentration (0.02 mM, 0.04 mM,
0.06 mM, 0.1 mM, 0.2 mM, 0.4 mM, 1 mM and 2 mM) separately. The used
enzyme concentration in the cuvette was consistently 15.8 µM.
The dose response curve to AMP was measured under standard assay
conditions with AMP concentrations in the cuvette being 0 mM, 0.05 mM,
0.1 mM, 0.2 mM, 0.5 mM, 1 mM, 2 mM and 5 mM for the Core mutant and
0 mM, 0.2 mM, 0.4 mM, 0.6 mM, 1 mM, 2 mM, 3 mM, 5 mM and 8 mM in
case of the wild type.
The dose response curve to PR-ATP was also measured under standard
assay conditions with PR-ATP concentrations in the cuvette being 0 mM,
0.002 mM, 0.005 mM, 0.01 mM, 0.02 mM, 0.05 mM and 0.1 mM.
6.3.4 ITC
AMP and ATP binding experiments on the CjeATP-PRT Core mutant were
performed as described in section 6.1.39 using an enzyme concentration of
100 µM in the cell and 2 mM nucleotide as titrant.
Histidine binding experiments on the CjeATP-PRT ACT mutant were
performed as described in section 6.1.39 using an enzyme concentration of
57 µM in the cell and 1.5 mM histidine as titrant.
Activity measurements of CjeATP-PRT Core in the presence of CjeATP-
PRT ACT were performed under the standard assay conditions (section
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6.1.33) with constant concentrations of ATP (2 mM), PRPP (0.12 mM),
CjeATP-PRT Core (1.7 µM) and histidine (0.5 mM). The concentrations of
CjeATP-PRT ACT used were 1.7 µM, 17 µM and 35 µM according to the
ratios 1:1, 1:10 and 1:20.
6.3.5 Crystallisation conditions
All procedures were performed as described in section 6.1.44. The CjeATP-
PRT Core mutant was crystallised in the following condition with exceptional
consistency and reproducibility. It is derived from the PACT premier
TM
HT-
96 condition A12 in which the enzyme was found to crystallise during initial
screens. The used protein concentration ranged between 5 and 11 mg mL −1
in the drop with best results on the high end of the range.
0.1 M sodium acetate, 0.01 M ZnCl2, 7–10 % w/v PEG 6000, pH 5.0
Crystals formed over night and continued to grow for up to one day and
were suitable for soaking of the ligands ATP (10 mM), PRPP (10 mM) and
PR-ATP (14 mM) in a 1:2 mixture with 30–60 minutes incubation time. A
misture of 20 % w/v PEG 400 and 80 % condition was used as cryoprotectant.
The CjeATP-PRT ACT mutant (4 mg mL −1 average drop concentra-
tion) formed crystals in JCSGplus premier
TM
HT-96 screen condition E1:
1.0 M sodium citrate tribasic dihydrate, 0.1 M sodium cacodylate, pH 6.5.
Crystals grown from this condition were cryoprotected with a mixture of 50
% saturated sucrose and 50 % reservoir and delivered diffraction data out to
4 Å.
The CjeATP-PRT ACT crystallised in a large variety of other screen
conditions: JCSGplus premier
TM
HT-96 B9, G10 and PACT premier
TM
HT-
96 A4, C7, E6 and G1. Of these only B9 (0.1 M sodium citrate, 20 % w/v
PEG 6000, pH 5.0) was able to be up-scaled with reasonable reproducibility,
but were of very poor diffraction quality.
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6.4 Methods for Chapter 4
6.4.1 Cloning of CjeATP-PRT single site mutants
All single site mutants mentioned in this chapter were created by apply-
ing the general SDM protocol described previously (Section 6.1.15). The
pDEST
TM
17 vector carrying the CjeATP-PRT gene was used as the template
and a temperature range from 45–65 ◦C was employed during the annealing
step of the SDM. All mutagenesis primers are listed below with the mutated
base pairs highlighted in bolt script.









H33A H35S FWD GAATGTGGTGTTAAAATGGCTATCTCTGAACAAAGCT
TGATCG
H33A H35S REV CGATCAAGCTTTGTTCAGAGATAGCCATTTTAACACC
ACATTC
H33A H35S L FWD GAATGTGGTGTTAAAATGGCTATCTCTGAACAAAGCT
TGATCGCTTTTTC
H33A H35S L REV GAAAAAGCGATCAAGCTTTGTTCAGAGATAGCCATTT
TAACACCACATTC
The resulting reaction mixtures were first screened for the presence of
suitable amounts of vector by agarose gel electrophoresis and then trans-
formed into chemically competent E. coli TOP10 cells. Two or more clones
were picked for each mutant and grown overnight at 37 ◦C and 180 rpm
before plasmid extraction. The purified vectors were sequence analysed to
confirm the introduced mutations and transformed into E. coli expression
strains (BL21* (DE3), BL21* (DE3) pLysS and Chaperone 3) thereafter.
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6.4.2 Expression trials
The mutant enzymes were expressed in small test cultures (200 mL vol-
ume) for 2 hours at 37 ◦C and 180 rpm after induction with 0.5 mM IPTG
during the logarithmic phase. Cells were harvested and lysed as described
(section 6.1.22). His SpinTrap
TM
single use columns (GE Healthcare) were
used according to the manual for fast IMAC binding tests of a small fraction
(0.5–1.0 mL) of each clarified supernatant. The solubility and approximate
yields from the used expression strains were compared by SDS-PAGE analy-
sis and the eluates of the His SpinTrap
TM
runs were tested for activity under
standard assay conditions (section 6.1.33).
6.4.3 Determination of the kinetic properties of the
R216A mutant
Michaelis-Menten constants and turn over rates for CjeATP-PRT R216A
were measured under standard assay conditions (section 6.1.33) altering the
PRPP concentration (6 µM, 12 µM, 24 µM, 60 µM, 120 µM, 240 µM and
360 µM) and ATP concentration (0.01 mM, 0.05 mM, 0.1 mM, 0.2 mM, 0.4
mM, 1 mM, 2 mM and 4 mM) separately. The used enzyme concentration
in the cuvette was consistently 6.9 µM.
The dose response curve to histidine was measured under standard
assay conditions at 0, 0.2, 2 and 20 mM histidine concentrations.
The dose response curve to AMP was also measured under standard
assay conditions with AMP concentrations in the cuvette being 0 mM, 0.05
mM, 0.1 mM, 0.2 mM, 0.5 mM, 1 mM, 2 mM and 5 mM.
6.4.4 ITC
Histidine binding experiments on the CjeATP-PRT R216A mutant were per-
formed as described in section 6.1.39 using an enzyme concentration of 100
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µM in the cell and 1.5 mM histidine as titrant.
6.4.5 Crystallisation conditions
All procedures were performed as described in section 6.1.44. The CjeATP-
PRT R216A and R54A mutants were crystallised in the following conditions
after manual adjustment of the initial CjeATP-PRT conditions. The used
protein concentration ranged between 1.5 and 2.5 mg mL −1 in the drop
comparable to the concentrations used for the CjeATP-PRT wild type.
0.1 M Tris/HCl, 0.2 M KSCN, 15–16 % w/v PEG 4000, 1 mM histidine, pH
7.5
0.1 M Tris/HCl, 0.2 M KSCN, 8 % PEG 1000/ 8 % PEG 8000, 10 mM ATP,
pH 7.5





Raw kinetic data as proof of E.
coli pyrophosphatase function
Figure A.1: Raw absorbance data showing the equilibrium character of the
CjeATP-PRT reaction. The reaction can be driven to completeness in the biosyn-
thetic direction by the addition of EcoPPase.
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Figure A.2: Raw absorbance data showing the inversion of the CjeATP-PRT
reaction by addition of EcoPPase.
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Appendix B
Michaelis-Menten plots for the
determination of KM values cal-
culated for CjeATP-PRT mutants
Figure B.1: Michaelis-Menten plots used for determination of the KM values of
PRPP and ATP for CjeATP-PRT Core. KM and kcat values were determined
according to section 6.1.33.
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Figure B.2: Michaelis-Menten plots used for determination of the KM values of
PRPP and ATP for CjeATP-PRT R216A. KM and kcat values were determined
according to section 6.1.33.
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Appendix C
Michaelis-Menten plots for the
determination of Ki values cal-
culated for CjeATP-PRT
Figure C.1: Michaelis-Menten plots used for determination of the Ki values of
AMP against PRPP and ATP for CjeATP-PRT. Ki values were determined by
global fitting of the data to the equation for competitive inhibition using GraFit
(version 5.0.13, Erithacus Software Limited).
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Figure C.2: Michaelis-Menten plots used for determination of the Ki values of
histidine against PRPP and ATP for CjeATP-PRT. Ki values were determined
by global fitting of the data to the equation for non-competitive inhibition using
GraFit (version 5.0.13, Erithacus Software Limited).
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Appendix D
Guinier analysis and pair distri-
bution functions for CjeATP-PRT
Figure D.1: Guinier analysis and pair distribution functions for CjeATP-PRT
wild type. Plots were generated by PRIMUS107 and GNOM.95
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Figure D.2: Guinier analysis and pair distribution functions for CjeATP-PRT
wild type in the presence of 1 mM Histidine and 2 mM AMP. Guinier plots were
calculated by PRIMUS.107 Pair wise distribution function P(r) was generated using
GNOM.95
209
Figure D.3: Guinier analysis and pair distribution functions for CjeATP-PRT
Core. Guinier plots were calculated by PRIMUS.107 Pair wise distribution function
P(r) was generated using GNOM.95
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Figure D.4: Guinier analysis and pair distribution functions for CjeATP-PRT
Core in the presence of 2 mM AMP. Guinier plots were calculated by PRIMUS.107
Pair wise distribution function P(r) was generated using GNOM.95
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